<SEC-DOCUMENT>0001564590-21-017827.txt : 20210406
<SEC-HEADER>0001564590-21-017827.hdr.sgml : 20210406
<ACCEPTANCE-DATETIME>20210406163635
ACCESSION NUMBER:		0001564590-21-017827
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		6
FILED AS OF DATE:		20210406
DATE AS OF CHANGE:		20210406

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-254585
		FILM NUMBER:		21809537

	BUSINESS ADDRESS:	
		STREET 1:		10170 CHURCH RANCH WAY
		STREET 2:		SUITE 100
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		7209402200

	MAIL ADDRESS:	
		STREET 1:		10170 CHURCH RANCH WAY
		STREET 2:		SUITE 100
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>abio-424b5.htm
<DESCRIPTION>424B5
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
abio-424b5.DOCX.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As Filed Pursuant to Rule 424(b)(5)</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registration&#160;No.&#160;<font style="Background-color:#FFFFFF;">333-254585</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PROSPECTUS SUPPLEMENT<br />(To Prospectus Dated March 30, 2021)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gp5m5bivuamv000001.jpg" title="" alt="" style="width:192px;height:77px;"><font style="color:#000000;font-size:11pt;">&nbsp;</font></p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$50,000,000 </p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock </p>
<p style="text-align:center;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 6, 2021, we entered into an amendment, or the Amendment No. 1, to our <font style="color:#000000;">Capital on Demand&#8482;</font><font style="color:#000000;font-family:Arial;"> </font>Sales Agreement, dated July&#160;22,&#160;2020 with JonesTrading Institutional Services LLC, or JonesTrading, or the Original Agreement and, together with the Amendment No. 1, the Sales Agreement, relating to shares of our common stock, $0.001 par value per share, offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the Sales Agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $50,000,000 from time to time through or to JonesTrading, acting as our agent or principal. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock is listed on the Exchange under the symbol <font style="color:#000000;">&#8220;</font>ABIO.<font style="color:#000000;">&#8221;</font> On April 1, 2021, the last reported sale price of our common stock was $3.76 per share. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of our common stock, if any, under this prospectus supplement and accompanying prospectus may be made in sales deemed to be <font style="color:#000000;">&#8220;</font>at the market offerings<font style="color:#000000;">&#8221;</font> as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, or the Securities Act. JonesTrading is not required to sell any specific number or dollar amount of securities, but will act as a sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between JonesTrading and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The compensation to JonesTrading for sales of common stock sold pursuant to the Sales Agreement will be an amount equal to 3.0% of the gross proceeds of any shares of common stock sold under the Sales Agreement. In connection with the sale of the common stock on our behalf, JonesTrading will be deemed to be an <font style="color:#000000;">&#8220;</font>underwriter<font style="color:#000000;">&#8221;</font> within the meaning of the Securities Act and the compensation of JonesTrading will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to JonesTrading with respect to certain liabilities, including liabilities under the Securities Act or the Exchange Act of 1934, as amended, or the Exchange Act. </p>
<p style="text-align:center;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading &#8220;<a href="#RISK_FACTORS"><font style="text-decoration:underline;color:#000000;">Risk Factors</font></a><font style="font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#8221; on page S-9</font><font style="font-weight:normal;font-style:normal;color:#000000;"> </font>of this prospectus supplement and under similar headings in the accompanying prospectus and other documents that are incorporated by reference into this prospectus supplement and accompanying prospectus. </p>
<p style="text-align:center;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS SUPPLEMENT OR THE ACCOMPANYING PROSPECTUS ARE TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. </p>
<p style="text-align:center;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;<img src="gp5m5bivuamv000002.jpg" title="" alt="" style="width:232px;height:69px;"><font style="font-weight:normal;"></font></p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">The date of this prospectus supplement is April 6, 2021. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;">&nbsp;</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TABLE OF CONTENTS </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PROSPECTUS SUPPLEMENT</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:3.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:3.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ABOUT_THIS_PROSPECTUS_SUPPLEMENT"><font style="text-decoration:underline;">ABOUT THIS PROSPECTUS SUPPLEMENT</font></a></p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PROSPECTUS_SUPPLEMENT_SUMMARY"><font style="text-decoration:underline;">PROSPECTUS SUPPLEMENT SUMMARY</font></a></p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:4.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-2</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#FERING"><font style="text-decoration:underline;">THE OFFERING</font></a></p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:4.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-8</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#RISK_FACTORS"><font style="text-decoration:underline;">RISK FACTORS</font></a></p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:4.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-9</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#FORWARDLOOKING_STATEMENTS"><font style="text-decoration:underline;">FORWARD-LOOKING STATEMENTS</font></a></p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:4.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-12</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#USE_PROCEEDS"><font style="text-decoration:underline;">USE OF PROCEEDS</font></a></p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:4.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:-2.25pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-14</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#DILUTION"><font style="text-decoration:underline;">DILUTION</font></a></p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:4.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:-2.25pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-15</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PLAN_DISTRIBUTION"><font style="text-decoration:underline;">PLAN OF DISTRIBUTION</font></a></p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:4.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:-2.25pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-17</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#LEGAL_MATTERS"><font style="text-decoration:underline;">LEGAL MATTERS</font></a></p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:4.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:-2.25pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-18</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#EXPERTS"><font style="text-decoration:underline;">EXPERTS</font></a></p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:4.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:-2.25pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-18</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#WHERE_YOU_CAN_FIND_MORE_INFORMATION"><font style="text-decoration:underline;">WHERE YOU CAN FIND MORE INFORMATION</font></a></p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:4.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:-2.25pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-18</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#INCORPORATION_CERTAIN_INFORMATION_BY_REF"><font style="text-decoration:underline;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</font></a></p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:4.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:-2.25pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-19</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PROSPECTUS</p></td>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ABOUT_THIS_PROSPECTUS"><font style="text-decoration:underline;">ABOUT THIS PROSPECTUS</font></a></p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PROSPECTUS_SUMMARY"><font style="text-decoration:underline;">PROSPECTUS SUMMARY</font></a></p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#RISK_FACTORS_1"><font style="text-decoration:underline;">RISK FACTORS</font></a></p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#FORWARDLOOKING_STATEMENTS_1"><font style="text-decoration:underline;">FORWARD-LOOKING STATEMENTS</font></a></p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#USE_PROCEEDS_1"><font style="text-decoration:underline;">USE OF PROCEEDS</font></a></p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#DESCRIPTION_CAPITAL_STOCK"><font style="text-decoration:underline;">DESCRIPTION OF CAPITAL STOCK</font></a></p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#DESCRIPTION_DEBT_SECURITIES"><font style="text-decoration:underline;">DESCRIPTION OF DEBT SECURITIES</font></a></p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#DESCRIPTION_WARRANTS"><font style="text-decoration:underline;">DESCRIPTION OF WARRANTS</font></a></p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#LEGAL_OWNERSHIP_SECURITIES"><font style="text-decoration:underline;">LEGAL OWNERSHIP OF SECURITIES</font></a></p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PLAN_DISTRIBUTION_1"><font style="text-decoration:underline;">PLAN OF DISTRIBUTION</font></a></p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#LEGAL_MATTERS_1"><font style="text-decoration:underline;">LEGAL MATTERS</font></a></p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#EXPERTS_1"><font style="text-decoration:underline;">EXPERTS</font></a></p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#WHERE_YOU_CAN_FIND_MORE_INFORMATION_1"><font style="text-decoration:underline;">WHERE YOU CAN FIND MORE INFORMATION</font></a></p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#INCORPORATION_CERTAIN_INFORMATION_1"><font style="text-decoration:underline;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</font></a></p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
</tr>
</table></div>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ABOUT_THIS_PROSPECTUS_SUPPLEMENT"></a><a name="ABOUT_THIS_PROSPECTUS_SUPPLEMENT"></a>ABOUT THIS PROSPECTUS SUPPLEMENT</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This document is in two parts. The first part is this prospectus supplement, which describes the specific terms of this offering and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference herein. The second part, the accompanying prospectus, provides more general information. Generally, when we refer to this prospectus, we are referring to both parts of this document combined. To the extent there is a conflict between the information contained in this prospectus supplement and the information contained in the accompanying prospectus or any document incorporated by reference therein filed prior to the date of this prospectus supplement, you should rely on the information in this prospectus supplement; provided that if any statement in one of these documents is inconsistent with a statement in another document having a later date&#8212;for example, a document incorporated by reference in the accompanying prospectus&#8212;the statement in the document having the later date modifies or supersedes the earlier statement.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreement, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not, and JonesTrading has not, authorized anyone to provide any information other than that contained or incorporated by reference in this prospectus supplement, in the accompanying prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We and JonesTrading take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This prospectus supplement and accompanying prospectus do not constitute an offer to sell, or a solicitation of an offer to purchase, the securities offered by this prospectus supplement and the accompanying prospectus in any jurisdiction to or from any person to whom or from whom it is unlawful to make such offer or solicitation of an offer in such jurisdiction. You should assume that the information appearing in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and in any free writing prospectus that we have authorized for use in connection with this offering is accurate only as of the date of those respective documents. It is important for you to read and consider all information contained in this prospectus supplement and in the accompanying prospectus, including the documents incorporated by reference herein and therein, in making your investment decision. You should also read and consider the information in the documents to which we have referred you in the sections entitled &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation of Certain Information by Reference&#8221; in this prospectus supplement and in the accompanying prospectus.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other than in the United States, no action has been taken by us or JonesTrading that would permit a public offering of the securities offered by this prospectus supplement and accompanying prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus supplement and accompanying prospectus may not be offered or sold, directly or indirectly, nor may this prospectus supplement, accompanying prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus supplement and accompanying prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus supplement and accompanying prospectus. This prospectus supplement and accompanying prospectus do not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus supplement and accompanying prospectus in any jurisdiction in which such an offer or a solicitation is unlawful.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="PROSPECTUS_SUPPLEMENT_SUMMARY"></a><a name="PROSPECTUS_SUPPLEMENT_SUMMARY"></a>PROSPECTUS SUPPLEMENT SUMMARY </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">This summary highlights certain information about us, this offering and selected information contained elsewhere in or incorporated by reference into this prospectus supplement and accompanying prospectus. This summary is not complete and does not contain all of the information that you should consider before deciding whether to invest in our common stock. For a more complete understanding of our company and this offering, we encourage you to read and consider carefully the more detailed information in this prospectus supplement and accompanying prospectus, including the information incorporated by reference in this prospectus supplement and accompanying prospectus, and the information included in any prospectus supplement or free writing prospectus that we have authorized for use in connection with this offering, including the information under the heading &#8220;Risk Factors&#8221; in this prospectus supplement on page S-6 and in the documents incorporated by reference into this prospectus supplement and accompanying prospectus. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The terms &#8220;ARCA,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar terms refer to ARCA biopharma, Inc. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Company Overview </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. Precision medicine refers to the tailoring of medical treatment to the individual characteristics of patients, using genomic, non-genomic biomarker and other information that extends beyond routine diagnostic categorization. We believe that when implemented correctly precision medicine can enhance therapeutic response, improve patient outcomes, and reduce healthcare costs. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our lead product candidates are rNAPc2 (AB201) as a potential treatment for diseases caused by ribonucleic acid, or RNA, viruses, initially focusing on COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">rNAPc2 (AB201) for treatment of COVID-19</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recombinant Nematode Anticoagulant Protein c2, or rNAPc2 (AB201), is a protein therapeutic in clinical development as a potential treatment for patients with COVID-19. Based on its unique mechanism of action, development history and the clinical evidence from the SARS-CoV-2 pandemic, we believe rNAPc2 has potential to be a beneficial therapy for patients with this serious viral disease. We initiated a Phase 2 clinical trial of rNAPc2 as a potential treatment for patients hospitalized with COVID-19 in the fourth quarter of 2020 and are currently enrolling patients. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain patients with severe COVID-19 disease exhibit thrombotic complications and other inflammatory responses suggesting potential dysregulation of the coagulation and immune systems. rNAPc2 is a potent inhibitor of tissue factor, a cellular receptor responsible for initiation of the primary coagulation pathway and appears to be the major activator of the coagulation cascade during viral infection. Tissue factor is also implicated in the immune system inflammatory response to viral infections and in the process of viral dissemination during infection. We believe that evidence from the pandemic implicates tissue factor pathways as an important part of the COVID-19 disease process, and provides a rationale to test rNAPc2 as a potential therapeutic for COVID&#8209;19 for its anticoagulant and potential anti-inflammatory properties.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rNAPc2 was originally developed for potential use as an anticoagulant due to its inhibition of the TF-initiated coagulation process. It was evaluated for the prevention of thrombosis in Phase 1 and Phase 2 clinical studies involving over 800 subjects and demonstrated both safety and efficacy in these studies. rNAPc2 has also been investigated as a potential therapeutic for severe viral infections other than COVID-19. Research has shown that viral infections can provoke dysregulated activation of the TF pathway, resulting in abnormal systemic coagulation and related inflammation, leading to potential organ failure and mortality. For this reason, rNAPc2 was tested as a therapeutic in non-human primates, or NHPs, in studies against lethal doses of the Ebola and Marburg viruses, where it showed evidence of efficacy in the form of mortality reduction, decreases in inflammatory biomarkers and, evidence of reduced disseminated intravascular coagulation, or DIC. DIC is a serious condition that causes abnormal blood&#160;clotting&#160;throughout the body's blood vessels.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SARS-CoV-2 is a new coronavirus identified in late 2019 that belongs to a family of enveloped RNA viruses that include Middle East Respiratory Syndrome, or MERS, and Severe Acute Respiratory Syndrome (SARS-CoV-1), both of which caused serious human infections of the respiratory system. The disease caused by the SARS-CoV-2 virus has been designated COVID-19. Since this outbreak was first reported in late 2019, there have been over 119 million confirmed cases of COVID-19 and over 2.6&#160;million deaths worldwide attributed to the virus (as of March 2021).</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVID-19 is associated with a high incidence of both arterial and venous coagulation-related adverse events in large and small blood vessels. These include, stroke, myocardial infarction, or MI, (i.e., heart attack) and pulmonary emboli; as well as, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">blockage of the smaller peripheral blood vessels in the fingers/toes (COVID-digit). This syndrome is so frequently observed in COVID-19 that it has received the name of COVID-19 Associated Coagulopathy, or CAC. The underlying pathology of CAC is believed to result from thrombo-inflammatory processes triggered by the viral infection. A commonly used biomarker for assessing the presence of abnormal coagulation is a D-dimer test, which is elevated (greater than 0.5) in nearly 70% of hospitalized COVID-19 patients and is associated with adverse clinical outcomes. Some researchers believe that this and other evidence points to dysregulation of TF pathways in COVID-19 patients that result in the development of thrombotic complications.&nbsp;&nbsp;</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rNAPc2 has shown potential in addressing the coagulation disorder caused by severe viral infections. In preliminary, non-human studies in NHPs against lethal doses of the Ebola and Marburg virus, rNAPc2 lowered D-dimer levels, reduced mortality and exhibited anti-inflammatory effects. We believe more recent research supports our belief that rNAPc2 has the ability to inhibit the activity of TF in multiple processes that contribute to severe viral disease. Taken together, we believe this evidence suggests that rNAPc2 may have therapeutic benefits for patients with serious COVID-19 infections and the accompanying high risk of thrombosis. To our knowledge, rNAPc2 is the only NME anticoagulant, and the only tissue factor inhibitor, currently under evaluation for COVID-19.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a therapeutic aimed at a host response to a disease syndrome, we believe rNAPc2 potentially could be used in combination with other antiviral drugs. We believe its potential efficacy is not linked to a specific viral genome and may not be diminished by genetic drift or the development of new strains of the SARS-CoV-2 virus. As a therapeutic addressing a disease, we believe rNAPc2 may have broad spectrum potential against multiple pathogens that have disease elements in common with COVID&#8209;19, such as other coronaviruses and other RNA viruses. Therefore, we believe that rNAPc2 has therapeutic potential for future viral outbreaks beyond the current pandemic.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rNAPc2 is a single-chain, 85 amino acid, recombinant protein administered subcutaneously, that has previously been evaluated under three FDA Investigational New Drug, or IND, applications in six Phase 1 and three Phase 2 clinical studies in the United States and Europe. These clinical trials primarily examined the safety, dosing and anticoagulation effects of rNAPc2 in patients with acute coronary syndromes, in patients undergoing knee replacement surgery and in patients undergoing percutaneous coronary interventions. In these trials, involving more than 800 human patients with over 700 exposed to drug, rNAPc2 was generally well-tolerated with a safety profile comparable to commercially available anticoagulants. rNAPc2 is manufactured in an engineered yeast strain by an established methodology following current Good Manufacturing Practices, or cGMP, and we believe this process can be readily scaled to commercial quantities. FDA granted rNAPc2 Orphan Drug Designation status in 2014 for the treatment of viral hemorrhagic fever post-exposure to Ebola virus, but human clinical trials were not conducted. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2020, FDA approved the IND application for rNAPc2 as a potential treatment for patients hospitalized with COVID-19 and it received a Fast-Track designation in November 2020. We initiated the Phase 2b clinical trial of rNAPc2 (AB201), ASPEN-COVID-19, in patients hospitalized with COVID-19 in the fourth quarter of 2020. We anticipate announcing topline data from this approximately 100 patient Phase 2b clinical trial in the third quarter of 2021. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are evaluating rNAPc2 as a treatment for patients hospitalized with COVID-19 who are at high risk for thrombotic complications, as indicated by elevated D-dimer levels. The Phase 2b clinical trial is designed to be a randomized comparison of two-dose regimens of rNAPc2 versus heparin prescribed per local standard of care. The primary endpoint of the clinical trial is the change in D-dimer level from baseline to Day 8. If Phase 2b results indicate a favorable effect on D-dimer levels and safety is confirmed, following FDA review of the data and identification of the proposed Phase&#160;3 rNAPc2 dose, we anticipate that clinical investigative sites will begin enrolling patients in a planned Phase 3 clinical trial. The primary endpoint of Phase 3 is planned to be clinical recovery as measured by the Adaptive COVID-19 Treatment Trial ordinal scale, with secondary endpoints that include D-dimer levels and the number of thrombotic events. We believe the Phase 3 clinical trial will be event driven, with an estimated requirement of 450 patients. We believe that favorable results from this Phase 2b/3 clinical trial program could support use of rNAPc2 in COVID-19 patients, given its potential efficacy both as an anticoagulant and an anti-viral agent that we believe counters the dysregulatory immune response and improves clinical recovery.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The clinical trial is being managed in collaboration with the Colorado Prevention Center, or CPC, the University of Colorado's Academic Research Organization with extensive experience in managing vascular and anticoagulation clinical trials. <font style="margin-left:36pt;"></font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have financed the development of rNAPc2 through public equity sales. Our rNAPc2 development plans, including the timeline, depend on our ability to enroll patients during the COVID-19 pandemic, the results of our Phase 2b clinical trial, FDA guidance, and availability of drug product, all of which are currently uncertain.&nbsp;&nbsp; <font style="margin-left:36pt;"></font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own the clinical development program of rNAPc2, including Phase 2 clinical trials.&#160; If rNAPc2 is successfully developed, we believe it will have intellectual property protection, including 12 years of market exclusivity as an innovative biologic </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product under FDA law in the United States, 10 years data protection exclusivity in the European Union, or EU, and </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">potentially patent protection in addition to this. We plan to pursue strategic co-development and partnering opportunities for rNAPc2 development and commercialization</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Gencaro&#8482; (bucindolol hydrochloride) for Atrial Fibrillation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gencaro&#8482; (bucindolol hydrochloride) is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties that we are developing for the treatment of atrial fibrillation in patients with heart failure. We believe the pharmacology of Gencaro is unique and its efficacy can be enhanced by prescribing it to patients with a common genotypic variant that is present in approximately 50% of the North American and European general populations. This gene can be detected with a simple genetic test. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing Gencaro to treat atrial fibrillation, or AF, in patients with chronic heart failure, or HF. AF is the most common form of cardiac arrhythmia, a disruption of the heart&#8217;s normal rhythm or rate. HF is a chronic condition in which the heart is unable to pump enough blood to meet the body&#8217;s needs. AF and HF commonly occur together. In HF patients, the development of AF leads to worsening symptoms, and increased risk of hospitalization and death. Current treatment options for AF in HF patients are limited, and can be invasive, costly and dangerous.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our development plan for Gencaro focuses on the treatment of AF in patients with higher ejection fraction HF, those who have an ejection fraction, or EF, of 40% and higher who also have the genotype we believe is optimal for Gencaro efficacy. This population of HF encompasses more than half of all HF patients in the United States and Europe. There are currently few approved or effective drug therapies to treat AF or HF in this patient population.&nbsp;&nbsp; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our development plan for Gencaro is based on our recent analysis of the Phase 2b clinical trial of Gencaro for the prevention of AF in HF patients, known as GENETIC-AF. This analysis showed novel results for Gencaro in patients in the clinical trial with EF&#8217;s of 40% and higher. We are planning a new design for a Phase 3 pivotal clinical trial of Gencaro based on this analysis that addresses what we believe are important clinical assessments, including the total amount of time that a patient experiences AF, known as AF burden, maintenance of normal sinus rhythm, rhythm control interventions such as electrical cardioversion, catheter ablation and use of anti-arrhythmic drugs and drug-related complications such as bradycardia. Based on these analyses, we were issued a United States patent in February 2021 for the use of Gencaro in this patient population. We believe this patent will substantially extend the patent protection for our planned development of Gencaro into 2039. We are seeking similar patent protection in other countries. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have an agreement with the FDA, known as a Special Protocol Assessment, or SPA, for the requirements of a Gencaro Phase 3 clinical trial, PRECISION-AF, that would support approval of Gencaro if successful. Based on our recent analyses of the GENETIC-AF data, we may alter the design of PRECISION-AF to focus on endpoints that are not covered in the SPA agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that patients with HF and AF represent a major unmet medical need, and this need is most pronounced in patients with EF values of 40% and above. This EF range constitutes more than half of all chronic HF in the United States and Europe, as well as in Japan and China, and there are currently few approved, effective or guideline-recommended therapies for these patients to treat either their AF or HF. AF is a very common complication in these patients, with estimates of AF incidence ranging from 40% to 60%. Beta-blockers approved for HF are commonly used off-label to control heart rate in these patients, but they are not considered effective in preventing AF and none are approved for patients with EF &#8805; 40%. Other anti-arrhythmic drugs approved for the treatment of AF have adverse side effects and in HF patients are either contraindicated or have label warnings for use due to an increased risk of mortality. Interventional procedures for AF, such as catheter ablation and electrical cardioversion, are invasive, expensive, and often temporary; these interventions also typically require the continued use of beta blockers and other anti-arrhythmic drugs post-intervention.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that Gencaro, if approved, may be a safe and more effective therapy for the treatment of higher ejection fraction HF patients with AF. We believe there are several potentially important attributes that would differentiate Gencaro from existing therapies, including:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">More effective rhythm control compared to the current standard of care;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Reduction in the need for catheter ablation, electrical cardioversion, or toxic anti-arrhythmic drugs;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Maintenance of rhythm control after a successful AF catheter ablation;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Effective rate control with lower risk of treatment-limiting bradycardia;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Reduction in symptoms and improvement in quality of life;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Reduced health care burden;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Foundational beta-blocker benefits for HF and unique evidence of efficacy in HF patients with AF;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">One of the only drug therapies approved and shown effective for AF in HF patients with EF &#8805; 40%, and the only one in its drug class.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have an international patent portfolio for Gencaro in the United States, the EU, and other major markets, as well as new chemical entity status, including a new patent that we believe will give us a strong intellectual property position to at least approximately 2039 in the United States; we have filed applications similar to this new patent in international territories. We have developed a laboratory platform for the diagnostic test that would be used to prescribe Gencaro; this platform was approved by FDA for use in the Phase 2B clinical trial. We retain all rights to this test platform; we expect to use it in future clinical trials, and we believe it could be one of multiple diagnostic platforms used for commercialization. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">To support the continued development of </font><font style="color:#000000;">rNAPc2</font><font style="Background-color:#FFFFFF;"> and Gencaro, we will need additional financing to fully fund the planned </font>clinical trials, <font style="Background-color:#FFFFFF;">and our general and administrative costs through the clinical trials&#8217; projected completion and potential commercialization. Considering the substantial time and costs associated with the development of </font><font style="color:#000000;">rNAPc2</font><font style="Background-color:#FFFFFF;"> and Gencaro and the risk that we may be unable to raise a significant amount of capital on acceptable terms, we are also pursuing co-development and commercialization partnering opportunities with large pharmaceutical and/or specialty pharmaceutical companies and may pursue a strategic combination or other strategic transactions. If we are unable to obtain sufficient financing or are unable to complete a strategic transaction, we may discontinue our development activities on </font><font style="color:#000000;">rNAPc2</font><font style="Background-color:#FFFFFF;"> or Gencaro or discontinue our operations</font><font style="color:#000000;">.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Associated with Our Business </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business is subject to numerous risks and uncertainties, including those highlighted in the section titled <font style="color:#000000;">&#8220;</font>Risk Factors<font style="color:#000000;">&#8221;</font> immediately following this prospectus supplement summary and those described under similar headings in the documents incorporated by reference into this prospectus supplement<font style="font-style:italic;color:#000000;">&#160;</font>and accompanying prospectus. <font style="color:#000000;">You should read these risks before you invest in our securities. We may be unable, for many reasons, including those that are beyond our control, to implement our business strategy. In particular, some of our risks include</font>: </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of rNAPc2 Gencaro in a timely manner, we may not be able to continue our business operations.</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will need to raise substantial additional funds through public or private equity or debt transactions and/or complete one or more strategic transactions, to continue development of rNAPc2, Gencaro or any of our other product candidates. If we are unable to raise such financing or complete such a transaction, we may not be able to continue operations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audited financial statements for the fiscal year ended December 31, 2020 were prepared assuming that we will continue as a going concern. Our management has concluded that due to our need for additional capital, and the uncertainties surrounding our ability to raise such funding, there may be uncertainty about our ability to continue as a going concern in future years.</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business could be adversely affected by the effects of health epidemics, including the ongoing COVID-19 global pandemic, in regions where we or third parties on which we rely may have clinical trial sites or other business operations. We anticipate having clinical trial sites in countries that have been directly affected by COVID-19 and depend on third party manufacturing operations for various stages of our supply chain.</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have received an SPA agreement from the FDA relating to our planned Phase 3 program for Gencaro. This SPA agreement does not guarantee approval of Gencaro or any other particular outcome from regulatory review.</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are not able to maintain the requirements for listing on the Nasdaq Capital Market, we could be delisted, which could have a material adverse effect on our ability to raise additional funds as well as the price and liquidity of our common stock.</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rNAPc2 may not yield results that will enable us to further develop it as a therapy and obtain regulatory approvals necessary to be used as a drug.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we encounter difficulties enrolling patients in our clinical trial of rNAPc2, any potential enrollment milestones or potential regulatory approvals could be delayed or otherwise adversely affected.</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any future clinical trial for Gencaro will require the use of a third-party diagnostic services provider to administer a genetic test needed to identify the patient receptor genotypes of clinical trial participants, and as a result, we will be unable to directly control the timing, conduct and expense of the genetic test.</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will need to establish a collaborative arrangement with a third-party diagnostics services provider to obtain marketing clearance or approval of the companion genetic test. There is no guarantee that the FDA will grant timely clearance or approval of the genetic test, if at all, and failure to obtain such timely clearance or approval would adversely affect our ability to market Gencaro.</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates are subject to extensive regulation, which can be costly and time-consuming, and unsuccessful or delayed regulatory approvals could increase our future development costs or impair our future revenue.</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If approved by the FDA, rNAPc2 or Gencaro will be entering a competitive marketplace and may not succeed.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Corporate Information </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">On January&#160;27, 2009, we completed a business combination, or the Merger, between Nuvelo, Inc., or Nuvelo, a corporation originally incorporated in 1992, and its subsidiary, ARCA biopharma, Inc. Immediately following the Merger, we changed our name from Nuvelo, Inc. to ARCA biopharma, Inc. </font>Our principal offices are located at 10170&#160;Church Ranch Way, Suite&#160;100, Westminster, Colorado 80021. Our telephone number is (720) 940-2200, and our website is http://www.arcabio.com. <font style="color:#000000;">The information contained on our website is not incorporated by reference into this prospectus, and you should not consider any information contained on, or that can be accessed through, our website as part of this prospectus or in deciding whether to purchase our common stock</font>. For further information regarding us and our financial information, you should refer to our recent filings with the SEC. See &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation of Certain Information by Reference<font style="color:#000000;">.</font>&#8221;<font style="color:#000000;"> </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each of ARCA, ARCA biopharma, Gencaro and Gencaro Test is a registered trademark of ARCA biopharma, Inc. Each of the other trademarks, trade names or service marks appearing in this prospectus supplement and accompanying prospectus belongs to its respective holder. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;">&nbsp;</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="FERING"></a><a name="FERING"></a>THE OFFERING </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:34%;"></td>
<td style="width:2%;"></td>
<td style="width:64%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common Stock Offered By Us</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares of our common stock having an aggregate offering price of up to $50,000,000.</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common Stock to be Outstanding After this Offering</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,708,015 shares, based on an assumed offering price of $3.76 per share, the last reported sale price of our common stock on the Exchange on April&#160;1,&#160;2021.</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manner of Offering</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="color:#000000;">At the market offering</font>&#8221;<font style="color:#000000;"> that may be made from time to time through or to JonesTrading, as sales agent or principal. See </font>&#8220;<font style="color:#000000;">Plan of Distribution</font>&#8221;<font style="color:#000000;"> on page S-17 of this prospectus supplement.</font></p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Use of Proceeds</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently intend to use the net proceeds from the sale of the securities under this prospectus supplement and accompanying prospectus for working capital and general corporate purposes, including research and development expenses and general and administrative expenses. See <font style="color:#000000;">&#8220;</font>Use of Proceeds<font style="color:#000000;">&#8221;</font> on page S-14 of this prospectus supplement.</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk Factors</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investing in our common stock involves significant risks. See <font style="color:#000000;">&#8220;</font>Risk Factors<font style="color:#000000;">&#8221;</font> on page S-9 of this prospectus supplement and under similar headings in the accompanying prospectus and the other documents incorporated by reference into this prospectus supplement and accompanying prospectus.</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NASDAQ Capital Market Symbol</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="color:#000000;">ABIO</font>&#8221;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The above discussion and table are based on 14,410,143 shares of our common stock outstanding as of April&#160;1, 2021 and excludes: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:99.4%;">
<tr>
<td style="width:4.47%;"></td>
<td style="width:2.72%;"></td>
<td style="width:1.69%;"></td>
<td style="width:90.53%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">596,497 shares of our common stock issuable upon the exercise of stock options outstanding as of April&#160;1,&#160;2021, at a weighted average exercise price of $8.01 per share; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:99.4%;">
<tr>
<td style="width:4.47%;"></td>
<td style="width:2.72%;"></td>
<td style="width:1.69%;"></td>
<td style="width:90.53%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133,401 shares of our common stock issuable upon exercise of warrants outstanding as of April&#160;1, 2021, at a weighted average exercise price of $109.80 per share; and</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:99.4%;">
<tr>
<td style="width:4.47%;"></td>
<td style="width:2.72%;"></td>
<td style="width:1.69%;"></td>
<td style="width:90.53%;"></td>
</tr>
<tr>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">571,088 shares of our common stock reserved for issuance under our equity incentive and non-employee director stock award plans as of April&#160;1, 2021.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="RISK_FACTORS"></a><a name="RISK_FACTORS"></a>RISK FACTORS</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Investing in our common stock involves significant risks, some of which are described below. You should carefully consider these risks, as well as the other information in this prospectus supplement, accompanying prospectus and any free writing prospectus authorized in connection with this offering, including documents incorporated by reference, such as our most recent annual report on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, and in other documents that we have filed or subsequently file with the SEC that are incorporated by reference, before deciding whether to invest in our common stock. Each of the risk factors could adversely affect our business, operating results and financial condition, as well as adversely affect the value of an investment in our securities, and the occurrence of any of these risks might cause you to lose all or part of your investment. Additional risks not presently known to us or that we currently believe are immaterial may also significantly impair our business operations. Please also read carefully the section below titled &#8220;Forward-Looking Statements.&#8221; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional Risks Related to this Offering </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If you purchase our common stock in this offering, you may incur immediate dilution in the book value of your investment. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The offering price per share in this offering may exceed the net tangible book value per share of our common stock outstanding prior to this offering. Assuming that an aggregate of 13,297,872 shares of our common stock are sold at a price of $3.76 per share, the last reported sale price of our common stock on the Exchange on April 1, 2021, for aggregate gross proceeds of $50,000,000, and after deducting commissions and estimated offering expenses payable by us, you would experience immediate dilution of $(0.40) per share, representing the difference between our as adjusted net tangible book value per share as December 31, 2020 after giving effect to this offering and the assumed offering price. If we were to sell shares of our common stock in this offering at a price per share greater than our net tangible book value, it would result in dilution of your investment. The exercise of outstanding stock options and warrants or the settlement of outstanding restricted stock units would result in further dilution of your investment. See the section entitled &#8220;Dilution&#8221; below for a more detailed illustration of the dilution you may incur if you participate in this offering. Because the sales of the shares offered hereby will be made directly into the market or in negotiated transactions, the prices at which we sell these shares will vary and these variations may be significant. Purchasers of the shares we sell, as well as our existing shareholders, will experience significant dilution if we sell shares at prices significantly below the price at which they invested. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Future sales or the possibility of future sales of our common stock may depress the market price of our common stock. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales in the public market of substantial amounts of our common stock could depress prevailing market prices of our common stock. As of December 31, 2020, approximately 9.5 million shares of common stock were outstanding, and all of these shares are freely transferable without restriction or further registration under the Securities Act, except for shares held by our directors, officers and other affiliates and unregistered shares held by non-affiliates. The sale of these additional shares, or the perception that such sales may occur, could depress the market price of our common stock. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, approximately 133,000 shares of our common stock were issuable upon the exercise of outstanding warrants. Once a warrant is exercised, if the shares of our common stock issued upon the exercise of any such warrant are not available for sale in the open market without further registration under the Securities Act, then the holder can arrange for the resale of shares either by invoking any applicable registration rights, causing the shares to be registered under the Securities Act and thus freely transferable, or by relying on an exemption to the Securities Act. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, there were approximately 531,000 shares of our common stock which may be issued upon the exercise of outstanding stock options and the settlement of restricted stock units, and we anticipate that we will continue to issue stock option and restricted stock unit awards to our employees and consultants in the fiscal year ended December&#160;31,&#160;2021 and thereafter. If and when these options are exercised and these restricted stock units are vested, such shares will be available for sale in the open market without further registration under the Securities Act. The existence of these outstanding options and restricted stock units may negatively affect our ability to complete future equity financings at acceptable prices and on acceptable terms. The exercise of those options and settlement of the restricted stock units, and the prompt resale of shares of our common stock received, may also result in downward pressure on the price of our common stock. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the absence of a significant strategic transaction, we will need to raise significant additional capital to finance the research, development and commercialization of rNAPc2and Gencaro. If future securities offerings occur, they would dilute our current stockholders&#8217; equity interests and could reduce the market price of our common stock</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have implemented anti-takeover provisions that could discourage, prevent or delay a takeover, even if the acquisition would be beneficial to our stockholders.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions of our certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us, even if doing so would benefit our stockholders. These provisions: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:99.4%;">
<tr>
<td style="width:4.56%;"></td>
<td style="width:2.72%;"></td>
<td style="width:1.69%;"></td>
<td style="width:90.44%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">establish a classified board of directors so that not all members of our board may be elected at one time; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:99.4%;">
<tr>
<td style="width:4.37%;"></td>
<td style="width:2.72%;"></td>
<td style="width:1.69%;"></td>
<td style="width:90.63%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">authorize the issuance of up to approximately 5 million additional shares of preferred stock that could be issued by our board of directors to increase the number of outstanding shares and hinder a takeover attempt; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:99.4%;">
<tr>
<td style="width:4.4%;"></td>
<td style="width:2.72%;"></td>
<td style="width:1.69%;"></td>
<td style="width:90.6%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">limit who may call a special meeting of stockholders; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:99.4%;">
<tr>
<td style="width:4.4%;"></td>
<td style="width:2.72%;"></td>
<td style="width:1.69%;"></td>
<td style="width:90.6%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prohibit stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our stockholders; and </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:99.4%;">
<tr>
<td style="width:4.41%;"></td>
<td style="width:2.72%;"></td>
<td style="width:1.69%;"></td>
<td style="width:90.59%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">establish advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted upon at a stockholder meeting. </p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Specifically, our certificate of incorporation provides that all stockholder action must be effected at a duly called meeting and not by a written consent. The bylaws provide, however, that our stockholders may call a special meeting of stockholders only upon a request of stockholders owning at least 50% of our outstanding common stock. These provisions of our certificate of incorporation and bylaws could discourage potential acquisition proposals and could delay or prevent a change in control. We designed these provisions to reduce our vulnerability to unsolicited acquisition proposals and to discourage certain tactics that may be used in proxy fights. These provisions, however, could also have the effect of discouraging others from making tender offers for our shares. As a consequence, they also may inhibit fluctuations in the market price of our shares that could result from actual or rumored takeover attempts. Such provisions also may have the effect of preventing changes in our management. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are permitted to issue shares of our preferred stock without stockholder approval upon such terms as our board of directors determines. Therefore, the rights of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of our preferred stock that may be issued in the future. In addition, the issuance of preferred stock could have a dilutive effect on the holdings of our current stockholders. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to the Delaware anti-takeover laws regulating corporate takeovers. These anti-takeover laws prevent a Delaware corporation from engaging in a merger or sale of more than 10% of its assets with any stockholder, including all affiliates and associates of the stockholder, who owns 15% or more of the corporation<font style="color:#000000;">&#8217;</font>s outstanding voting stock, for three years following the date that the stockholder acquired 15% or more of the corporation<font style="color:#000000;">&#8217;</font>s stock unless: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:99.4%;">
<tr>
<td style="width:4.37%;"></td>
<td style="width:2.72%;"></td>
<td style="width:1.69%;"></td>
<td style="width:90.63%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the board of directors approved the transaction where the stockholder acquired 15% or more of the corporation<font style="color:#000000;">&#8217;</font>s stock; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:99.4%;">
<tr>
<td style="width:4.38%;"></td>
<td style="width:2.72%;"></td>
<td style="width:1.69%;"></td>
<td style="width:90.62%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-size:10pt;color:#000000;">&#160;</font></p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">after the transaction in which the stockholder acquired 15% or more of the corporation<font style="color:#000000;">&#8217;</font>s stock, the stockholder owned at least 85% of the corporation<font style="color:#000000;">&#8217;</font>s outstanding voting stock, excluding shares owned by directors, officers and employee stock plans in which employee participants do not have the right to determine confidentially whether shares held under the plan will be tendered in a tender or exchange offer; or </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:99.4%;">
<tr>
<td style="width:4.44%;"></td>
<td style="width:2.72%;"></td>
<td style="width:1.69%;"></td>
<td style="width:90.56%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on or after this date, the merger or sale is approved by the board of directors and the holders of at least two-thirds of the outstanding voting stock that is not owned by the stockholder. </p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The provisions of our governing documents and current Delaware law may collectively: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:99.4%;">
<tr>
<td style="width:4.56%;"></td>
<td style="width:2.72%;"></td>
<td style="width:1.69%;"></td>
<td style="width:90.44%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lengthen the time required for a person or entity to acquire control of us through a proxy contest for the election of a majority of our board of directors; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:99.4%;">
<tr>
<td style="width:4.5%;"></td>
<td style="width:2.72%;"></td>
<td style="width:1.69%;"></td>
<td style="width:90.5%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">discourage bids for our common stock at a premium over market price; and </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:99.4%;">
<tr>
<td style="width:4.56%;"></td>
<td style="width:2.72%;"></td>
<td style="width:1.69%;"></td>
<td style="width:90.44%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">generally deter efforts to obtain control of us. </p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Terms of subsequent financings may adversely impact our stockholders.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To finance our future business plans and working capital needs, including to complete our ongoing clinical trial of rNAPc2 (AB201), we will have to raise funds through the issuance of equity or debt securities in addition to sales in this offering. Depending on the type and the terms of any financing we pursue, stockholders&#8217; rights and the value of their investment in our common stock and the warrants could be reduced. A financing could involve one or more types of securities including common stock, convertible debt or warrants to acquire common stock. These securities could be issued at or below the then prevailing market price for our common stock. In addition, if we issue secured debt securities, the holders of the debt would have a claim to our assets that would be senior to the rights of stockholders until the debt is paid. Interest on these debt securities would increase costs and negatively impact operating results. If the issuance of new securities results in diminished rights to holders of our common stock, the market price of our common stock could be negatively impacted and the value of the warrants could decline.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our management might apply the net proceeds from this offering in ways with which you do not agree and in ways that may impair the value of your investment. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently intend to use the net proceeds from the sale of the securities under this prospectus for our <font style="color:#000000;">clinical trial of rNAPc2</font> and for working capital and general corporate purposes, including research and development expenses and general and administrative expenses. Our management has broad discretion as to the use of these proceeds and you will be relying on the judgment of our management regarding the application of these proceeds. We might apply these proceeds in ways with which you do not agree, or in ways that do not yield a favorable return. If our management applies these proceeds in a manner that does not yield a significant return, if any, on our investment of these net proceeds, it could compromise our ability to pursue our growth strategy and adversely affect the market price of our common stock. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="FORWARDLOOKING_STATEMENTS"></a><a name="FORWARDLOOKING_STATEMENTS"></a>FORWARD-LOOKING STATEMENTS </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This prospectus supplement and accompanying prospectus, the documents incorporated by reference and any free writing prospectus that we have authorized for use in connection with this offering contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These are based on our management<font style="color:#000000;">&#8217;</font>s current beliefs, expectations and assumptions about future events, conditions and results and on information currently available to us. Discussions containing these forward-looking statements may be found, among other places, in the Sections entitled <font style="color:#000000;">&#8220;</font>Business,<font style="color:#000000;">&#8221;</font> <font style="color:#000000;">&#8220;</font>Risk Factors<font style="color:#000000;">&#8221;</font> and <font style="color:#000000;">&#8220;</font>Management<font style="color:#000000;">&#8217;</font>s Discussion and Analysis of Financial Condition and Results of Operations<font style="color:#000000;">&#8221;</font> incorporated by reference from our most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as any amendments thereto, filed with the SEC. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any statements in this prospectus supplement and accompanying prospectus or incorporated herein, about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. While we believe that we have a reasonable basis for each forward-looking statement contained in this prospectus supplement and accompanying prospectus, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result of these factors, we cannot assure you that the forward-looking statements in this prospectus supplement and accompanying prospectus or documents incorporated by reference will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this prospectus supplement. You should read this prospectus supplement and accompanying prospectus and the documents incorporated by reference completely and with the understanding that our actual future results may be materially different from what we expect. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These forward-looking statements include, but are not limited to, statements regarding: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:99.4%;">
<tr>
<td style="width:4.46%;"></td>
<td style="width:2.72%;"></td>
<td style="width:1.69%;"></td>
<td style="width:90.54%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the timing and results of any clinical trials, including potential future clinical trials of rNAPc2, the potential for rNAPc2 to treat COVID-19, the potential for rNAPc2 to be the first novel anticoagulant and inhibitor of tissue factor for the treatment of COVID-19, rNAPc2&#8217;s potential use in combination with other antiviral drugs, future treatment options for patients with COVID-19, rNAPc2&#8217;s potential for future viral outbreaks beyond the current COVID-19 pandemic , and the ability to fund clinical trials and research of rNAPc2; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:99.4%;">
<tr>
<td style="width:4.51%;"></td>
<td style="width:2.72%;"></td>
<td style="width:1.69%;"></td>
<td style="width:90.49%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our ability to resume and fund PRECISION-AF clinical trials in the future as well as the potential for genetic variations to predict individual patient response to Gencaro, Gencaro<font style="color:#000000;">&#8217;</font>s potential to treat AF, future treatment options for patients with AF, the potential for Gencaro to be the first genetically-targeted atrial fibrillation prevention treatment;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our expectations regarding the potential impact of rNAPc2, Gencaro, and future treatment options for patients with AF;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:99.4%;">
<tr>
<td style="width:4.51%;"></td>
<td style="width:2.72%;"></td>
<td style="width:1.69%;"></td>
<td style="width:90.49%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our ability to obtain U.S. and foreign regulatory approval for our product candidates and the ability of our product candidates to meet existing or future regulatory standards;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:99.4%;">
<tr>
<td style="width:4.39%;"></td>
<td style="width:2.72%;"></td>
<td style="width:1.69%;"></td>
<td style="width:90.61%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our expectations regarding federal, state and foreign regulatory requirements; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:99.4%;">
<tr>
<td style="width:4.41%;"></td>
<td style="width:2.72%;"></td>
<td style="width:1.69%;"></td>
<td style="width:90.59%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the therapeutic benefits and effectiveness of our product candidates; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:99.4%;">
<tr>
<td style="width:4.37%;"></td>
<td style="width:2.72%;"></td>
<td style="width:1.69%;"></td>
<td style="width:90.63%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the accuracy of our estimates of the size and characteristics of the markets that may be addressed by our product candidates; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:99.4%;">
<tr>
<td style="width:4.47%;"></td>
<td style="width:2.72%;"></td>
<td style="width:1.69%;"></td>
<td style="width:90.53%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our ability to obtain sufficient or additional funding or enter into a strategic or other transaction; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:99.4%;">
<tr>
<td style="width:4.46%;"></td>
<td style="width:2.72%;"></td>
<td style="width:1.69%;"></td>
<td style="width:90.54%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the extent to which our issued and pending patents may protect our products and technology; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:99.4%;">
<tr>
<td style="width:4.42%;"></td>
<td style="width:2.72%;"></td>
<td style="width:1.69%;"></td>
<td style="width:90.58%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the potential of such product candidates to lead to the development of safe or effective therapies; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:99.4%;">
<tr>
<td style="width:4.35%;"></td>
<td style="width:2.72%;"></td>
<td style="width:1.69%;"></td>
<td style="width:90.65%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our ability to enter into collaborations; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:99.4%;">
<tr>
<td style="width:4.53%;"></td>
<td style="width:2.72%;"></td>
<td style="width:1.69%;"></td>
<td style="width:90.47%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our ability to maintain listing of our common stock on a national exchange; </p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:99.4%;">
<tr>
<td style="width:4.4%;"></td>
<td style="width:2.72%;"></td>
<td style="width:1.69%;"></td>
<td style="width:90.6%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our future operating expenses, our future losses, our future expenditures, and the sufficiency of our cash resources to maintain operations; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:99.4%;">
<tr>
<td style="width:4.46%;"></td>
<td style="width:2.72%;"></td>
<td style="width:1.69%;"></td>
<td style="width:90.54%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our ability to compete with other companies that are or may be developing or selling products that are competitive with our product candidates; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:99.4%;">
<tr>
<td style="width:4.5%;"></td>
<td style="width:2.72%;"></td>
<td style="width:1.69%;"></td>
<td style="width:90.5%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">anticipated trends and challenges in our potential markets; and </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:99.4%;">
<tr>
<td style="width:4.52%;"></td>
<td style="width:2.72%;"></td>
<td style="width:1.69%;"></td>
<td style="width:90.48%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our ability to attract and retain key personnel. </p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some cases, you can identify forward-looking statements by the words <font style="color:#000000;">&#8220;</font>may,<font style="color:#000000;">&#8221;</font> <font style="color:#000000;">&#8220;</font>might,<font style="color:#000000;">&#8221;</font> <font style="color:#000000;">&#8220;</font>can,<font style="color:#000000;">&#8221;</font> <font style="color:#000000;">&#8220;</font>will,<font style="color:#000000;">&#8221;</font> <font style="color:#000000;">&#8220;</font>to be,<font style="color:#000000;">&#8221;</font> <font style="color:#000000;">&#8220;</font>could,<font style="color:#000000;">&#8221;</font> <font style="color:#000000;">&#8220;</font>would,<font style="color:#000000;">&#8221;</font> <font style="color:#000000;">&#8220;</font>should,<font style="color:#000000;">&#8221;</font> <font style="color:#000000;">&#8220;</font>expect,<font style="color:#000000;">&#8221;</font> <font style="color:#000000;">&#8220;</font>intend,<font style="color:#000000;">&#8221;</font> <font style="color:#000000;">&#8220;</font>plan,<font style="color:#000000;">&#8221;</font> <font style="color:#000000;">&#8220;</font>objective,<font style="color:#000000;">&#8221;</font> <font style="color:#000000;">&#8220;</font>anticipate,<font style="color:#000000;">&#8221;</font> <font style="color:#000000;">&#8220;</font>believe,<font style="color:#000000;">&#8221;</font> <font style="color:#000000;">&#8220;</font>estimate,<font style="color:#000000;">&#8221;</font> <font style="color:#000000;">&#8220;</font>predict,<font style="color:#000000;">&#8221;</font> <font style="color:#000000;">&#8220;</font>project,<font style="color:#000000;">&#8221;</font> <font style="color:#000000;">&#8220;</font>potential,<font style="color:#000000;">&#8221;</font> <font style="color:#000000;">&#8220;</font>likely,<font style="color:#000000;">&#8221;</font> <font style="color:#000000;">&#8220;</font>continue<font style="color:#000000;">&#8221;</font> and <font style="color:#000000;">&#8220;</font>ongoing,<font style="color:#000000;">&#8221;</font> or the negative of these terms, or other comparable terminology intended to identify statements about the future, although not all forward-looking statements contain these words. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You should refer to the <font style="color:#000000;">&#8220;</font>Risk Factors<font style="color:#000000;">&#8221;</font> section, or under similar heading, contained in this prospectus supplement, accompanying prospectus, the documents incorporated by reference and any related free writing prospectus for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to revise any forward-looking statements to reflect events or developments occurring after the date of this prospectus supplement, even if new information becomes available in the future. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="USE_PROCEEDS"></a><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-13</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;"><a name="USE_PROCEEDS"></a>USE OF PR</font><font style="font-weight:bold;font-size:10pt;">OCEEDS</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the terms of the Sales Agreement, we may issue and sell shares of our common stock from time to time through or to JonesTrading, acting as sales agent or principal. Because there is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. There can be no assurance that we will sell any shares under or fully utilize the Sales Agreement with JonesTrading as a source of financing. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to use the net proceeds from the sale of the common stock under this prospectus supplement and accompanying prospectus for<font style="letter-spacing:-0.25pt;"> </font><font style="letter-spacing:-0.1pt;">w</font><font style="letter-spacing:-0.05pt;">ork</font><font style="letter-spacing:0.05pt;">i</font><font style="letter-spacing:-0.25pt;">n</font>g<font style="letter-spacing:0.1pt;"> </font><font style="letter-spacing:-0.2pt;">c</font><font style="letter-spacing:0.05pt;">a</font><font style="letter-spacing:-0.05pt;">p</font><font style="letter-spacing:-0.2pt;">i</font><font style="letter-spacing:0.05pt;">t</font><font style="letter-spacing:-0.2pt;">a</font>l<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:0.05pt;">a</font><font style="letter-spacing:-0.25pt;">n</font>d<font style="letter-spacing:0.1pt;"> </font><font style="letter-spacing:-0.05pt;">g</font><font style="letter-spacing:-0.2pt;">e</font>n<font style="letter-spacing:-0.2pt;">e</font>r<font style="letter-spacing:0.05pt;">a</font>l <font style="letter-spacing:-0.2pt;">c</font><font style="letter-spacing:-0.05pt;">orpor</font><font style="letter-spacing:-0.2pt;">a</font><font style="letter-spacing:0.05pt;">t</font>e<font style="letter-spacing:-0.05pt;"> p</font><font style="letter-spacing:-0.25pt;">u</font><font style="letter-spacing:-0.05pt;">rpo</font><font style="letter-spacing:-0.1pt;">s</font><font style="letter-spacing:0.05pt;">e</font><font style="letter-spacing:-0.1pt;">s, including research and development expenses and general and administrative expenses</font>. We believe the amount raised in this offering will allow us to fund our clinical trial, including costs for clinical study drug, site selection, and contract research organization, or CRO,<font style="font-weight:bold;font-style:italic;"> </font>selection and patient enrollment. We may also use a portion of the net proceeds and our existing cash and cash equivalents to in-license, acquire, or invest in businesses, technologies, products or assets; however, we have no current plans, commitments or obligations to do so. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our expected use of proceeds from this offering described above represents our current intentions based on our present plans and business condition. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the proceeds to be received upon the closing of this offering or the actual amounts that we will spend on the uses set forth above. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="DILUTION"></a><a name="DILUTION"></a>DILUTION </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our net tangible book value as of December 31, 2020 was approximately $46.5 million, or $4.87 per share. Net tangible book value per share is determined by dividing our total tangible assets, less total liabilities, by the number of shares of our common stock outstanding as of December 31, 2020. Dilution with respect to net tangible book value per share represents the difference between the amount per share paid by purchasers of shares of common stock in this offering and the net tangible book value per share of our common stock immediately after this offering. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After giving effect to the sale of 13,297,872 shares of our common stock in this offering at an assumed offering price of $3.76 per share, the last reported sale price of our common stock on the Exchange on April&#160;1, 2021, and after deducting estimated offering commissions and offering expenses payable by us, our as adjusted net tangible book value as of December&#160;31,&#160;2020 would have been approximately $95.0 million, or $4.16 per share. This represents a $0.71 decrease in our net tangible book value per share, and immediate dilution of $(0.40) per share to investors purchasing our common stock in this offering at the assumed public offering price. The following table illustrates this dilution on a per share basis: </p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assumed public offering price per share</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.76</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net tangible book value per share as of December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.87</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Decrease in net tangible book value per share attributable to this offering</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.71</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.36%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As adjusted net tangible book value per share as of December 31, 2020, after</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; giving effect to this offering</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.16</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dilution per share to investors purchasing our common stock in this offering</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.36%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.40</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The above discussion and table are based on 9,548,150 shares of our common stock outstanding as of December 31, 2020 and excludes: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:99.4%;">
<tr>
<td style="width:4.47%;"></td>
<td style="width:2.72%;"></td>
<td style="width:1.69%;"></td>
<td style="width:90.53%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">531,238 shares of our common stock issuable upon the exercise of stock options outstanding as of December&#160;31,&#160;2020, at a weighted average exercise price of $8.71 per share; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:99.4%;">
<tr>
<td style="width:4.47%;"></td>
<td style="width:2.72%;"></td>
<td style="width:1.69%;"></td>
<td style="width:90.53%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133,401 shares of our common stock issuable upon exercise of warrants outstanding as of December&#160;31,&#160;2020, at a weighted average exercise price of $109.80 per share; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:99.4%;">
<tr>
<td style="width:4.47%;"></td>
<td style="width:2.72%;"></td>
<td style="width:1.69%;"></td>
<td style="width:90.53%;"></td>
</tr>
<tr>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">636,347 shares of our common stock reserved for issuance under our equity incentive and non-employee director stock award plans as of December&#160;31,&#160;2020; and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:99.4%;">
<tr>
<td style="width:4.47%;"></td>
<td style="width:2.72%;"></td>
<td style="width:1.69%;"></td>
<td style="width:90.53%;"></td>
</tr>
<tr>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,861,993 shares of our common stock issued pursuant to &#8220;at the market offerings&#8221; from January 1, 2021 through February 22, 2021. </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table above assumes for illustrative purposes that an aggregate of 13,297,872 shares of our common stock are sold during the term of the Sales Agreement with JonesTrading at a price of $3.76 per share, the last reported sale price of our common stock on the Exchange on April&#160;1, 2021, for aggregate gross proceeds of $50,000,000. The shares subject to the Sales Agreement with JonesTrading are being sold from time to time at various prices. An increase of $1.00 per share in the price at which the shares are sold from the assumed offering price of $3.76 per share shown in the table above, assuming all of our common stock in the aggregate amount of $50,000,000 during the term of the Sales Agreement with JonesTrading is sold at that price, would increase our adjusted net tangible book value per share after the offering to $4.74 per share and would increase the dilution in net tangible book value per share to new investors in this offering to $0.02 per share, after deducting commissions and estimated aggregate offering expenses payable by us. A decrease of $1.00 per share in the price at which the shares are sold from the assumed offering price of $3.76 per share shown in the table above, assuming all of our common stock in the aggregate amount of $50,000,000 during the term of the Sales Agreement with JonesTrading is sold at that price, would decrease our adjusted net tangible book value per share after the offering to $3.43 per share and would decrease the dilution in net tangible book value per share to new investors in this offering to $(0.67) per share, after deducting commissions and estimated aggregate offering expenses payable by us. This information is supplied for illustrative purposes only. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-15</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that options or warrants outstanding as of December&#160;31,&#160;2020 have been or may be exercised or other shares issued, investors purchasing our common stock in this offering may experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-16</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="PLAN_DISTRIBUTION"></a><a name="PLAN_DISTRIBUTION"></a>PLAN OF DISTRIBUTION</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">On April 6, 2021, we entered into an amendment, or the Amendment No. 1, to our Capital on Demand&#8482; Sales Agreement, dated July 22, 2020 with JonesTrading Institutional Services LLC, or JonesTrading, or the Original Agreement and, together with the Amendment No. 1, the Sales Agreement, relating to shares of our common stock, $0.001 par value per share, offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the Sales Agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $50,000,000 from time to time through or to JonesTrading, acting as our agent or principal.</font><font style="color:#000000;"> Sales of our common stock, if any, under this prospectus supplement and accompanying prospectus may be made in sales deemed to be </font>&#8220;<font style="color:#000000;">at the market offerings</font>&#8221;<font style="color:#000000;"> as defined in Rule 415 promulgated under the Securities Act. The Original Agreement has previously been filed as an exhibit to our Current Report on Form 8-K filed with the SEC on July&#160;22, 2020.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each time we wish to issue and sell common stock, we will notify JonesTrading of the number of shares to be issued, the dates on which such sales are anticipated to be made, any minimum price below which sales may not be made and other sales parameters as we deem appropriate. Once we have so instructed JonesTrading, unless JonesTrading declines to accept the terms of the notice, JonesTrading has agreed, subject to the terms and conditions of the Sales Agreement, to use its commercially reasonable efforts consistent with its normal trading and sales practices to sell such shares up to the amount specified on such terms. We may instruct JonesTrading not to sell shares of common stock if the sales cannot be effected at or above the price designated by us in any such instruction. We or JonesTrading may suspend the offering of shares of common stock being made through JonesTrading under the Sales Agreement upon proper notice to the other party. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will pay JonesTrading commissions for its services in acting as agent in the sale of our common stock. JonesTrading will be entitled to compensation at a commission rate equal to 3.0% of the aggregate gross sales price of the shares sold. Because there is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. We estimate that the total expenses for this offering (inclusive of expenses paid in connection with entering into the Sales Agreement), excluding compensation and reimbursements payable to JonesTrading under the terms of the Sales Agreement, will be approximately $65,000. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Settlement for sales of common stock will occur on the second business day following the date on which any sales are made or such earlier day as is industry practice for regular-way trading, or on some other date that is agreed upon by us and JonesTrading in connection with a particular transaction, in return for payment of the net proceeds to us. There is no arrangement for funds to be received in an escrow, trust or similar arrangement. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the sale of the common stock on our behalf, JonesTrading will be deemed to be an <font style="color:#000000;">&#8220;</font>underwriter<font style="color:#000000;">&#8221;</font> within the meaning of the Securities Act and the compensation of JonesTrading will be deemed to be underwriting commissions or discounts. We have agreed to provide indemnification and contribution to JonesTrading against certain civil liabilities, including liabilities under the Securities Act. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock is listed on the Exchange and trades under the symbol <font style="color:#000000;">&#8220;</font>ABIO.<font style="color:#000000;">&#8221;</font> The transfer agent of our common stock is Computershare Trust Company, N.A. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JonesTrading and/or its affiliates have in the past and may in the future provide various investment banking and other financial services for us for which services they may in the future receive customary fees. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-17</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;">&nbsp;</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="LEGAL_MATTERS"></a><a name="LEGAL_MATTERS"></a>LEGAL MATTERS </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The validity of the common stock offered by this prospectus supplement will be passed upon by Cooley LLP, Broomfield, Colorado. Duane Morris LLP, New York, New York, is counsel for JonesTrading in connection with this offering. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="EXPERTS"></a><a name="EXPERTS"></a>EXPERTS </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial statements of ARCA biopharma, Inc. as of December 31, 2020 and 2019, and for the years then ended, have been incorporated by reference herein and in the registration statement in reliance upon the report of KPMG LLP, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="WHERE_YOU_CAN_FIND_MORE_INFORMATION"></a><a name="WHERE_YOU_CAN_FIND_MORE_INFORMATION"></a>WHERE YOU CAN FIND MORE INFORMATION </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This prospectus supplement and accompanying prospectus is part of a registration statement on Form S-3 we filed with the SEC. This prospectus supplement and accompanying prospectus does not contain all of the information set forth in the registration statement or the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus supplement and accompanying prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Whenever a reference is made in this prospectus supplement or accompanying prospectus to any of our contracts, agreements or other documents, the reference may not be complete and you should refer to the exhibits that are a part of the registration statement or the exhibits to the reports or other documents incorporated by reference into this prospectus supplement and accompanying prospectus for a copy of such contract, agreement or other document. You should rely only on the information contained in this prospectus supplement, accompanying prospectus or incorporated by reference. We have not authorized anyone else to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus supplement or accompanying prospectus is accurate as of any date other than the date on the front page of this prospectus supplement or the date on the front page of the accompanying prospectus, as applicable, regardless of the time of delivery of this prospectus supplement and accompanying prospectus or any sale of the securities offered by this prospectus supplement and accompanying prospectus. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC&#8217;s website that contains reports, proxy statements and other information regarding issuers that file electronically with the SEC, including ARCA biopharma, at www.sec.gov.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including any amendments to those reports, and other information that we file with or furnish to the SEC pursuant to Section 13(a) or 15(d) of the Exchange Act can also be accessed free of charge at our website at www.arcabio.com. These filings will be available as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Information contained in or accessible through our website does not constitute a part of this prospectus supplement or accompanying prospectus. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-18</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="INCORPORATION_CERTAIN_INFORMATION_BY_REF"></a><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="INCORPORATION_CERTAIN_INFORMATION_BY_REF"></a>INCORPORATION OF CERTAIN I</font><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NFORMATION BY REFERENCE </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The SEC allows us to <font style="color:#000000;">&#8220;</font>incorporate by reference<font style="color:#000000;">&#8221;</font> information from other documents that we file with it, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus supplement and accompanying prospectus. Information in this prospectus supplement and accompanying prospectus supersedes information incorporated by reference that we filed with the SEC prior to the date of this prospectus supplement and accompanying prospectus, while information that we file later with the SEC will automatically update and supersede the information in this prospectus supplement and accompanying prospectus. We incorporate by reference into this prospectus supplement and the registration statement of which this prospectus supplement and accompanying prospectus is a part the information or documents listed below that we have filed with the SEC (Commission File No. 000-22873):&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:99.4%;">
<tr>
<td style="width:4.53%;"></td>
<td style="width:2.72%;"></td>
<td style="width:1.69%;"></td>
<td style="width:90.47%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our<font style="letter-spacing:-0.15pt;"> A</font>nnu<font style="letter-spacing:-0.2pt;">a</font>l R<font style="letter-spacing:0.05pt;">e</font>po<font style="letter-spacing:-0.25pt;">r</font>t on<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:0.15pt;">F</font><font style="letter-spacing:-0.25pt;">o</font>rm 1<font style="letter-spacing:-0.25pt;">0</font>-K<font style="letter-spacing:-0.2pt;"> </font>for<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:0.05pt;">t</font>he <font style="letter-spacing:-0.25pt;">y</font><font style="letter-spacing:0.05pt;">e</font><font style="letter-spacing:-0.2pt;">a</font>r<font style="letter-spacing:0.1pt;"> </font><font style="letter-spacing:-0.2pt;">e</font>nd<font style="letter-spacing:-0.2pt;">e</font>d<font style="letter-spacing:0.1pt;"> </font><font style="letter-spacing:-0.1pt;">D</font><font style="letter-spacing:-0.2pt;">e</font><font style="letter-spacing:0.05pt;">c</font><font style="letter-spacing:-0.2pt;">e</font><font style="letter-spacing:0.05pt;">m</font><font style="letter-spacing:-0.25pt;">b</font><font style="letter-spacing:0.05pt;">e</font>r<font style="letter-spacing:-0.1pt;"> </font>31, 2<font style="letter-spacing:-0.25pt;">020</font>, f<font style="letter-spacing:-0.2pt;">i</font><font style="letter-spacing:0.05pt;">l</font><font style="letter-spacing:-0.2pt;">e</font>d<font style="letter-spacing:0.1pt;"> </font><font style="letter-spacing:-0.1pt;">w</font><font style="letter-spacing:-0.2pt;">i</font><font style="letter-spacing:0.05pt;">t</font>h<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:0.05pt;">t</font>he <font style="letter-spacing:-0.1pt;">S</font><font style="letter-spacing:-0.2pt;">E</font>C<font style="letter-spacing:-0.15pt;"> </font>on<font style="letter-spacing:-0.15pt;"> </font><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459021014148/abio-10k_20201231.htm"><font style="text-decoration:underline;color:#0000FF;letter-spacing:-0.15pt;">March 18, 2021</font></a><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">;</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:99.4%;">
<tr>
<td style="width:4.57%;"></td>
<td style="width:2.72%;"></td>
<td style="width:1.69%;"></td>
<td style="width:90.43%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our Current Reports on Form 8-K filed with the SEC on <a href="http://www.sec.gov/Archives/edgar/data/907654/000156459021003874/abio-8k_20210129.htm"><font style="text-decoration:underline;color:#0000FF;">February 2, 2021</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </font><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459021003874/abio-8k_20210129.htm"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459021017811/abio-8k_20210402.htm"><font style="text-decoration:underline;">April 6, 2021</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (other than any portion of such current reports furnished under Item 2.02 or Item 7.01 of Form&#160;8&#8209;K and exhibits filed on such form that are related to such items unless such Form 8-K expressly provides to the contrary); and </font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:99.4%;">
<tr>
<td style="width:4.43%;"></td>
<td style="width:2.72%;"></td>
<td style="width:1.69%;"></td>
<td style="width:90.57%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the description of our securities set forth in our annual report on Form 10-K filed with the SEC on <a href="http://www.sec.gov/Archives/edgar/data/907654/000156459020005032/abio-ex47_80.htm"><font style="text-decoration:underline;color:#0000FF;">February&#160;18,&#160;2020</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, including any amendments thereto or reports filed for the purpose of updating such description. </font></p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also incorporate by reference any future filings (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that are related to such items unless such Form 8-K expressly provides to the contrary) made with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, including (i) those made after the date of the initial filing of the registration statement of which this prospectus supplement and accompanying prospectus is a part and prior to effectiveness of such registration statement, and (ii) those made after the date of this prospectus supplement until we file a post-effective amendment that indicates the termination of the offering of the securities covered by this prospectus supplement and accompanying prospectus, and will become a part of this from the date that such documents are filed with the SEC. Information in such future filings updates and supplements the information provided in this prospectus supplement and accompanying prospectus. Any statements in any such future filings will automatically be deemed to modify and supersede any information in any document we previously filed with the SEC that is incorporated or deemed to be incorporated herein by reference to the extent that statements in the later filed document modify or replace such earlier statements. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">w</font><font style="letter-spacing:0.05pt;">i</font>ll<font style="letter-spacing:-0.05pt;"> furn</font>i<font style="letter-spacing:0.15pt;">s</font>h<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.1pt;">w</font><font style="letter-spacing:0.05pt;">i</font>t<font style="letter-spacing:-0.05pt;">hou</font>t<font style="letter-spacing:-0.05pt;"> </font>c<font style="letter-spacing:-0.05pt;">h</font>ar<font style="letter-spacing:-0.05pt;">g</font>e<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:0.05pt;">t</font>o<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.05pt;">yo</font><font style="letter-spacing:-0.25pt;">u</font>, <font style="letter-spacing:-0.05pt;">o</font>n<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.1pt;">w</font>r<font style="letter-spacing:0.05pt;">i</font>t<font style="letter-spacing:0.05pt;">te</font>n<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.05pt;">o</font>r<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.05pt;">or</font>al<font style="letter-spacing:-0.05pt;"> r</font><font style="letter-spacing:0.05pt;">e</font><font style="letter-spacing:-0.25pt;">q</font><font style="letter-spacing:-0.05pt;">u</font><font style="letter-spacing:0.05pt;">e</font><font style="letter-spacing:-0.1pt;">s</font>t, a<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:0.05pt;">c</font><font style="letter-spacing:-0.05pt;">o</font><font style="letter-spacing:-0.25pt;">p</font>y<font style="letter-spacing:0.1pt;"> </font><font style="letter-spacing:-0.25pt;">o</font>f<font style="letter-spacing:0.1pt;"> </font>a<font style="letter-spacing:-0.05pt;">n</font>y<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.05pt;">o</font>r<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:0.05pt;">al</font>l<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.25pt;">o</font>f<font style="letter-spacing:0.1pt;"> </font>t<font style="letter-spacing:-0.05pt;">h</font>e reports or<font style="letter-spacing:-0.05pt;"> do</font>c<font style="letter-spacing:-0.05pt;">u</font>m<font style="letter-spacing:0.05pt;">e</font><font style="letter-spacing:-0.05pt;">n</font>ts<font style="letter-spacing:0.05pt;"> i</font><font style="letter-spacing:-0.25pt;">n</font><font style="letter-spacing:0.05pt;">c</font><font style="letter-spacing:-0.05pt;">or</font><font style="letter-spacing:-0.25pt;">p</font><font style="letter-spacing:-0.05pt;">or</font><font style="letter-spacing:0.05pt;">a</font>t<font style="letter-spacing:0.05pt;">e</font>d<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.05pt;">b</font>y<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.05pt;">r</font>e<font style="letter-spacing:-0.05pt;">f</font><font style="letter-spacing:0.05pt;">e</font><font style="letter-spacing:-0.05pt;">r</font><font style="letter-spacing:-0.15pt;">e</font><font style="letter-spacing:-0.05pt;">n</font>c<font style="letter-spacing:0.05pt;">e</font>, <font style="letter-spacing:0.05pt;">i</font><font style="letter-spacing:-0.25pt;">n</font><font style="letter-spacing:0.05pt;">c</font>l<font style="letter-spacing:-0.05pt;">ud</font><font style="letter-spacing:0.05pt;">i</font><font style="letter-spacing:-0.05pt;">n</font>g<font style="letter-spacing:-0.15pt;"> </font>e<font style="letter-spacing:-0.05pt;">xh</font><font style="letter-spacing:0.05pt;">i</font><font style="letter-spacing:-0.25pt;">b</font><font style="letter-spacing:0.05pt;">it</font>s <font style="letter-spacing:0.05pt;">t</font>o<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:0.05pt;">t</font><font style="letter-spacing:-0.25pt;">h</font><font style="letter-spacing:0.05pt;">e</font><font style="letter-spacing:-0.1pt;">s</font>e<font style="letter-spacing:-0.05pt;"> do</font>c<font style="letter-spacing:-0.05pt;">u</font>m<font style="letter-spacing:0.05pt;">e</font><font style="letter-spacing:-0.05pt;">n</font>t<font style="letter-spacing:0.15pt;">s</font>.<font style="letter-spacing:-0.25pt;"> </font><font style="letter-spacing:-0.1pt;">Y</font><font style="letter-spacing:-0.05pt;">o</font>u<font style="letter-spacing:0.1pt;"> </font><font style="letter-spacing:-0.1pt;">s</font><font style="letter-spacing:-0.05pt;">h</font><font style="letter-spacing:-0.25pt;">o</font><font style="letter-spacing:-0.05pt;">u</font><font style="letter-spacing:0.05pt;">l</font>d<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.05pt;">d</font><font style="letter-spacing:0.05pt;">i</font><font style="letter-spacing:-0.25pt;">r</font><font style="letter-spacing:0.05pt;">e</font>ct<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:0.05pt;">a</font><font style="letter-spacing:-0.05pt;">n</font>y<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.05pt;">r</font>e<font style="letter-spacing:-0.05pt;">qu</font>e<font style="letter-spacing:0.15pt;">s</font>ts<font style="letter-spacing:0.05pt;"> </font><font style="letter-spacing:-0.05pt;">fo</font>r<font style="letter-spacing:-0.1pt;"> </font><font style="letter-spacing:-0.05pt;">do</font>c<font style="letter-spacing:-0.05pt;">u</font>m<font style="letter-spacing:0.05pt;">e</font><font style="letter-spacing:-0.05pt;">n</font>ts<font style="letter-spacing:0.05pt;"> </font>to<font style="letter-spacing:0.1pt;"> </font><font style="letter-spacing:-0.1pt;">A</font><font style="letter-spacing:-0.05pt;">RC</font>A <font style="letter-spacing:-0.05pt;">b</font><font style="letter-spacing:0.05pt;">i</font><font style="letter-spacing:-0.25pt;">o</font><font style="letter-spacing:-0.05pt;">ph</font><font style="letter-spacing:0.05pt;">a</font><font style="letter-spacing:-0.25pt;">r</font><font style="letter-spacing:0.05pt;">m</font>a, <font style="letter-spacing:-0.05pt;">In</font>c<font style="letter-spacing:0.1pt;">.</font>, Attention: Secretary, 10170 Church Ranch Way, Suite 100, Westminster, <font style="letter-spacing:-0.05pt;">C</font>O <font style="letter-spacing:-0.05pt;">80021</font>;<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:0.05pt;">te</font>l<font style="letter-spacing:0.05pt;">e</font><font style="letter-spacing:-0.25pt;">p</font><font style="letter-spacing:-0.05pt;">hon</font>e:<font style="letter-spacing:-0.05pt;"> (720</font>)<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.05pt;">940-</font><font style="letter-spacing:-0.25pt;">2</font><font style="letter-spacing:-0.05pt;">200; investors@arcabio.com.&nbsp;&nbsp;The documents outlined above are also available on our website at </font><font style="text-decoration:underline;color:#0000FF;">https://arcabio.com/investors/sec-filings/</font>. <font style="letter-spacing:-0.05pt;">Ou</font>r<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.05pt;">w</font><font style="letter-spacing:0.05pt;">e</font><font style="letter-spacing:-0.05pt;">bs</font>i<font style="letter-spacing:0.05pt;">t</font>e, <font style="letter-spacing:0.05pt;">a</font><font style="letter-spacing:-0.05pt;">n</font>d<font style="letter-spacing:-0.15pt;"> </font>t<font style="letter-spacing:-0.05pt;">h</font>e<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:0.05pt;">i</font><font style="letter-spacing:-0.05pt;">nf</font><font style="letter-spacing:-0.25pt;">o</font><font style="letter-spacing:-0.05pt;">r</font><font style="letter-spacing:0.05pt;">m</font>a<font style="letter-spacing:0.05pt;">t</font>i<font style="letter-spacing:-0.05pt;">o</font>n<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:0.05pt;">c</font><font style="letter-spacing:-0.05pt;">on</font>t<font style="letter-spacing:0.05pt;">a</font>i<font style="letter-spacing:-0.05pt;">n</font><font style="letter-spacing:0.05pt;">e</font>d<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.05pt;">o</font>n<font style="letter-spacing:-0.15pt;"> </font>t<font style="letter-spacing:-0.05pt;">h</font>e<font style="letter-spacing:-0.05pt;"> w</font><font style="letter-spacing:0.05pt;">e</font><font style="letter-spacing:-0.05pt;">bs</font>i<font style="letter-spacing:0.05pt;">t</font>e, <font style="letter-spacing:0.05pt;">i</font>s <font style="letter-spacing:-0.05pt;">no</font>t<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:0.05pt;">i</font><font style="letter-spacing:-0.05pt;">n</font>c<font style="letter-spacing:-0.05pt;">orp</font><font style="letter-spacing:-0.25pt;">o</font>r<font style="letter-spacing:0.05pt;">a</font>t<font style="letter-spacing:0.05pt;">e</font>d<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:0.05pt;">i</font><font style="letter-spacing:-0.05pt;">n</font>to<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:0.05pt;">a</font><font style="letter-spacing:-0.05pt;">n</font>d<font style="letter-spacing:-0.15pt;"> </font>are <font style="letter-spacing:-0.05pt;">no</font>t<font style="letter-spacing:-0.05pt;"> p</font>a<font style="letter-spacing:-0.05pt;">r</font>t<font style="letter-spacing:-0.05pt;"> o</font>f<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:0.05pt;">t</font><font style="letter-spacing:-0.25pt;">h</font><font style="letter-spacing:0.05pt;">i</font>s<font style="letter-spacing:0.05pt;"> </font><font style="letter-spacing:-0.25pt;">p</font>r<font style="letter-spacing:-0.05pt;">o</font><font style="letter-spacing:-0.1pt;">s</font><font style="letter-spacing:-0.05pt;">p</font><font style="letter-spacing:0.05pt;">e</font>c<font style="letter-spacing:0.05pt;">t</font><font style="letter-spacing:-0.05pt;">u</font><font style="letter-spacing:-0.1pt;">s</font>. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This prospectus supplement and accompanying prospectus is part of a registration statement we filed with the SEC. That registration statement and the exhibits filed along with the registration statement contain more information about us and the shares in this offering. Because information about documents referred to in this prospectus supplement and accompanying prospectus is not always complete, you should read the full documents which are filed as exhibits to the registration statement. You may read and copy the full registration statement and its exhibits at the SEC<font style="color:#000000;">&#8217;</font>s public reference rooms or its website. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-19</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PROSPECTUS</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gp5m5bivuamv000003.jpg" title="" alt="" style="width:196px;height:77px;"></p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$150,000,000</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Debt Securities</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may offer and sell up to $150,000,000 of any combination of the securities described in this prospectus, either individually or in combination with other securities. We may also offer common stock or preferred stock upon conversion of debt securities, common stock upon conversion of preferred stock, or common stock, preferred stock or debt securities upon the exercise of warrants.</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This prospectus provides a general description of securities we may offer. Each time we offer and sell securities, we will provide the specific terms of these offerings and securities in one or more supplements to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free writing prospectus may also add, update or change information contained in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as the documents incorporated by reference, before buying any of the securities being offered.</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock is listed on The NASDAQ Capital Market under the trading symbol &#8220;ABIO.&#8221; On March&#160;18,&#160;2021, the last reported sale price of our common stock was $4.06 per share. The applicable prospectus supplement will contain information, where applicable, as to other listings, if any, on The NASDAQ Capital Market or other securities exchange of the securities covered by the applicable prospectus supplement.</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.14%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INVESTING IN OUR SECURITIES INVOLVES A HIGH DEGREE OF RISK. YOU SHOULD REVIEW CAREFULLY THE RISKS AND UNCERTAINTIES DESCRIBED UNDER THE HEADING &#8220;RISK FACTORS&#8221; CONTAINED IN THE APPLICABLE PROSPECTUS SUPPLEMENT AND IN ANY FREE WRITING PROSPECTUS WE HAVE AUTHORIZED FOR USE IN CONNECTION WITH A SPECIFIC OFFERING, AND UNDER SIMILAR HEADINGS IN THE DOCUMENTS THAT ARE INCORPORATED BY REFERENCE INTO THIS PROSPECTUS AS DESCRIBED ON PAGE 34.</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.14%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THIS PROSPECTUS MAY NOT BE USED TO CONSUMMATE A SALE OF SECURITIES UNLESS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT.</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The securities may be sold directly by us to investors, through agents designated from time to time or to or through underwriters or dealers, on a continuous or delayed basis. For additional information on the methods of sale, you should refer to the section entitled &#8220;Plan of Distribution&#8221; in this prospectus. If any agents or underwriters are involved in the sale of any securities with respect to which this prospectus is being delivered, the names of such agents or underwriters and any applicable fees, commissions, discounts and over-allotment options will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds we expect to receive from such sale will also be set forth in a prospectus supplement.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.14%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The date of this prospectus is March 30, 2021.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TABLE OF CONTENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ABOUT_THIS_PROSPECTUS"><font style="text-decoration:underline;">ABOUT THIS PROSPECTUS</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PROSPECTUS_SUMMARY"><font style="text-decoration:underline;">PROSPECTUS SUMMARY</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#RISK_FACTORS_1"><font style="text-decoration:underline;">RISK FACTORS</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#FORWARDLOOKING_STATEMENTS_1"><font style="text-decoration:underline;">FORWARD-LOOKING STATEMENTS</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#USE_PROCEEDS_1"><font style="text-decoration:underline;">USE OF PROCEEDS</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#DESCRIPTION_CAPITAL_STOCK"><font style="text-decoration:underline;">DESCRIPTION OF CAPITAL STOCK</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#DESCRIPTION_DEBT_SECURITIES"><font style="text-decoration:underline;">DESCRIPTION OF DEBT SECURITIES</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#DESCRIPTION_WARRANTS"><font style="text-decoration:underline;">DESCRIPTION OF WARRANTS</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#LEGAL_OWNERSHIP_SECURITIES"><font style="text-decoration:underline;">LEGAL OWNERSHIP OF SECURITIES</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PLAN_DISTRIBUTION_1"><font style="text-decoration:underline;">PLAN OF DISTRIBUTION</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#LEGAL_MATTERS_1"><font style="text-decoration:underline;">LEGAL MATTERS</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#EXPERTS_1"><font style="text-decoration:underline;">EXPERTS</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#WHERE_YOU_CAN_FIND_MORE_INFORMATION_1"><font style="text-decoration:underline;">WHERE YOU CAN FIND MORE INFORMATION</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#INCORPORATION_CERTAIN_INFORMATION_1"><font style="text-decoration:underline;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a>.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ABOUT_THIS_PROSPECTUS"></a><a name="ABOUT_THIS_PROSPECTUS"></a>ABOUT THIS PROSPECTUS</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This prospectus is part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission, or SEC, utilizing a &#8220;shelf&#8221; registration process. Under this shelf registration process, we may offer and sell shares of our common stock and preferred stock, various series of debt securities and/or warrants to purchase any of such securities, either individually or in combination with other securities, in one or more offerings, up to an aggregate offering price of $150,000,000. This prospectus provides you with a general description of the securities we may offer.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each time we offer securities under this prospectus, we will provide a prospectus supplement that will contain more specific information about the terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change any of the information contained in this prospectus or in the documents that we have incorporated by reference into this prospectus. This prospectus, together with any applicable prospectus supplement, any related free writing prospectus and the documents incorporated by reference into this prospectus and any applicable prospectus supplement, will include all material information relating to the applicable offering. We urge you to read carefully this prospectus, any applicable prospectus supplement and any free writing prospectus we have authorized for use in connection with a specific offering, together with the information incorporated herein by reference as described under the heading &#8220;Incorporation of Certain Information by Reference,&#8221; before buying any of the securities being offered.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">This prospectus may not be used to consummate a sale of securities unless it is accompanied by a prospectus supplement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You should rely only on the information contained in, or incorporated by reference into, this prospectus and any applicable prospectus supplement, along with the information contained in any free writing prospectus we have authorized for use in connection with a specific offering. We have not authorized anyone to provide you with different or additional information. We are not making an offer to sell or seeking an offer to buy securities under this prospectus or any applicable prospectus supplement and any related free writing prospectus in any jurisdiction where the offer or sale is not permitted. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information appearing in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate only as of the date on the front of the document and any information we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus, any applicable prospectus supplement or any related free writing prospectus, or any sale of a security. Our business, financial condition, results of operations and prospects may have changed since those dates. You should read this prospectus, any accompanying prospectus supplement, the documents incorporated by reference in this prospectus, and any free writing prospectus that we have authorized for use in connection with this offering, in their entirety before making an investment decision.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the section entitled &#8220;Where You Can Find More Information.&#8221;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This prospectus incorporates by reference, and any prospectus supplement or free writing prospectus may contain and incorporate by reference, industry, statistical and market data from our own internal estimates and research as well as from industry and general publications and research, surveys and studies conducted by third parties. Industry publications, studies and surveys generally state that they have been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe that each of these studies and publications is reliable, we have not independently verified statistical, market and industry data from third-party sources. While we believe our internal company research is reliable and the market definitions are appropriate, neither such research nor these definitions have been verified by any independent source.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a>.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit or incorporated by reference to the registration statement of which this prospectus forms a part were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This prospectus and the information incorporated herein by reference include trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included or incorporated by reference into this prospectus, any applicable prospectus supplement or any related free writing prospectus are the property of their respective owners.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a>.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="PROSPECTUS_SUMMARY"></a><a name="PROSPECTUS_SUMMARY"></a>PROSPECTUS SUMMARY</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">This prospectus summary highlights selected information contained elsewhere in this prospectus or incorporated by reference in this prospectus, and does not contain all of the information that you need to consider in making your investment decision. You should carefully read the entire prospectus, the applicable prospectus supplement and any related free writing prospectus, including the risks of investing in our securities discussed under the heading &#8220;Risk Factors&#8221; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus. You should also carefully read the information incorporated by reference into this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The terms &#8220;ARCA,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar terms refer to ARCA biopharma, Inc.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. Precision medicine refers to the tailoring of medical treatment to the individual characteristics of patients, using genomic, non-genomic biomarker and other information that extends beyond routine diagnostic categorization. We believe that when implemented correctly precision medicine can enhance therapeutic response, improve patient outcomes, and reduce healthcare costs. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our lead product candidates are rNAPc2 (AB201) as a potential treatment for diseases caused by ribonucleic acid, or RNA, viruses, initially focusing on COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">rNAPc2 (AB201) for treatment of COVID-19</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recombinant Nematode Anticoagulant Protein c2, or rNAPc2 (AB201), is a protein therapeutic in clinical development as a potential treatment for patients with COVID-19. Based on its unique mechanism of action, development history and the clinical evidence from the SARS-CoV-2 pandemic, we believe rNAPc2 has potential to be a beneficial therapy for patients with this serious viral disease. We initiated a Phase 2 clinical trial of rNAPc2 as a potential treatment for patients hospitalized with COVID-19 in the fourth quarter of 2020 and are currently enrolling patients. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain patients with severe COVID-19 disease exhibit thrombotic complications and other inflammatory responses suggesting potential dysregulation of the coagulation and immune systems. rNAPc2 is a potent inhibitor of tissue factor, a cellular receptor responsible for initiation of the primary coagulation pathway and appears to be the major activator of the coagulation cascade during viral infection. Tissue factor is also implicated in the immune system inflammatory response to viral infections and in the process of viral dissemination during infection. We believe that evidence from the pandemic implicates tissue factor pathways as an important part of the COVID-19 disease process, and provides a rationale to test rNAPc2 as a potential therapeutic for COVID&#8209;19 for its anticoagulant and potential anti-inflammatory properties.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rNAPc2 was originally developed for potential use as an anticoagulant due to its inhibition of the TF-initiated coagulation process. It was evaluated for the prevention of thrombosis in Phase 1 and Phase 2 clinical studies involving over 800 subjects and demonstrated both safety and efficacy in these studies. rNAPc2 has also been investigated as a potential therapeutic for severe viral infections other than COVID-19. Research has shown that viral infections can provoke dysregulated activation of the TF pathway, resulting in abnormal systemic coagulation and related inflammation, leading to potential organ failure and mortality. For this reason, rNAPc2 was tested as a therapeutic in non-human primates, or NHPs, in studies against lethal doses of the Ebola and Marburg viruses, where it showed evidence of efficacy in the form of mortality reduction, decreases in inflammatory biomarkers and, evidence of reduced disseminated intravascular coagulation, or DIC. DIC is a serious condition that causes abnormal blood&#160;clotting&#160;throughout the body's blood vessels.</p></div></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a>.</p>
<hr style="page-break-after:always;width:100%;">
<div style="width:100%;border-top:Solid 0.75pt #000000;border-bottom:Solid 0.75pt #000000;border-left:Solid 0.75pt #000000;border-right:Solid 0.75pt #000000;">
<div style="padding-left:0.65%;padding-Right:0.65%;padding-Top:0.13%;padding-Bottom:0.13%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SARS-CoV-2 is a new coronavirus identified in late 2019 that belongs to a family of enveloped RNA viruses that include Middle East Respiratory Syndrome, or MERS, and Severe Acute Respiratory Syndrome (SARS-CoV-1), both of which caused serious human infections of the respiratory system. The disease caused by the SARS-CoV-2 virus has been designated COVID-19. Since this outbreak was first reported in late 2019, there have been over 119 million confirmed cases of COVID-19 and over 2.6&#160;million deaths worldwide attributed to the virus (as of March 2021).</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVID-19 is associated with a high incidence of both arterial and venous coagulation-related adverse events in large and small blood vessels. These include, stroke, myocardial infarction, or MI, (i.e., heart attack) and pulmonary emboli; as well as, blockage of the smaller peripheral blood vessels in the fingers/toes (COVID-digit). This syndrome is so frequently observed in COVID-19 that it has received the name of COVID-19 Associated Coagulopathy, or CAC. The underlying pathology of CAC is believed to result from thrombo-inflammatory processes triggered by the viral infection. A commonly used biomarker for assessing the presence of abnormal coagulation is a D-dimer test, which is elevated (greater than 0.5) in nearly 70% of hospitalized COVID-19 patients and is associated with adverse clinical outcomes. Some researchers believe that this and other evidence points to dysregulation of TF pathways in COVID-19 patients that result in the development of thrombotic complications.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rNAPc2 has shown potential in addressing the coagulation disorder caused by severe viral infections. In preliminary, non-human studies in NHPs against lethal doses of the Ebola and Marburg virus, rNAPc2 lowered D-dimer levels, reduced mortality and exhibited anti-inflammatory effects. We believe more recent research supports our belief that rNAPc2 has the ability to inhibit the activity of TF in multiple processes that contribute to severe viral disease. Taken together, we believe this evidence suggests that rNAPc2 may have therapeutic benefits for patients with serious COVID-19 infections and the accompanying high risk of thrombosis. To our knowledge, rNAPc2 is the only NME anticoagulant, and the only tissue factor inhibitor, currently under evaluation for COVID-19.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a therapeutic aimed at a host response to a disease syndrome, we believe rNAPc2 potentially could be used in combination with other antiviral drugs. We believe its potential efficacy is not linked to a specific viral genome and may not be diminished by genetic drift or the development of new strains of the SARS-CoV-2 virus. As a therapeutic addressing a disease, we believe rNAPc2 may have broad spectrum potential against multiple pathogens that have disease elements in common with COVID&#8209;19, such as other coronaviruses and other RNA viruses. Therefore, we believe that rNAPc2 has therapeutic potential for future viral outbreaks beyond the current pandemic.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk42023175"></a>rNAPc2 is a single-chain, 85 amino acid, recombinant protein administered subcutaneously, that has previously been evaluated under three FDA Investigational New Drug, or IND, applications in six Phase 1 and three Phase 2 clinical studies in the United States and Europe. These clinical trials primarily examined the safety, dosing and anticoagulation effects of rNAPc2 in patients with acute coronary syndromes, in patients undergoing knee replacement surgery and in patients undergoing percutaneous coronary interventions. In these trials, involving more than 800 human patients with over 700 exposed to drug, rNAPc2 was generally well-tolerated with a safety profile comparable to commercially available anticoagulants. rNAPc2 is manufactured in an engineered yeast strain by an established methodology following current Good Manufacturing Practices, or cGMP, and we believe this process can be readily scaled to commercial quantities. FDA granted rNAPc2 Orphan Drug Designation status in 2014 for the treatment of viral hemorrhagic fever post-exposure to Ebola virus, but human clinical trials were not conducted. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2020, FDA approved the IND application for rNAPc2 as a potential treatment for patients hospitalized with COVID-19 and it received a Fast-Track designation in November 2020. We initiated the Phase 2b clinical trial of rNAPc2 (AB201), ASPEN-COVID-19, in patients hospitalized with COVID-19 in the fourth quarter of 2020. We anticipate announcing topline data from this approximately 100 patient Phase 2b clinical trial in the third quarter of 2021. </p></div></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a>.</p>
<hr style="page-break-after:always;width:100%;">
<div style="width:100%;border-top:Solid 0.75pt #000000;border-bottom:Solid 0.75pt #000000;border-left:Solid 0.75pt #000000;border-right:Solid 0.75pt #000000;">
<div style="padding-left:0.65%;padding-Right:0.65%;padding-Top:0.13%;padding-Bottom:0.13%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are evaluating </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rNAPc2</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as a treatment for patients hospitalized with COVID-19 who are at high risk for thrombotic complications, as indicated by elevated D-dimer levels. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Phase 2b clinical trial is designed to be a randomized comparison of two-dose regimens of </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rNAPc2</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> versus heparin prescribed per local standard of care. The primary endpoint of the clinical trial is the change in D-dimer level from baseline to Day 8. If Phase 2b results indicate a favorable effect on D-dimer levels and safety is confirmed, following FDA review of the data and identification of the proposed Phase&#160;3 </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rNAPc2</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> dose, we anticipate that clinical investigative sites will begin enrolling patients in a planned Phase 3 clinical trial. The primary endpoint of Phase 3 is planned to be clinical recovery as measured by the Adaptive COVID-19 Treatment Trial ordinal scale, with secondary endpoints that include D-dimer levels and the number of thrombotic events. We believe the Phase 3 clinical trial will be event driven, with an estimated requirement of 450 patients. We believe that favorable results from this Phase 2b/3 clinical trial program could support use of </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rNAPc2</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in COVID-19 patients, given its potential efficacy both as an anticoagulant and an anti-viral agent that we believe counters the </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">dysregulatory</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> immune response and improves clinical recovery.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The clinical trial is being managed in collaboration with the Colorado Prevention Center, or CPC, the University of Colorado's Academic Research Organization with extensive experience in managing vascular and anticoagulation clinical trials. <font style="margin-left:36pt;"></font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have financed the development of rNAPc2 through public equity sales. Our rNAPc2 development plans, including the timeline, depend on our ability to enroll patients during the COVID-19 pandemic, the results of our Phase 2b clinical trial, FDA guidance, and availability of drug product, all of which are currently uncertain.&nbsp;&nbsp; <font style="margin-left:36pt;"></font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own the clinical development program of rNAPc2, including Phase 2 clinical trials.&#160; If rNAPc2 is successfully developed, we believe it will have intellectual property protection, including 12 years of market exclusivity as an innovative biologic product under FDA law in the United States, 10 years data protection exclusivity in the European Union, or EU, and potentially patent protection in addition to this. We plan to pursue strategic co-development and partnering opportunities for rNAPc2 development and commercialization.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Gencaro&#8482; (bucindolol hydrochloride) for Atrial Fibrillation </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gencaro&#8482; (bucindolol hydrochloride) is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties that we are developing for the treatment of atrial fibrillation in patients with heart failure. We believe the pharmacology of Gencaro is unique and its efficacy can be enhanced by prescribing it to patients with a common genotypic variant that is present in approximately 50% of the North American and European general populations. This gene can be detected with a simple genetic test. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing Gencaro to treat atrial fibrillation, or AF, in patients with chronic heart failure, or HF. AF is the most common form of cardiac arrhythmia, a disruption of the heart&#8217;s normal rhythm or rate. HF is a chronic condition in which the heart is unable to pump enough blood to meet the body&#8217;s needs. AF and HF commonly occur together. In HF patients, the development of AF leads to worsening symptoms, and increased risk of hospitalization and death. Current treatment options for AF in HF patients are limited, and can be invasive, costly and dangerous.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our development plan for Gencaro focuses on the treatment of AF in patients with higher ejection fraction HF, those who have an ejection fraction, or EF, of 40% and higher who also have the genotype we believe is optimal for Gencaro efficacy. This population of HF encompasses more than half of all HF patients in the United States and Europe. There are currently few approved or effective drug therapies to treat AF or HF in this patient population.&nbsp;&nbsp; </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our development plan for Gencaro is based on our recent analysis of the Phase 2b clinical trial of Gencaro for the prevention of AF in HF patients, known as GENETIC-AF. This analysis showed novel results for Gencaro in patients in the clinical trial with EF&#8217;s of 40% and higher. We are planning a new design for a Phase 3 pivotal clinical trial of Gencaro based on this analysis that addresses what we believe are important clinical assessments, including the total amount of time that a patient experiences AF, known as AF burden, maintenance of normal sinus rhythm, rhythm control interventions such as electrical cardioversion, catheter ablation and use of anti-arrhythmic drugs and drug-related complications such as bradycardia. Based on these analyses, we were issued a United States patent in February 2021 for the use of Gencaro in this patient population. We believe this patent will substantially extend the patent protection for our planned development of Gencaro into 2039. We are seeking similar patent protection in other countries. </p></div></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a>.</p>
<hr style="page-break-after:always;width:100%;">
<div style="width:100%;border-top:Solid 0.75pt #000000;border-bottom:Solid 0.75pt #000000;border-left:Solid 0.75pt #000000;border-right:Solid 0.75pt #000000;">
<div style="padding-left:0.65%;padding-Right:0.65%;padding-Top:0.13%;padding-Bottom:0.13%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have an agreement with the FDA, known as a Special Protocol Assessment, or SPA, for the requirements of a </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gencaro</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Phase 3 clinical trial, PRECISION-AF, that would support approval of </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gencaro</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> if successful. Based on our recent analyses of the GENETIC-AF data, we may alter the design of PRECISION-AF to focus on endpoints that are not covered in the SPA agreement.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that patients with HF and AF represent a major unmet medical need, and this need is most pronounced in patients with EF values of 40% and above. This EF range constitutes more than half of all chronic HF in the United States and Europe, as well as in Japan and China, and there are currently few approved, effective or guideline-recommended therapies for these patients to treat either their AF or HF. AF is a very common complication in these patients, with estimates of AF incidence ranging from 40% to 60%. Beta-blockers approved for HF are commonly used off-label to control heart rate in these patients, but they are not considered effective in preventing AF and none are approved for patients with EF &#8805; 40%. Other anti-arrhythmic drugs approved for the treatment of AF have adverse side effects and in HF patients are either contraindicated or have label warnings for use due to an increased risk of mortality. Interventional procedures for AF, such as catheter ablation and electrical cardioversion, are invasive, expensive, and often temporary; these interventions also typically require the continued use of beta blockers and other anti-arrhythmic drugs post-intervention.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that Gencaro, if approved, may be a safe and more effective therapy for the treatment of higher ejection fraction HF patients with AF. We believe there are several potentially important attributes that would differentiate Gencaro from existing therapies, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">More effective rhythm control compared to the current standard of care;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Reduction in the need for catheter ablation, electrical cardioversion, or toxic anti-arrhythmic drugs;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Maintenance of rhythm control after a successful AF catheter ablation;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Effective rate control with lower risk of treatment-limiting bradycardia;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Reduction in symptoms and improvement in quality of life;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Reduced health care burden;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Foundational beta-blocker benefits for HF and unique evidence of efficacy in HF patients with AF;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">One of the only drug therapies approved and shown effective for AF in HF patients with EF &#8805; 40%, and the only one in its drug class.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have an international patent portfolio for Gencaro in the United States, the EU, and other major markets, as well as new chemical entity status, including a new patent that we believe will give us a strong intellectual property position to at least approximately 2039 in the United States; we have filed applications similar to this new patent in international territories. We have developed a laboratory platform for the diagnostic test that would be used to prescribe Gencaro; this platform was approved by FDA for use in the Phase 2B clinical trial. We retain all rights to this test platform; we expect to use it in future clinical trials, and we believe it could be one of multiple diagnostic platforms used for commercialization. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">To support the continued development of </font><font style="color:#000000;">rNAPc2</font><font style="Background-color:#FFFFFF;"> and Gencaro, we will need additional financing to fully fund the planned </font>clinical trials, <font style="Background-color:#FFFFFF;">and our general and administrative costs through the clinical trials&#8217; projected completion and potential commercialization. Considering the substantial time and costs associated with the development of </font><font style="color:#000000;">rNAPc2</font><font style="Background-color:#FFFFFF;"> and Gencaro and the risk that we may be unable to raise a significant amount of capital on acceptable terms, we are also pursuing co-development and commercialization partnering opportunities with large pharmaceutical and/or specialty pharmaceutical companies and may pursue a strategic combination or other strategic transactions. If we are unable to obtain sufficient financing or are unable to complete a strategic transaction, we may discontinue our development activities on </font><font style="color:#000000;">rNAPc2</font><font style="Background-color:#FFFFFF;"> or Gencaro or discontinue our operations</font><font style="color:#000000;">.</font><font style="Background-color:#FFFFFF;"> </font></p>
<p style="text-align:justify;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-right:2.35%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a>.</p>
<hr style="page-break-after:always;width:100%;">
<div style="width:100%;border-top:Solid 0.75pt #000000;border-bottom:Solid 0.75pt #000000;border-left:Solid 0.75pt #000000;border-right:Solid 0.75pt #000000;">
<div style="padding-left:0.65%;padding-Right:0.65%;padding-Top:0.13%;padding-Bottom:0.13%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Associated with Our Business</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business is subject to numerous risks, as more fully described in the section entitled &#8220;Risk Factors&#8221; beginning on page 10, and under similar headings in any applicable prospectus supplement or any document incorporated by reference herein. You should read these risks before you invest in our securities. We may be unable, for many reasons, including those that are beyond our control, to implement our business strategy. In particular, some of our risks include:</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">If we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of rNAPc2 Gencaro in a timely manner, we may not be able to continue our business operations.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">We will need to raise substantial additional funds through public or private equity or debt transactions and/or complete one or more strategic transactions, to continue development of rNAPc2, Gencaro or any of our other product candidates. If we are unable to raise such financing or complete such a transaction, we may not be able to continue operations.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Our audited financial statements for the fiscal year ended December 31, 2020 were prepared assuming that we will continue as a going concern. Our management has concluded that due to our need for additional capital, and the uncertainties surrounding our ability to raise such funding, there may be uncertainty about our ability to continue as a going concern in future years.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Our business could be adversely affected by the effects of health epidemics, including the ongoing COVID-19 global pandemic, in regions where we or third parties on which we rely may have clinical trial sites or other business operations. We anticipate having clinical trial sites in countries that have been directly affected by COVID-19 and depend on third party manufacturing operations for various stages of our supply chain.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;font-size:3pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;font-size:3pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">We have received an SPA agreement from the FDA relating to our planned Phase 3 program for Gencaro. This SPA agreement does not guarantee approval of Gencaro or any other particular outcome from regulatory review.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">If we are not able to maintain the requirements for listing on the Nasdaq Capital Market, we could be delisted, which could have a material adverse effect on our ability to raise additional funds as well as the price and liquidity of our common stock.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">rNAPc2 may not yield results that will enable us to further develop it as a therapy and obtain regulatory approvals necessary to be used as a drug.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">If we encounter difficulties enrolling patients in our clinical trial of rNAPc2, any potential enrollment milestones or potential regulatory approvals could be delayed or otherwise adversely affected.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Any future clinical trial for Gencaro will require the use of a third-party diagnostic services provider to administer a genetic test needed to identify the patient receptor genotypes of clinical trial participants, and as a result, we will be unable to directly control the timing, conduct and expense of the genetic test.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">We will need to establish a collaborative arrangement with a third-party diagnostics services provider to obtain marketing clearance or approval of the companion genetic test. There is no guarantee that the FDA will grant timely clearance or approval of the genetic test, if at all, and failure to obtain such timely clearance or approval would adversely affect our ability to market Gencaro.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Our product candidates are subject to extensive regulation, which can be costly and time-consuming, and unsuccessful or delayed regulatory approvals could increase our future development costs or impair our future revenue.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">If approved by the FDA, rNAPc2 or Gencaro will be entering a competitive marketplace and may not succeed.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p></div></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a>.</p>
<hr style="page-break-after:always;width:100%;">
<div style="width:100%;border-top:Solid 0.75pt #000000;border-bottom:Solid 0.75pt #000000;border-left:Solid 0.75pt #000000;border-right:Solid 0.75pt #000000;">
<div style="padding-left:0.65%;padding-Right:0.65%;padding-Top:0.13%;padding-Bottom:0.13%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Company Information</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">On January&#160;27, 2009, we completed a business combination, or the Merger, between Nuvelo, Inc., or Nuvelo, a corporation originally incorporated in 1992, and its subsidiary, ARCA biopharma, Inc. Immediately following the Merger, we changed our name from Nuvelo, Inc. to ARCA biopharma, Inc. </font>Our principal offices are located at 10170&#160;Church Ranch Way, Suite 100, Westminster, Colorado 80021. Our telephone number is (720) 940-2200, and our website is http://www.arcabio.com. <font style="color:#000000;">The information contained on our website is not incorporated by reference into this prospectus, and you should not consider any information contained on, or that can be accessed through, our website as part of this prospectus or in deciding whether to purchase our common stock</font>. For further information regarding us and our financial information, you should refer to our recent filings with the SEC. See &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation of Certain Information by Reference.&#8221;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each of ARCA, ARCA biopharma, Gencaro and Gencaro Test is a registered trademark of ARCA&#160;biopharma, Inc. Each of the other trademarks, trade names or service marks appearing in this prospectus belongs to its respective holder.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">The Securities We May Offer</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may offer shares of our common stock and preferred stock, various series of debt securities and/or warrants to purchase any of such securities, either individually or in combination with other securities, with an aggregate offering price of up to $150,000,000 from time to time under this prospectus, together with any applicable prospectus supplement and any related free writing prospectus, at prices and on terms to be determined by market conditions at the time of any offering. This prospectus provides you with a general description of the securities we may offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities, including, to the extent applicable:</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">designation or classification;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">aggregate principal amount or aggregate offering price;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">maturity date, if applicable;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">original issue discount, if any;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rates and times of payment of interest or dividends, if any;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">redemption, conversion, exercise, exchange or sinking fund terms, if any;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ranking;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">restrictive covenants, if any;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conversion or exchange prices or rates, if any, and, if applicable, any provisions for changes to or adjustments in the conversion or exchange prices or rates and in the securities or other property receivable upon conversion or exchange; and</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">material or special U.S. federal income tax considerations, if any.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The applicable prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change any of the information contained in this prospectus or in the documents we have incorporated by reference. However, no prospectus supplement or free writing prospectus will offer a security that is not registered and described in this prospectus at the time of the effectiveness of the registration statement of which this prospectus is a part.</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br /></p></div></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a>.</p>
<hr style="page-break-after:always;width:100%;">
<div style="width:100%;border-top:Solid 0.75pt #000000;border-bottom:Solid 0.75pt #000000;border-left:Solid 0.75pt #000000;border-right:Solid 0.75pt #000000;">
<div style="padding-left:0.65%;padding-Right:0.65%;padding-Top:0.13%;padding-Bottom:0.13%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THIS PROSPECTUS MAY NOT BE USED TO CONSUMMATE A SALE OF SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may sell the securities directly to investors or to or through agents, underwriters or dealers. We, and our agents or underwriters, reserve the right to accept or reject all or part of any proposed purchase of securities. If we do offer securities to or through agents or underwriters, we will include in the applicable prospectus supplement:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the names of those agents or underwriters;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">applicable fees, discounts and commissions to be paid to them;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">details regarding over-allotment options, if any; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the net proceeds to us.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Common Stock. <font style="font-style:normal;">We may issue shares of our common stock from time to time. The holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders, except on matters relating solely to terms of preferred stock. Under our amended and restated certificate of incorporation and amended and restated bylaws, our stockholders do not have cumulative voting rights. Because of this, the holders of a majority of the shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they should so choose. Subject to preferences that may be applicable to any outstanding shares of preferred stock, the holders of common stock are entitled to receive ratably such dividends as may be declared by our board of directors out of legally available funds. Upon our liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preferences of any outstanding shares of preferred stock. Holders of common stock have no preemptive rights and no right to convert their common stock into any other securities. There are no redemption provisions applicable to our common stock. . The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that we may designate in the future. In this prospectus, we have summarized certain general features of the common stock under &#8220;Description of Capital Stock-Common Stock.&#8221; We urge you, however, to read the applicable prospectus supplement (and any related free writing prospectus that we may authorize to be provided to you) related to any common stock being offered.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Preferred Stock. <font style="font-style:normal;">We may issue shares of our preferred stock from time to time, in one or more series. Under our certificate of incorporation, our board of directors has the authority to designate up to 5,000,000 shares of preferred stock, $0.001 par value per share, in one or more series and to fix the privileges, preferences and rights of each series of preferred stock, any or all of which may be greater than the rights of the common stock. If we sell any new series of preferred stock under this prospectus and any applicable prospectus supplement, our board of directors will determine the designations, voting powers, preferences and rights of the preferred stock being offered, as well as the qualifications, limitations or restrictions thereof, including dividend rights, conversion rights, preemptive rights, terms of redemption or repurchase, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of any series. Preferred stock may be convertible into our common stock or other securities of ours, or may be exchangeable for debt securities. Conversion may be mandatory or at the holder&#8217;s option and would be at prescribed conversion rates. We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of the certificate of designation that describes the terms of the series of preferred stock that we are offering before the issuance of the related series of preferred stock. In this prospectus, we have summarized certain general features of the preferred stock under &#8220;Description of Capital Stock-Preferred Stock.&#8221; We urge you, however, to read the applicable prospectus supplement (and any related free writing prospectus that we may authorize to be provided to you) related to the series of preferred stock being offered, as well as the complete certificate of designation that contains the terms of the applicable series of preferred stock.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Debt Securities. <font style="font-style:normal;">We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. The senior debt securities will rank equally with any other unsecured and unsubordinated debt. The subordinated debt securities will be subordinate and junior in right of payment, to the extent and in the manner described in the instrument governing the debt, to all of our senior indebtedness. Convertible debt securities will be convertible into or exchangeable for our common stock or our other securities. Conversion may be mandatory or at the holder&#8217;s option and would be at prescribed conversion rates.</font></p></div></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a>.</p>
<hr style="page-break-after:always;width:100%;">
<div style="width:100%;border-top:Solid 0.75pt #000000;border-bottom:Solid 0.75pt #000000;border-left:Solid 0.75pt #000000;border-right:Solid 0.75pt #000000;">
<div style="padding-left:0.65%;padding-Right:0.65%;padding-Top:0.13%;padding-Bottom:0.13%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The debt securities will be issued under one or more documents called indentures, which are contracts between us and a national banking association or other eligible party, as trustee. In this prospectus, we have summarized certain general features of the debt securities under &#8220;Description of Debt Securities.&#8221; We urge you, however, to read the applicable prospectus supplement (and any related free writing prospectus that we may authorize to be provided to you) related to the series of debt securities being offered, as well as the complete indenture and any supplemental indentures that contain the terms of the debt securities. We have filed a form of indenture as an exhibit to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Warrants. <font style="font-style:normal;">We may issue warrants for the purchase of common stock, preferred stock and/or debt securities in one or more series. We may issue warrants independently or in combination with common stock, preferred stock and/or debt securities, and the warrants may be attached to or separate from these securities. In this prospectus, we have summarized certain general features of the warrants under &#8220;Description of Warrants.&#8221; We urge you, however, to read the applicable prospectus supplement (and any related free writing prospectus that we may authorize to be provided to you) related to the particular series of warrants being offered, as well as the form of warrant and/or the warrant agreement and warrant certificate, as applicable, that contain the terms of the warrants. We have filed the forms of the warrant agreements and forms of warrant certificates containing the terms of the warrants that we may offer as exhibits to the registration statement of which this prospectus is a part. We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of warrant and/or the warrant agreement and warrant certificate, as applicable, that contain the terms of the particular series of warrants we are offering, and any supplemental agreements, before the issuance of such warrants.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants may be issued under a warrant agreement that we enter into with a warrant agent. We will indicate the name and address of the warrant agent, if any, in the applicable prospectus supplement relating to a particular series of warrants.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a>.</p>
<hr style="page-break-after:always;width:100%;">
<div style="width:100%;border-top:Solid 0.75pt #000000;border-bottom:Solid 0.75pt #000000;border-left:Solid 0.75pt #000000;border-right:Solid 0.75pt #000000;">
<div style="padding-left:0.65%;padding-Right:0.65%;padding-Top:0.13%;padding-Bottom:0.13%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="RISK_FACTORS_1"></a><a name="RISK_FACTORS_1"></a>RISK FACTORS</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">An investment in our securities involves a high degree of risk. Before you make a decision to invest in our securities, you should consider carefully the risks described in the section entitled &#8220;Risk Factors&#8221; contained in the applicable prospectus supplement and in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the SEC, as well as any amendment or update thereto reflected in subsequent filings with the SEC or in any Current Report on Form 8-K we may file. The risks described in these documents are not the only ones we face, but those that we consider to be material. There may be other unknown or unpredictable economic, business, competitive, regulatory or other factors that could have material adverse effects on our future results. Past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results or trends in future periods. If any of these risks actually occur, our business, operating results, prospects or financial condition could be materially and adversely affected. This could cause the trading price of our securities to decline and you may lose part or all of your investment. Moreover, the risks described are not the only ones that we face. Additional risks not presently known to us or that we currently deem immaterial may also affect our business, operating results, prospects or financial condition. Please also read carefully the discussion below under the heading &#8220;Forward-Looking Statements.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p></div></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a>.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="FORWARDLOOKING_STATEMENTS_1"></a><a name="FORWARDLOOKING_STATEMENTS_1"></a>FORWARD-LOOKING STATEMENTS</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This prospectus, any prospectus supplement and the documents we have filed with the SEC that are incorporated by reference herein contain &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements relate to future events or to our future operating or financial performance and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. All statements, other than statements of historical fact, are forward-looking statements, including, but not limited to, statements about:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">the timing and results of any clinical trials, including potential future clinical trials of rNAPc2, the potential for rNAPc2 to treat COVID-19, the potential for rNAPc2 to be the first novel anticoagulant and inhibitor of tissue factor for the treatment of COVID-19, rNAPc2&#8217;s potential use in combination with other antiviral drugs, future treatment options for patients with COVID-19, rNAPc2&#8217;s potential for future viral outbreaks beyond the current COVID-19 pandemic, and the ability to fund clinical trials and research of rNAPc2; </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">our ability to resume and fund PRECISION-AF clinical trials in the future as well as the potential for genetic variations to predict individual patient response to Gencaro, Gencaro</font>&#8217;<font style="color:#000000;">s potential to treat AF, future treatment options for patients with AF, the potential for Gencaro to be the first genetically-targeted atrial fibrillation prevention treatment;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">our ability to obtain U.S. and foreign regulatory approval for our product candidates and the ability of our product candidates to meet existing or future regulatory standards;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">our expectations regarding federal, state and foreign regulatory requirements; </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">the therapeutic benefits and effectiveness of our product candidates; </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">the accuracy of our estimates of the size and characteristics of the markets that may be addressed by our product candidates; </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">our ability to obtain additional funding or enter into a strategic or other transaction; </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">the extent to which our issued and pending patents may protect our products and technology; </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">the potential of such product candidates to lead to the development of safe or effective therapies; </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">our ability to enter into collaborations; </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">our ability to maintain listing of our common stock on a national exchange; </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">our future operating expenses, our future losses, our future expenditures, and the sufficiency of our cash resources to maintain operations; </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">our ability to compete with other companies that are or may be developing or selling products that are competitive with our product candidates; </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">anticipated trends and challenges in our potential markets; and </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">our ability to attract and retain key personnel. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a>.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;projects,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; or the negative of these terms or other similar expressions intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements reflect our current views with respect to future events, are based on assumptions and are subject to substantial risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Discussions containing these forward-looking statements may be found, among other places, under the heading &#8220;Risk Factors&#8221; contained in the applicable prospectus supplement, in any free writing prospectus we may authorize for use in connection with a specific offering, and under the headings &#8220;Business&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operation&#8221; in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q, as well as any amendments thereto reflected in subsequent filings with the SEC, each incorporated by reference herein in its entirety. Also, these forward-looking statements represent our estimates and assumptions only as of the date of the document containing the applicable statement. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events and trends discussed in this prospectus may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. If our forward-looking statements prove to be inaccurate, the inaccuracy may be material. Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. You should read this prospectus and the applicable prospectus supplement, together with the documents we have filed with the SEC that are incorporated by reference and any free writing prospectus that we may authorize for use in connection with this offering, completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in the foregoing documents by these cautionary statements.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a>.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="USE_PROCEEDS_1"></a><a name="USE_PROCEEDS_1"></a>USE OF PROCEEDS</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will retain broad discretion over the use of the net proceeds from the sale of the securities offered by this prospectus. Except as described in any applicable prospectus supplement or in any free writing prospectus we have authorized for use in connection with a specific offering, we currently intend to use the net proceeds from the sale of the securities under this prospectus, if any, for working capital and general corporate purposes. We may also use a portion of the net proceeds to invest in or acquire businesses or technologies that we believe are complementary to our own. We will set forth in the prospectus supplement applicable to a specific offering our intended use for the net proceeds received from the sale of any securities in that offering.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amounts and timing of our use of the net proceeds from any offerings hereunder will depend on a number of factors, such as the timing and progress of our clinical trials and research and development efforts, the timing of regulatory approval of our product candidates, if any, the timing and progress of any partnering and collaboration efforts, technological advances and the competitive environment for our product candidates. As of the date of this prospectus, we cannot specify with certainty all of the particular uses for the net proceeds to us from offerings hereunder. Accordingly, our management will have broad discretion in the timing and application of these proceeds. Pending application of the net proceeds as described above, we intend to temporarily invest the proceeds in short-term, interest-bearing instruments.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a>.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="DESCRIPTION_CAPITAL_STOCK"></a><a name="DESCRIPTION_CAPITAL_STOCK"></a>DESCRIPTION OF CAPITAL STOCK</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The following description of our capital stock and provisions of our amended and restated certificate of incorporation and amended and restated bylaws are summaries. You should also refer to our amended and restated certificate of incorporation and the amended and restated bylaws, which are filed as exhibits to the registration statement of which this prospectus is part.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">General</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of the date of this prospectus, our amended and restated certificate of incorporation, as amended, or the Restated Certificate, authorizes us to issue 100,000,000 shares of common stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, $0.001 par value per share. As of March 18, 2021, 14,410,143 shares of common stock were outstanding and no shares of preferred stock were outstanding.&nbsp;&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following summary description of our capital stock is based on the provisions of our Restated Certificate, our second amended and restated bylaws, or the Bylaws, and applicable provisions of the Delaware General Corporation Law. This information may not be complete in all respects and is qualified entirely by reference to the applicable provisions of our Restated Certificate, our Bylaws and the Delaware General Corporation Law. For information on how to obtain copies of our Restated Certificate and Bylaws, which are exhibits to the registration statement of which this prospectus is a part, see &#8220;Where You Can Find More Information.&#8221;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Voting Rights<font style="font-style:normal;">. Each holder of our common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors; provided, however, holders of our common stock may not, unless otherwise required by law, vote on any amendment to our Restated Certificate that relates solely to the terms of one or more series of preferred stock that we may issue if the holders of such preferred stock are entitled to vote on such amendment. In all such matters other than the election of directors, the affirmative vote of the majority of shares present in person, by remote communication, or represented by proxy at a meeting of the stockholders and entitled to vote generally on the subject matter shall be the act of the stockholders. Directors shall be elected by a plurality of the votes of the shares present in person, by remote communication, or represented by proxy at a meeting of the stockholders and entitled to vote generally on the election of directors. Our stockholders do not have cumulative voting rights in the election of directors. Accordingly, holders of a majority of the voting shares are able to elect all of the directors to be elected at any particular time. See &#8220;Anti-Takeover Effects of Provisions of Delaware Law and Our Charter Documents &#8211; Certificate of Incorporation and Bylaws &#8211; Classified Board&#8221; for a description of elections of members of our board of directors.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Dividends<font style="font-style:normal;">. Subject to preferences that may be applicable to any then outstanding preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Liquidation<font style="font-style:normal;">. In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then outstanding shares of preferred stock.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Rights and Preferences<font style="font-style:normal;">. Holders of our common stock have no preemptive, conversion, subscription or other rights, and there are no redemption provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our preferred stock that we may designate in the future.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Fully Paid and Nonassessable<font style="font-style:normal;">. All of our outstanding shares of common stock are, and the shares of common stock to be issued in any offering hereunder will be, upon our receipt of the purchase price for such shares, fully paid and nonassessable.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a>.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to our Restated Certificate, our board of directors has the authority, without further action by our stockholders, to issue up to 5,000,000 shares of preferred stock, $0.001 par value per share, in one or more series, to establish from time to time the number of shares to be included in each such series, and to fix the designations, powers, preferences, privileges and relative participating, optional or special rights and the qualifications, limitations or restrictions thereof, including dividend rights, conversion rights, preemptive rights, voting rights, terms of redemption and repurchase, liquidation preferences and sinking fund terms, any or all of which may be greater than the rights of the common stock. Preferred stock may be convertible into our common stock or other securities of ours, or may be exchangeable for debt securities. Conversion may be mandatory or at the holder&#8217;s option and would be at prescribed conversion rates. Because our board of directors, without stockholder approval, can issue preferred stock with voting, conversion or other rights, preferred stock could be issued quickly with terms calculated to delay or prevent a change in control of our company or make removal of management more difficult. Additionally, the issuance of preferred stock may have the effect of decreasing the market price of the common stock and may adversely affect the voting power of holders of common stock and reduce the likelihood that common stockholders will receive dividend payments and payments upon liquidation.</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors will fix the rights, preferences, privileges, qualifications and restrictions of the preferred stock of each series that we sell under this prospectus and applicable prospectus supplements in the certificate of designation relating to that series. We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of any certificate of designation that describes the terms of the series of preferred stock we are offering before the issuance of the related series of preferred stock. This description will include:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the title and stated value;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the number of shares we are offering;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the liquidation preference per share;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the purchase price per share;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the dividend rate per share, dividend period and payment dates and method of calculation for dividends;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">whether dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our right, if any, to defer payment of dividends and the maximum length of any such deferral period;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the procedures for any auction and remarketing, if any;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the provisions for a sinking fund, if any;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those redemption and repurchase rights;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">any listing of the preferred stock on any securities exchange or market;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">whether the preferred stock will be convertible into our common stock or other securities of ours, including warrants, and, if applicable, the conversion period, the conversion price, or how it will be calculated, and under what circumstances it may be adjusted;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">whether the preferred stock will be exchangeable for debt securities, and, if applicable, the exchange period, the exchange price, or how it will be calculated, and under what circumstances it may be adjusted;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">voting rights, if any, of the preferred stock;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">preemptive rights, if any;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">restrictions on transfer, sale or other assignment, if any;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">a discussion of any material or special United States federal income tax considerations applicable to the preferred stock;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a>.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;">any limitations on issuances of any class or series of preferred stock ranking senior to or on a parity with the series of preferred stock being issued as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">any other specific terms, rights, preferences, privileges, qualifications or restrictions of the preferred stock.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:12pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When we issue shares of preferred stock under this prospectus, upon our receipt of the purchase price for such shares, the shares will be fully paid and nonassessable and will not have, or be subject to, any preemptive or similar rights. Unless we specify otherwise in the applicable prospectus supplement, the preferred stock will rank, with respect to dividends and upon our liquidation, dissolution or winding up:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">senior to all classes or series of our common stock and to all of our equity securities ranking junior to the preferred stock;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">on a parity with all of our equity securities the terms of which specifically provide that the equity securities rank on a parity with the preferred stock; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">junior to all of our equity securities the terms of which specifically provide that the equity securities rank senior to the preferred stock.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term &#8220;equity securities&#8221; does not include convertible debt securities.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Delaware General Corporation Law provides that the holders of any class or series of preferred stock will have the right to vote separately as a class on any proposed amendment to the Restated Certificate that would alter or change the powers, preferences or special rights of the holders of such class or series of preferred stock so as to affect them adversely. This right is in addition to any voting rights that may be provided for in the applicable certificate of designation.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The issuance of preferred stock could adversely affect the voting power of holders of common stock and reduce the likelihood that common stockholders will receive dividend payments and payments upon liquidation. The issuance could have the effect of decreasing the market price of the common stock. The issuance of preferred stock also could have the effect of delaying, deterring or preventing a chance in control of us.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding Warrants</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 18, 2021, we had outstanding warrants to purchase 133,401 shares of our common stock, having an exercise price of $109.80 per share. Any of the outstanding warrants may be exercised by applying the value of a portion of the warrant, which is equal to the number of shares issuable under the warrant being exercised multiplied by the fair market value of the security receivable upon the exercise of the warrant, less the per share price, in lieu of payment of the exercise price per share.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These warrants, if unexercised, will expire on June 16, 2022.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock Options</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 18, 2021, there were 1,167,585 shares of common stock reserved for issuance under our equity incentive plans.&nbsp;&nbsp;Of this number, 596,497 shares were reserved for issuance upon exercise of outstanding options.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Anti-Takeover Effects of Provisions of Delaware Law and Our Charter Documents</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Certificate of Incorporation and Bylaws</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Restated Certificate and Second Amended and Restated Bylaws, or Bylaws, include a number of provisions that may deter or impede hostile takeovers or changes of control. These provisions include:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Issuance of Undesignated Preferred Stock<font style="font-style:normal;">. Under our Restated Certificate, our board of directors has the authority, without further action by the stockholders, to issue up to 5,000,000 shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by the board of directors. The existence of authorized but unissued shares of preferred stock enables our board of directors to make it more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</a>.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Classified Board</font><font style="font-style:normal;">. Our Restated Certificate provides for a classified board of directors consisting of three classes of directors, with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. This provision may have the effect of delaying a change in control of the board.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Board of Directors Vacancies<font style="font-style:normal;">. Our Restated Certificate and Bylaws authorize only our board of directors to fill vacant directorships, unless our board of directors determines by resolution that the stockholders shall fill such vacant directorships. In addition, the number of directors constituting our board of directors may be set only by resolution adopted by a majority vote of our entire board of directors. These provisions prevent a stockholder from increasing the size of our board of directors and gaining control of our board of directors by filling the resulting vacancies with its own nominees.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stockholder Action; Special Meetings of Stockholders<font style="font-style:normal;">. Our Restated Certificate provides that our stockholders may not take action by written consent, but may only take action at annual or special meetings of our stockholders. Under our Bylaws, stockholders are not permitted to cumulate their votes for the election of directors. Our Bylaws further provide that special meetings of the stockholders may be called by the chief executive officer, president, the board of directors, or by holders of common stock who hold, in the aggregate, not less than fifty percent (50%) of the outstanding shares of common stock for the purpose or purposes stated in the call of the meeting. These provisions may prevent stockholders from corporate actions as stockholders at times when they otherwise would like to do so.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Advance Notice Requirements for Stockholder Proposals and Director Nominations<font style="font-style:normal;">. Our Bylaws provide advance notice procedures for stockholders seeking to bring business before our annual meeting of stockholders, or to nominate candidates for election as directors at our annual meeting of stockholders. Our Bylaws also specify certain requirements as to the form and content of a stockholder&#8217;s notice. These provisions may make it more difficult for our stockholders to bring matters before our annual meeting of stockholders or to nominate directors at our annual meeting of stockholders.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and its policies and to discourage certain types of transactions that may involve an actual or threatened acquisition of us. These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal. The provisions also are intended to discourage certain tactics that may be used in proxy fights. However, these provisions could have the effect of discouraging others from making tender offers for our shares and, as a consequence, they may also reduce fluctuations in the market price of our shares that could result from actual or rumored takeover attempts.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Section 203 of the Delaware General Corporation Law</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to Section 203 of the Delaware General Corporation Law. Section 203 generally prohibits certain Delaware corporations from engaging, under certain circumstances, in a &#8220;business combination&#8221; with any &#8220;interested stockholder for a period of three years following the time that such stockholder became an interested stockholder, unless:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;">prior to such time the board of directors approved either the business combination or transaction which resulted in the stockholder becoming an interested stockholder; </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (a) shares owned by persons who are directors and also officers and (b) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;">at or subsequent to such time the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66-2/3% of the outstanding voting stock which is not owned by the interested stockholder. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 203 defines a business combination to include:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;">any merger or consolidation involving the corporation and the interested stockholder; </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;">any sale, lease, exchange, mortgage, pledge, transfer or other disposition (in one transaction or a series of transactions) involving the interested stockholder of 10% or more of the assets of the corporation (or its majority-owned subsidiary); </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</a>.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;">subject to exceptions, any transaction involving the corporation that has the effect, directly or indirectly, of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; and </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;">the receipt by the interested stockholder of the benefit, directly or indirectly (except proportionately as a stockholder of such corporation), of any loans, advances, guarantees, pledges or other financial benefits, other than certain benefits set forth in Section 203, provided by or through the corporation. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person that is an affiliate or associate of such entity or person.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Delaware corporation may &#8220;opt out&#8221; of these provisions with an express provision in its original certificate of incorporation or an express provision in its certificate of incorporation or bylaws resulting from a stockholders&#8217; amendment approved by a majority of the outstanding voting shares. We have not &#8220;opted out&#8221; of these provisions and do not plan to do so. The statute could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, may discourage attempts to acquire us.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Potential Effects of Authorized but Unissued Stock</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our shares of common stock and preferred stock available for future issuance without stockholder approval. We may utilize these additional shares for a variety of corporate purposes, including future public offerings to raise additional capital, to facilitate corporate acquisitions, payment as a dividend on the capital stock or as equity compensation to our service providers under our equity compensation plans.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The existence of unissued and unreserved common stock and preferred stock may enable our board of directors to issue shares to persons friendly to current management or to issue preferred stock with terms that could render more difficult or discourage a third-party attempt to obtain control by means of a merger, tender offer, proxy contest or otherwise, thereby protecting the continuity of our management. In addition, our board of directors has the discretion to determine designations, rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences of each series of preferred stock, all to the fullest extent permissible under the Delaware General Corporation Law and subject to any limitations set forth in our certificate of incorporation. The purpose of authorizing the board of directors to issue preferred stock and to determine the rights and preferences applicable to such preferred stock is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing desirable flexibility in connection with possible financings, acquisitions and other corporate purposes, could have the effect of making it more difficult for a third party to acquire, or could discourage a third party from acquiring, a majority of our outstanding voting stock.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Also, if we issue additional shares of our authorized, but unissued, common stock, these issuances will dilute the voting power and distribution rights of our existing common stockholders.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amendments to Governing Documents</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:12pt;margin-top:6pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Generally, the amendment of our Restated Certificate requires approval by our board of directors and a majority vote of stockholders, provided that the provisions of our Restated Certificate relating to (i)&#160;the requirement that all stockholder action be taken only at a duly called annual meeting or special meeting; (ii)&#160;the authority and power of the board of directors and the procedure required to amend our Bylaws; (iii)&#160;the percentage of the shares necessary to amend the Restated Certificate; (iv)&#160;the elimination of directors&#8217; personal liability for monetary damages arising from their negligence and gross negligence; and (v)&#160;indemnification of directors, officers and other persons requires approval of our stockholders holding at least&#160;66-2/3%&#160;of our capital stock then outstanding and entitled to vote. Any amendment to our Bylaws requires the approval of either a majority of our board of directors or approval of our stockholders holding at least&#160;66-2/3%&#160;of our capital stock then outstanding and entitled to vote.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Transfer Agent and Registrar</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transfer agent and registrar for our common stock is Computershare Trust Company N.A. The transfer agent for any series of preferred stock that we may offer under this prospectus will be named and described in the prospectus supplement for that series.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</a>.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Listing</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock is listed on The Nasdaq Capital Market under the symbol &#8220;ABIO.&#8221;</p><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</a>.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="DESCRIPTION_DEBT_SECURITIES"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="DESCRIPTION_DEBT_SECURITIES"></a>DESCRIPTION OF </font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DEBT SECURITIES</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. While the terms we have summarized below will apply generally to any debt securities that we may offer under this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the applicable prospectus supplement. The terms of any debt securities offered under a prospectus supplement may differ from the terms described below. Unless the context requires otherwise, whenever we refer to the indenture, we also are referring to any supplemental indentures that specify the terms of a particular series of debt securities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will issue the debt securities under the indenture that we will enter into with the trustee named in the indenture.&nbsp;&nbsp;The indenture will be qualified under the Trust Indenture Act of 1939, as amended, or the Trust Indenture Act.&nbsp;&nbsp;We have filed the form of indenture as an exhibit to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following summary of material provisions of the debt securities and the indenture is subject to, and qualified in its entirety by reference to, all of the provisions of the indenture applicable to a particular series of debt securities.&nbsp;&nbsp;We urge you to read the applicable prospectus supplements and any related free writing prospectuses related to the debt securities that we may offer under this prospectus, as well as the complete indenture that contains the terms of the debt securities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">General</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The indenture does not limit the amount of debt securities that we may issue. It provides that we may issue debt securities up to the principal amount that we may authorize and may be in any currency or currency unit that we may designate. Except for the limitations on consolidation, merger and sale of all or substantially all of our assets contained in the indenture, the terms of the indenture do not contain any covenants or other provisions designed to give holders of any debt securities protection against changes in our operations, financial condition or transactions involving us.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may issue the debt securities issued under the indenture as &#8220;discount securities,&#8221; which means they may be sold at a discount below their stated principal amount. These debt securities, as well as other debt securities that are not issued at a discount, may be issued with &#8220;original issue discount,&#8221; or OID, for U.S. federal income tax purposes because of interest payment and other characteristics or terms of the debt securities. Material U.S. federal income tax considerations applicable to debt securities issued with OID will be described in more detail in any applicable prospectus supplement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will describe in the applicable prospectus supplement the terms of the series of debt securities being offered, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the title of the series of debt securities;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">any limit upon the aggregate principal amount that may be issued;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the maturity date or dates;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the form of the debt securities of the series;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the applicability of any guarantees;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">whether the debt securities rank as senior debt, senior subordinated debt, subordinated debt or any combination thereof, and the terms of any subordination;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">if the price (expressed as a percentage of the aggregate principal amount thereof) at which such debt&nbsp;&nbsp;securities will be issued is a price other than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration of the maturity thereof, or if applicable, the portion of the principal amount of such debt securities that is convertible into another security or the method by which any such portion shall be determined;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</a>.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">our right, if any, to defer payment of interest and the maximum length of any such deferral period;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">if applicable, the date or dates after which, or the period or periods during which, and the price or prices at which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the date or dates, if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder&#8217;s option to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple thereof;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">any and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series and any security for our obligations with respect to such debt securities and any other terms which may be advisable in connection with the marketing of debt securities of that series;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">whether the debt securities of the series shall be issued in whole or in part in the form of a global security or securities; the terms and conditions, if any, upon which such global security or securities may be exchanged in whole or in part for other individual securities; and the depositary for such global security or securities;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">if applicable, the provisions relating to conversion or exchange of any debt securities of the series and the terms and conditions upon which such debt securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable, or how it will be calculated and may be adjusted, any mandatory or optional (at our option or the holders&#8217; option) conversion or exchange features, the applicable conversion or exchange period and the manner of settlement for any conversion or exchange;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">if other than the full principal amount thereof, the portion of the principal amount of debt securities of the series which shall be payable upon declaration of acceleration of the maturity thereof;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">additions to or changes in the covenants applicable to the particular debt securities being issued, including, among others, the consolidation, merger or sale covenant;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">additions to or changes in the events of default with respect to the securities and any change in the right of the trustee or the holders to declare the principal, premium, if any, and interest, if any, with respect to such securities to be due and payable;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">additions to or changes in or deletions of the provisions relating to covenant defeasance and legal defeasance;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">additions to or changes in the provisions relating to satisfaction and discharge of the indenture;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">additions to or changes in the provisions relating to the modification of the indenture both with and without the consent of holders of debt securities issued under the indenture;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the currency of payment of debt securities if other than U.S. dollars and the manner of determining the equivalent amount in U.S. dollars;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">whether interest will be payable in cash or additional debt securities at our or the holders&#8217; option and the terms and conditions upon which the election may be made;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the terms and conditions, if any, upon which we will pay amounts in addition to the stated interest, premium, if any and principal amounts of the debt securities of the series to any holder that is not a &#8220;United States person&#8221; for federal tax purposes;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">any restrictions on transfer, sale or assignment of the debt securities of the series; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, any other additions or changes in the provisions of the indenture, and any terms that may be required by us or advisable under applicable laws or regulations.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Conversion or Exchange Rights</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will set forth in the applicable prospectus supplement the terms on which a series of debt securities may be convertible into or exchangeable for our common stock or our other securities.&nbsp;&nbsp;We will include provisions as to settlement upon conversion or exchange and whether conversion or exchange is mandatory, at the option of the holder or at our option. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</a>.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may include provisions pursuant to which the number of shares of our common stock or our other securities that the holders of the series of debt securities receive would be subject to adjustment.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consolidation, Merger or Sale</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indenture will not contain any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of our assets as an entirety or substantially as an entirety.&nbsp;&nbsp;However, any successor to or acquirer of such assets (other than a subsidiary of ours) must assume all of our obligations under the indenture or the debt securities, as appropriate.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Events of Default under the Indenture</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the following are events of default under the indenture with respect to any series of debt securities that we may issue:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">if we fail to pay any installment of interest on any series of debt securities, as and when the same shall become due and payable, and such default continues for a period of 90 days; provided, however, that a valid extension of an interest payment period by us in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of interest for this purpose;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">if we fail to pay the principal of, or premium, if any, on any series of debt securities as and when the same shall become due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established with respect to such series; provided, however, that a valid extension of the maturity of such debt securities in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of principal or premium, if any;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">if we fail to observe or perform any other covenant or agreement contained in the debt securities or the indenture, other than a covenant specifically relating to another series of debt securities, and our failure continues for 90 days after we receive written notice of such failure, requiring the same to be remedied and stating that such is a notice of default thereunder, from the trustee or holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">if specified events of bankruptcy, insolvency or reorganization occur.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an event of default with respect to debt securities of any series occurs and is continuing, other than an event of default specified in the last bullet point above, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the trustee if notice is given by such holders, may declare the unpaid principal of, premium, if any, and accrued interest, if any, due and payable immediately.&nbsp;&nbsp;If an event of default specified in the last bullet point above occurs with respect to us, the principal amount of and accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other action on the part of the trustee or any holder.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of default with respect to the series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in accordance with the indenture.&nbsp;&nbsp;Any waiver shall cure the default or event of default.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to the terms of the indenture, if an event of default under an indenture shall occur and be continuing, the trustee will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have offered the trustee reasonable indemnity.&nbsp;&nbsp;The holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the direction so given by the holder is not in conflict with any law or the applicable indenture; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it in personal liability or might be unduly prejudicial to the holders not involved in the proceeding.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A holder of the debt securities of any series will have the right to institute a proceeding under the indenture or to appoint a receiver or trustee, or to seek other remedies only if:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the holder has given written notice to the trustee of a continuing event of default with respect to that series;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</a>.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made written request;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">such holders have offered to the trustee indemnity satisfactory to it against the costs, expenses and liabilities to be incurred by the trustee in compliance with the request; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount of the outstanding debt securities of that series other conflicting directions within 90 days after the notice, request and offer.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest on, the debt securities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will periodically file statements with the trustee regarding our compliance with specified covenants in the indenture.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Modification of Indenture; Waiver</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and the trustee may change an indenture without the consent of any holders with respect to specific matters:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">to cure any ambiguity, defect or inconsistency in the indenture or in the debt securities of any series;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">to comply with the provisions described above under &#8220;Description of Debt Securities-Consolidation, Merger or Sale;&#8221;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">to provide for uncertificated debt securities in addition to or in place of certificated debt securities;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">to add to our covenants, restrictions, conditions or provisions such new covenants, restrictions, conditions or provisions for the benefit of the holders of all or any series of debt securities, to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of default or to surrender any right or power conferred upon us in the indenture;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">to add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms, or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">to make any change that does not adversely affect the interests of any holder of debt securities of any series in any material respect;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">to provide for the issuance of and establish the form and terms and conditions of the debt securities of any series as provided above under &#8220;Description of Debt Securities-General&#8221; to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the rights of the holders of any series of debt securities;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">to evidence and provide for the acceptance of appointment under any indenture by a successor trustee; or</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust Indenture Act.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, under the indenture, the rights of holders of a series of debt securities may be changed by us and the trustee with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected.&nbsp;&nbsp;However, unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, we and the trustee may make the following changes only with the consent of each holder of any outstanding debt securities affected:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">extending the fixed maturity of any debt securities of any series;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any premium payable upon the redemption of any series of any debt securities; or</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">reducing the percentage of debt securities, the holders of which are required to consent to any amendment, supplement, modification or waiver.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</a>.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Discharge</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each indenture provides that we can elect to be discharged from our obligations with respect to one or more series of debt securities, except for specified obligations, including obligations to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">provide for payment;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">register the transfer or exchange of debt securities of the series;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">replace stolen, lost or mutilated debt securities of the series;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">pay principal of and premium and interest on any debt securities of the series;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">maintain paying agencies;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">hold monies for payment in trust;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">recover excess money held by the trustee;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">compensate and indemnify the trustee; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">appoint any successor trustee.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to exercise our rights to be discharged, we must deposit with the trustee money or government obligations sufficient to pay all the principal of, any premium, if any, and interest on, the debt securities of the series on the dates payments are due.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form, Exchange and Transfer</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will issue the debt securities of each series only in fully registered form without coupons and, unless we provide otherwise in the applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof.&nbsp;&nbsp;The indenture provides that we may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company, or DTC, or another depositary named by us and identified in the applicable prospectus supplement with respect to that series. To the extent the debt securities of a series are issued in global form and as book-entry, a description of terms relating to any book-entry securities will be set forth in the applicable prospectus supplement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the option of the holder, subject to the terms of the indenture and the limitations applicable to global securities described in the applicable prospectus supplement, the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to the terms of the indenture and the limitations applicable to global securities set forth in the applicable prospectus supplement, holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of the security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will impose no service charge for any registration of transfer or exchange, but we may require payment of any taxes or other governmental charges.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will name in the applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities.&nbsp;&nbsp;We may at any time designate additional transfer agents or rescind the designation of any transfer agent or approve a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we elect to redeem the debt securities of any series, we will not be required to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the opening of business 15 days before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing; or</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except the unredeemed portion of any debt securities we are redeeming in part.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</a>.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Information Concerning the Trustee</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those duties as are specifically set forth in the applicable indenture.&nbsp;&nbsp;Upon an event of default under an indenture, the trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs.&nbsp;&nbsp;Subject to this provision, the trustee is under no obligation to exercise any of the powers given it by the indenture at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might incur.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payment and Paying Agents</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents designated by us, except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the applicable prospectus supplement, we will designate the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement any other paying agents that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All money we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on any debt securities that remains unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment thereof.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Governing Law</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The indenture and the debt securities will be governed by and construed in accordance with the internal laws of the State of New York, except to the extent that the Trust Indenture Act of 1939 is applicable.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="DESCRIPTION_WARRANTS"></a><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="DESCRIPTION_WARRANTS"></a>DESCRIPTION</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> OF WARRANTS</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following description, together with the additional information we may include in any applicable prospectus supplements and free writing prospectuses, summarizes the material terms and provisions of the warrants that we may offer under this prospectus, which may consist of warrants to purchase common stock, preferred stock, and debt securities, and may be issued in one or more series. Warrants may be issued independently or together with common stock, preferred stock, or debt securities offered by any prospectus supplement, and may be attached to or separate from those securities. While the terms summarized below will apply generally to any warrants that we may offer under this prospectus, we will describe the particular terms of any series of warrants that we may offer in more detail in the applicable prospectus supplement. If we indicate in the prospectus supplement, the terms of any warrants offered under that prospectus supplement may differ from the terms described below. However, no prospectus supplement shall fundamentally change the terms that are set forth in this prospectus or offer a security that is not registered and described in this prospectus at the time of its effectiveness. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have filed forms of the warrant agreements and forms of warrant certificates as exhibits to the registration statement of which this prospectus is a part. We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of warrant agreement, if any, including a form of warrant certificate, that describes the terms of the particular series of warrants we are offering. The following summaries of material provisions of the warrants and the warrant agreements are subject to, and qualified in their entirety by reference to, all the provisions of the warrant agreement and warrant certificate applicable to the particular series of warrants that we may offer under this prospectus. We urge you to read any applicable prospectus supplements related to the particular series of warrants that we may offer under this prospectus, as well as any related free writing prospectuses, and the complete warrant agreements and warrant certificates that contain the terms of the warrants.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">General</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will describe in the applicable prospectus supplement the terms of the series of warrants being offered, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the offering price and aggregate number of warrants offered;</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the currency for which the warrants may be purchased;</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each principal amount of such security;</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">if applicable, the date on and after which the warrants and the related securities will be separately transferable;</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon exercise of one warrant and the price at, and currency in which, this principal amount of debt securities may be purchased upon such exercise;</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which these shares may be purchased upon such exercise;</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and the warrants;</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the terms of any rights to redeem or call the warrants;</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants;</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the dates on which the right to exercise the warrants will commence and expire;</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the manner in which the warrant agreements and warrants may be modified;</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">any material or special U.S. federal income tax consequences of holding or exercising the warrants;</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the terms of the securities issuable upon exercise of the warrants; and</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">any other specific terms, preferences, rights or limitations of or restrictions on the warrants.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</a>.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium, if any, or interest on, the debt securities purchasable upon exercise or to enforce covenants in the applicable indenture; or</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise of Warrants</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each warrant will entitle the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise price that we describe in the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to the specified time on the expiration date that we set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless we otherwise specify in any applicable prospectus supplement, holders of the warrants may exercise the warrants by delivering the warrant certificate representing the warrants to be exercised together with specified information, and paying the required amount to the warrant agent in immediately available funds, as provided in the applicable prospectus supplement. We will set forth on the reverse side of the warrant certificate and in the applicable prospectus supplement the information that the holder of the warrant will be required to deliver to the warrant agent in connection with the exercise of the warrant.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon receipt of the required payment and the warrant certificate properly completed and duly executed at the corporate trust office of the warrant agent or any other office indicated in the applicable prospectus supplement, we will issue and deliver the securities purchasable upon such exercise. If fewer than all of the warrants represented by the warrant certificate are exercised, then we will issue a new warrant certificate for the remaining amount of warrants. If we so indicate in the applicable prospectus supplement, holders of the warrants may surrender securities as all or part of the exercise price for warrants.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Enforceability of Rights by Holders of Warrants</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each warrant agent will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon exercise of, its warrants.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding Warrants</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 18, 2021, we had outstanding warrants to purchase 133,401 shares of our common stock, having an exercise price of $109.80 per share. Any of the outstanding warrants may be exercised by applying the value of a portion of the warrant, which is equal to the number of shares issuable under the warrant being exercised multiplied by the fair market value of the security receivable upon the exercise of the warrant, less the per share price, in lieu of payment of the exercise price per share.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These warrants, if unexercised, will expire on June 16, 2022.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</a>.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="LEGAL_OWNERSHIP_SECURITIES"></a><a name="LEGAL_OWNERSHIP_SECURITIES"></a>LEGAL OWNERSHIP OF SECURITIES</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We can issue securities in registered form or in the form of one or more global securities. We describe global securities in greater detail below. We refer to those persons who have securities registered in their own names on the books that we or any applicable trustee, depositary or warrant agent maintain for this purpose as the &#8220;holders&#8221; of those securities. These persons are the legal holders of the securities. We refer to those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names, as &#8220;indirect holders&#8221; of those securities. As we discuss below, indirect holders are not legal holders, and investors in securities issued in book-entry form or in street name will be indirect holders.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Book-Entry Holders</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may issue securities in book-entry form only, as we will specify in the applicable prospectus supplement. This means securities may be represented by one or more global securities registered in the name of a financial institution that holds them as depositary on behalf of other financial institutions that participate in the depositary&#8217;s book-entry system. These participating institutions, which are referred to as participants, in turn, hold beneficial interests in the securities on behalf of themselves or their customers.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Only the person in whose name a security is registered is recognized as the holder of that security. Securities issued in global form will be registered in the name of the depositary or its participants. Consequently, for securities issued in global form, we will recognize only the depositary as the holder of the securities, and we will make all payments on the securities to the depositary. The depositary passes along the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so under agreements they have made with one another or with their customers; they are not obligated to do so under the terms of the securities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result, investors in a book-entry security will not own securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker or other financial institution that participates in the depositary&#8217;s book-entry system or holds an interest through a participant. As long as the securities are issued in global form, investors will be indirect holders, and not legal holders, of the securities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Street Name Holders</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may terminate a global security or issue securities in non-global form. In these cases, investors may choose to hold their securities in their own names or in &#8220;street name.&#8221; Securities held by an investor in street name would be registered in the name of a bank, broker or other financial institution that the investor chooses, and the investor would hold only a beneficial interest in those securities through an account he or she maintains at that institution.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For securities held in street name, we or any applicable trustee or depositary will recognize only the intermediary banks, brokers and other financial institutions in whose names the securities are registered as the holders of those securities, and we or any applicable trustee or depositary will make all payments on those securities to them. These institutions pass along the payments they receive to their customers who are the beneficial owners, but only because they agree to do so in their customer agreements or because they are legally required to do so. Investors who hold securities in street name will be indirect holders, not holders, of those securities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Legal Holders</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our obligations, as well as the obligations of any applicable trustee and of any third parties employed by us or a trustee, run only to the legal holders of the securities. We do not have obligations to investors who hold beneficial interests in global securities, in street name or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of a security or has no choice because we are issuing the securities only in global form.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, once we make a payment or give a notice to the legal holder, we have no further responsibility for the payment or notice even if that legal holder is required, under agreements with its participants or customers or by law, to pass it along to the indirect holders but does not do so. Similarly, we may want to obtain the approval of the legal holders to amend an indenture, to relieve us of the consequences of a default or of our obligation to comply with a particular provision of the indenture or for other purposes. In such an event, we would seek approval only from the legal holders, and not the indirect holders, of the securities. Whether and how the holders contact the indirect holders is up to the legal holders.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</a>.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Special Considerations for Indirect Holders</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If you hold securities through a bank, broker or other financial institution, either in book-entry form because the securities are represented by one or more global securities or in street name, you should check with your own institution to find out:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the performance of third party service providers;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">how it handles securities payments and notices;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">whether it imposes fees or charges;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">how it would handle a request for the holders&#8217; consent, if ever required;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">whether and how you can instruct it to send you securities registered in your own name so you can be a holder, if that is permitted in the future;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">how it would exercise rights under the securities if there were a default or other event triggering the need for holders to act to protect their interests; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">if the securities are in book-entry form, how the depositary&#8217;s rules and procedures will affect these matters.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Global Securities</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A global security is a security that represents one or any other number of individual securities held by a depositary. Generally, all securities represented by the same global securities will have the same terms.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each security issued in book-entry form will be represented by a global security that we issue to, deposit with and register in the name of a financial institution or its nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless we specify otherwise in the applicable prospectus supplement, DTC will be the depositary for all securities issued in book-entry form.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A global security may not be transferred to or registered in the name of anyone other than the depositary, its nominee or a successor depositary, unless special termination situations arise. We describe those situations below under the section entitled &#8220;Special Situations When a Global Security Will Be Terminated&#8221; in this prospectus. As a result of these arrangements, the depositary, or its nominee, will be the sole registered owner and legal holder of all securities represented by a global security, and investors will be permitted to own only beneficial interests in a global security. Beneficial interests must be held by means of an account with a broker, bank or other financial institution that in turn has an account with the depositary or with another institution that does. Thus, an investor whose security is represented by a global security will not be a legal holder of the security, but only an indirect holder of a beneficial interest in the global security.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the prospectus supplement for a particular security indicates that the security will be issued in global form only, then the security will be represented by a global security at all times unless and until the global security is terminated. If termination occurs, we may issue the securities through another book-entry clearing system or decide that the securities may no longer be held through any book-entry clearing system.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Special Considerations for Global Securities</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The rights of an indirect holder relating to a global security will be governed by the account rules of the investor&#8217;s financial institution and of the depositary, as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of securities and instead deal only with the depositary that holds the global security.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If securities are issued only in the form of a global security, an investor should be aware of the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">an investor cannot cause the securities to be registered in his or her name, and cannot obtain non-global certificates for his or her interest in the securities, except in the special situations we describe below;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">an investor will be an indirect holder and must look to his or her own bank or broker for payments on the securities and protection of his or her legal rights relating to the securities, as we describe above;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</a>.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">an investor may not be able to sell interests in the securities to some insurance companies and to other institutions that are required by law to own their securities in non-book-entry form;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">an investor may not be able to pledge his or her interest in a global security in circumstances where certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the depositary&#8217;s policies, which may change from time to time, will govern payments, transfers, exchanges and other matters relating to an investor&#8217;s interest in a global security;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">we and any applicable trustee have no responsibility for any aspect of the depositary&#8217;s actions or for its records of ownership interests in a global security, nor do we or any applicable trustee supervise the depositary in any way;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the depositary may, and we understand that DTC will, require that those who purchase and sell interests in a global security within its book-entry system use immediately available funds, and your broker or bank may require you to do so as well; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">financial institutions that participate in the depositary&#8217;s book-entry system, and through which an investor holds its interest in a global security, may also have their own policies affecting payments, notices and other matters relating to the securities.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any of those intermediaries.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Special Situations When a Global Security Will Be Terminated</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In a few special situations described below, the global security will terminate and interests in it will be exchanged for physical certificates representing those interests. After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors must consult their own banks, brokers or other financial institutions to find out how to have their interests in securities transferred to their own name, so that they will be direct holders. We have described the rights of holders and street name investors above.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless we provide otherwise in the applicable prospectus supplement, the global security will terminate when the following special situations occur:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for that global security and we do not appoint another institution to act as depositary within 90 days;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">if we notify any applicable trustee that we wish to terminate that global security; or</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">if an event of default has occurred with regard to securities represented by that global security and has not been cured or waived.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The applicable prospectus supplement may also list additional situations for terminating a global security that would apply only to the particular series of securities covered by the applicable prospectus supplement. When a global security terminates, the depositary, and not we or any applicable trustee, is responsible for deciding the names of the institutions that will be the initial direct holders.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</a>.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="PLAN_DISTRIBUTION_1"></a><a name="PLAN_DISTRIBUTION_1"></a>PLAN OF DISTRIBUTION</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may sell the securities from time to time pursuant to underwritten public offerings, direct sales to the public, negotiated transactions, block trades or a combination of these methods. We may sell the securities to or through underwriters or dealers, through agents, or directly to one or more purchasers. We may distribute securities from time to time in one or more transactions:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">at a fixed price or prices, which may be changed;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">at market prices prevailing at the time of sale;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">at prices related to such prevailing market prices; or</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">at negotiated prices.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also sell equity securities covered by this registration statement in an &#8220;at the market offering&#8221; as defined in Rule 415 under the Securities Act. Such offering may be made into an existing trading market for such securities in transactions at other than a fixed price, either: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">on or through the facilities of The NASDAQ Capital Market or any other securities exchange or quotation or trading service on which such securities may be listed, quoted or traded at the time of sale; and/or </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">other than on The NASDAQ Capital Market or such other securities exchanges or quotation or trading services.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Such at the market offerings, if any, may be conducted by underwriters acting as principal or agent.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A prospectus supplement or supplements (and any related free writing prospectus that we may authorize to be provided to you) will describe the terms of the offering of the securities, including, to the extent applicable:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the name or names of the underwriters, if any;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the purchase price of the securities or other consideration therefor, and the proceeds, if any, we will receive from the sale;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">any over-allotment options under which underwriters may purchase additional securities from us;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">any agency fees or underwriting discounts and other items constituting agents&#8217; or underwriters&#8217; compensation;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">any public offering price;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">any discounts or concessions allowed or reallowed or paid to dealers; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">any securities exchange or market on which the securities may be listed.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Only underwriters named in the prospectus supplement will be underwriters of the securities offered by the prospectus supplement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable underwriting agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain conditions, the underwriters will be obligated to purchase all of the securities offered by the prospectus supplement, other than securities covered by any over-allotment option. Any public offering price and any discounts or concessions allowed or reallowed or paid to dealers may change from time to time. We may use underwriters with whom we have a material relationship. We will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may sell securities directly or through agents we designate from time to time. We will name any agent involved in the offering and sale of securities and we will describe any commissions we will pay the agent in the applicable prospectus supplement. Unless the applicable prospectus supplement states otherwise, our agent will act on a best-efforts basis for the period of its appointment.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</a>.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may authorize agents or underwriters to solicit offers by certain types of institutional investors to purchase securities from us at the public offering price set forth in the applicable prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may provide agents and underwriters with indemnification against civil liabilities, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to these liabilities. Agents and underwriters may engage in transactions with, or perform services for, us in the ordinary course of business. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All securities we may offer, other than common stock, will be new issues of securities with no established trading market. Any underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of the trading markets for any securities. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any underwriter may engage in over-allotment, stabilizing transactions, short-covering transactions and penalty bids in accordance with Regulation M under the Exchange Act. Over-allotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum price. Syndicate-covering or other short-covering transactions involve purchases of the securities, either through exercise of the over-allotment option or in the open market after the distribution is completed, to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any underwriters or agents that are qualified market makers on The NASDAQ Capital Market may engage in passive market making transactions in the common stock on The NASDAQ Capital Market in accordance with Regulation M under the Exchange Act, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the common stock. Passive market makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if all independent bids are lowered below the passive market maker&#8217;s bid, however, the passive market maker&#8217;s bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the securities at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In compliance with guidelines of the Financial Industry Regulatory Authority, or FINRA, the maximum consideration or discount to be received by any FINRA member or independent broker dealer may not exceed 8% of the aggregate amount of the securities offered pursuant to this prospectus and the applicable prospectus supplement.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="LEGAL_MATTERS_1"></a><a name="LEGAL_MATTERS_1"></a>LEGAL MATTERS</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless otherwise indicated in the applicable prospectus supplement, the validity of the securities offered by this prospectus, and any supplement thereto, will be passed upon for us by Cooley LLP, Broomfield, Colorado. Additional legal matters may be passed upon for us or any underwriters, dealers or agents by counsel that we name in any applicable prospectus supplement.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="EXPERTS_1"></a><a name="EXPERTS_1"></a>EXPERTS</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The financial statements of ARCA biopharma, Inc. as of December&#160;31, 2020 and 2019, and for the years then ended, have been incorporated by reference herein and in the registration statement in reliance upon the report of KPMG LLP, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing</font><font style="color:#000000;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</a>.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="WHERE_YOU_CAN_FIND_MORE_INFORMATION_1"></a><a name="WHERE_YOU_CAN_FIND_MORE_INFORMATION_1"></a>WHERE YOU CAN FIND MORE INFORMATION</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This prospectus is part of the registration statement on Form S-3 we filed with the SEC under the Securities Act and does not contain all the information set forth in the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Whenever a reference is made in this prospectus to any of our contracts, agreements or other documents, the reference may not be complete and you should refer to the exhibits that are a part of the registration statement or the exhibits to the reports or other documents incorporated by reference into this prospectus for a copy of such contract, agreement or other document. You should rely only on the information contained in this prospectus, any accompanying prospectus supplement or incorporated by reference. We have not authorized anyone else to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus or any accompanying prospectus supplement is accurate as of any date other than the date on the front page of this prospectus and the date on the front page of the applicable accompanying prospectus supplement, as applicable, regardless of the time of delivery of this prospectus and any accompanying prospectus supplement or any sale of the securities offered by this and any accompanying prospectus supplement. Because we are subject to the information and reporting requirements of the Exchange Act, we file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC&#8217;s website at http://www.sec.gov, which contains reports, proxy and information statements, and other information regarding issuers that file electronically.&nbsp;&nbsp;You can find additional information about the company at our website, <font style="text-decoration:underline;color:#0000FF;">http://www.arcabio.com</font>. Information contained in or accessible through our website does not constitute a part of this prospectus or any accompanying prospectus supplement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</a>.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="INCORPORATION_CERTAIN_INFORMATION_1"></a><a name="INCORPORATION_CERTAIN_INFORMATION_1"></a>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</p>
<p style="margin-top:12pt;line-height:11pt;margin-bottom:0pt;margin-right:1.07%;text-indent:3.85%;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T<font style="letter-spacing:-0.05pt;">h</font>e<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">S</font><font style="letter-spacing:0.05pt;">E</font>C<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:0.05pt;">a</font>l<font style="letter-spacing:0.05pt;">l</font><font style="letter-spacing:-0.25pt;">o</font><font style="letter-spacing:0.15pt;">w</font>s <font style="letter-spacing:-0.05pt;">u</font>s<font style="letter-spacing:0.05pt;"> </font>to<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:0.05pt;">&#8220;i</font><font style="letter-spacing:-0.25pt;">n</font><font style="letter-spacing:0.05pt;">c</font><font style="letter-spacing:-0.05pt;">or</font><font style="letter-spacing:-0.25pt;">p</font><font style="letter-spacing:-0.05pt;">or</font><font style="letter-spacing:0.05pt;">a</font>te<font style="letter-spacing:-0.05pt;"> b</font>y<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.05pt;">r</font><font style="letter-spacing:0.05pt;">e</font><font style="letter-spacing:-0.25pt;">f</font><font style="letter-spacing:0.05pt;">e</font><font style="letter-spacing:-0.05pt;">r</font>e<font style="letter-spacing:-0.05pt;">n</font><font style="letter-spacing:0.05pt;">c</font>e&#8221;<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:0.05pt;">i</font><font style="letter-spacing:-0.25pt;">n</font><font style="letter-spacing:-0.05pt;">for</font>m<font style="letter-spacing:0.05pt;">at</font>i<font style="letter-spacing:-0.05pt;">o</font>n<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.05pt;">fro</font>m<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.25pt;">o</font><font style="letter-spacing:0.05pt;">t</font><font style="letter-spacing:-0.05pt;">h</font>er<font style="letter-spacing:0.1pt;"> </font><font style="letter-spacing:-0.05pt;">d</font><font style="letter-spacing:-0.25pt;">o</font><font style="letter-spacing:0.05pt;">c</font><font style="letter-spacing:-0.05pt;">u</font>m<font style="letter-spacing:0.05pt;">e</font><font style="letter-spacing:-0.25pt;">n</font><font style="letter-spacing:0.05pt;">t</font>s<font style="letter-spacing:0.05pt;"> </font>t<font style="letter-spacing:-0.05pt;">h</font><font style="letter-spacing:0.05pt;">a</font>t<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">w</font>e<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.25pt;">f</font><font style="letter-spacing:0.05pt;">il</font>e<font style="letter-spacing:-0.3pt;"> </font><font style="letter-spacing:0.15pt;">w</font>i<font style="letter-spacing:0.05pt;">t</font>h<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:0.05pt;">i</font>t, <font style="letter-spacing:-0.1pt;">w</font><font style="letter-spacing:-0.05pt;">h</font>i<font style="letter-spacing:0.05pt;">c</font>h<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:0.05pt;">m</font>e<font style="letter-spacing:0.05pt;">a</font><font style="letter-spacing:-0.25pt;">n</font>s<font style="letter-spacing:0.05pt;"> t</font><font style="letter-spacing:-0.25pt;">h</font><font style="letter-spacing:0.05pt;">a</font>t<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">w</font>e<font style="letter-spacing:-0.05pt;"> </font>c<font style="letter-spacing:0.05pt;">a</font>n <font style="letter-spacing:-0.05pt;">d</font>i<font style="letter-spacing:0.15pt;">s</font>c<font style="letter-spacing:0.05pt;">l</font><font style="letter-spacing:-0.05pt;">o</font><font style="letter-spacing:-0.1pt;">s</font>e<font style="letter-spacing:-0.05pt;"> </font>i<font style="letter-spacing:0.05pt;">m</font><font style="letter-spacing:-0.25pt;">p</font><font style="letter-spacing:-0.05pt;">or</font><font style="letter-spacing:0.05pt;">t</font>a<font style="letter-spacing:-0.05pt;">n</font>t<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:0.05pt;">i</font><font style="letter-spacing:-0.25pt;">n</font><font style="letter-spacing:-0.05pt;">for</font>m<font style="letter-spacing:0.05pt;">at</font>i<font style="letter-spacing:-0.05pt;">o</font>n<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:0.05pt;">t</font>o<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.05pt;">yo</font>u<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.05pt;">b</font>y<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.05pt;">r</font>e<font style="letter-spacing:-0.05pt;">f</font><font style="letter-spacing:0.05pt;">e</font><font style="letter-spacing:-0.05pt;">rr</font>i<font style="letter-spacing:-0.05pt;">n</font>g<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.05pt;">yo</font>u<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:0.05pt;">t</font>o<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:0.05pt;">t</font><font style="letter-spacing:-0.25pt;">h</font><font style="letter-spacing:-0.05pt;">o</font><font style="letter-spacing:-0.1pt;">s</font>e<font style="letter-spacing:-0.05pt;"> do</font><font style="letter-spacing:0.05pt;">c</font><font style="letter-spacing:-0.25pt;">u</font><font style="letter-spacing:0.05pt;">m</font>e<font style="letter-spacing:-0.05pt;">n</font><font style="letter-spacing:0.05pt;">t</font><font style="letter-spacing:-0.1pt;">s</font>. T<font style="letter-spacing:-0.05pt;">h</font>e<font style="letter-spacing:-0.05pt;"> </font>i<font style="letter-spacing:-0.05pt;">nfor</font>m<font style="letter-spacing:0.05pt;">a</font>t<font style="letter-spacing:0.05pt;">i</font><font style="letter-spacing:-0.05pt;">o</font>n<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:0.05pt;">i</font><font style="letter-spacing:-0.25pt;">n</font><font style="letter-spacing:0.05pt;">c</font><font style="letter-spacing:-0.05pt;">orp</font><font style="letter-spacing:-0.25pt;">o</font>r<font style="letter-spacing:0.05pt;">a</font>t<font style="letter-spacing:0.05pt;">e</font>d<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.05pt;">b</font>y<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.05pt;">r</font><font style="letter-spacing:0.05pt;">e</font><font style="letter-spacing:-0.25pt;">f</font><font style="letter-spacing:0.05pt;">e</font><font style="letter-spacing:-0.05pt;">r</font>e<font style="letter-spacing:-0.05pt;">n</font><font style="letter-spacing:0.05pt;">c</font>e<font style="letter-spacing:-0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>c<font style="letter-spacing:-0.05pt;">on</font><font style="letter-spacing:-0.1pt;">s</font><font style="letter-spacing:0.05pt;">i</font><font style="letter-spacing:-0.25pt;">d</font><font style="letter-spacing:0.05pt;">e</font><font style="letter-spacing:-0.05pt;">r</font>ed <font style="letter-spacing:0.05pt;">t</font>o<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.05pt;">b</font>e<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.25pt;">p</font><font style="letter-spacing:0.05pt;">a</font><font style="letter-spacing:-0.05pt;">r</font>t<font style="letter-spacing:-0.05pt;"> o</font>f<font style="letter-spacing:-0.1pt;"> </font>t<font style="letter-spacing:-0.05pt;">h</font><font style="letter-spacing:0.05pt;">i</font>s<font style="letter-spacing:0.05pt;"> </font><font style="letter-spacing:-0.25pt;">p</font>r<font style="letter-spacing:-0.05pt;">o</font><font style="letter-spacing:-0.1pt;">s</font><font style="letter-spacing:-0.05pt;">p</font><font style="letter-spacing:0.05pt;">e</font>c<font style="letter-spacing:0.05pt;">t</font><font style="letter-spacing:-0.05pt;">u</font><font style="letter-spacing:-0.1pt;">s</font>. <font style="letter-spacing:-0.25pt;">I</font><font style="letter-spacing:-0.05pt;">nfor</font>m<font style="letter-spacing:0.05pt;">a</font>t<font style="letter-spacing:0.05pt;">i</font><font style="letter-spacing:-0.05pt;">o</font>n<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:0.05pt;">i</font>n<font style="letter-spacing:-0.15pt;"> </font>t<font style="letter-spacing:-0.05pt;">h</font><font style="letter-spacing:0.05pt;">i</font>s <font style="letter-spacing:-0.05pt;">pro</font><font style="letter-spacing:-0.1pt;">s</font><font style="letter-spacing:-0.05pt;">p</font><font style="letter-spacing:0.05pt;">e</font>c<font style="letter-spacing:0.05pt;">t</font><font style="letter-spacing:-0.25pt;">u</font>s<font style="letter-spacing:0.05pt;"> </font><font style="letter-spacing:-0.1pt;">s</font><font style="letter-spacing:-0.05pt;">up</font>e<font style="letter-spacing:-0.05pt;">r</font><font style="letter-spacing:0.15pt;">s</font>e<font style="letter-spacing:-0.05pt;">d</font>es<font style="letter-spacing:0.05pt;"> i</font><font style="letter-spacing:-0.25pt;">n</font><font style="letter-spacing:-0.05pt;">for</font>m<font style="letter-spacing:0.05pt;">a</font>t<font style="letter-spacing:0.05pt;">i</font><font style="letter-spacing:-0.05pt;">o</font>n<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:0.05pt;">i</font><font style="letter-spacing:-0.05pt;">n</font>c<font style="letter-spacing:-0.05pt;">orp</font><font style="letter-spacing:-0.25pt;">o</font>r<font style="letter-spacing:0.05pt;">a</font>t<font style="letter-spacing:0.05pt;">e</font>d<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.05pt;">b</font>y<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.05pt;">r</font><font style="letter-spacing:0.05pt;">e</font><font style="letter-spacing:-0.25pt;">f</font><font style="letter-spacing:0.05pt;">e</font><font style="letter-spacing:-0.05pt;">r</font>e<font style="letter-spacing:-0.05pt;">n</font><font style="letter-spacing:0.05pt;">c</font>e<font style="letter-spacing:-0.05pt;"> </font>t<font style="letter-spacing:-0.05pt;">h</font>at<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:0.15pt;">w</font>e<font style="letter-spacing:-0.3pt;"> </font><font style="letter-spacing:-0.05pt;">f</font><font style="letter-spacing:0.05pt;">i</font>l<font style="letter-spacing:0.05pt;">e</font>d<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.1pt;">w</font><font style="letter-spacing:0.05pt;">i</font>th<font style="letter-spacing:0.1pt;"> </font>t<font style="letter-spacing:-0.05pt;">h</font>e <font style="letter-spacing:-0.1pt;">S</font><font style="letter-spacing:0.05pt;">E</font>C<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.05pt;">pr</font>i<font style="letter-spacing:-0.05pt;">o</font>r<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:0.05pt;">t</font>o<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:0.05pt;">t</font><font style="letter-spacing:-0.25pt;">h</font>e<font style="letter-spacing:-0.05pt;"> d</font><font style="letter-spacing:0.05pt;">a</font>te<font style="letter-spacing:-0.05pt;"> o</font>f<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:0.05pt;">t</font><font style="letter-spacing:-0.05pt;">h</font>is<font style="letter-spacing:0.05pt;"> </font><font style="letter-spacing:-0.05pt;">pr</font><font style="letter-spacing:-0.25pt;">o</font><font style="letter-spacing:0.15pt;">s</font><font style="letter-spacing:-0.05pt;">p</font>e<font style="letter-spacing:0.05pt;">c</font>t<font style="letter-spacing:-0.05pt;">u</font><font style="letter-spacing:-0.1pt;">s, while information that we file later with the SEC will automatically update and supersede the information in this prospectus</font>. We<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:0.05pt;">i</font><font style="letter-spacing:-0.05pt;">n</font>c<font style="letter-spacing:-0.05pt;">orp</font><font style="letter-spacing:-0.25pt;">o</font>r<font style="letter-spacing:0.05pt;">a</font>te<font style="letter-spacing:-0.05pt;"> b</font>y<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.05pt;">r</font><font style="letter-spacing:0.05pt;">e</font><font style="letter-spacing:-0.05pt;">f</font>e<font style="letter-spacing:-0.05pt;">r</font><font style="letter-spacing:0.05pt;">e</font><font style="letter-spacing:-0.25pt;">n</font><font style="letter-spacing:0.05pt;">c</font>e<font style="letter-spacing:-0.05pt;"> </font>i<font style="letter-spacing:-0.05pt;">n</font><font style="letter-spacing:0.05pt;">t</font>o<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:0.05pt;">t</font><font style="letter-spacing:-0.25pt;">h</font><font style="letter-spacing:0.05pt;">i</font>s<font style="letter-spacing:0.05pt;"> </font><font style="letter-spacing:-0.25pt;">p</font>r<font style="letter-spacing:-0.05pt;">o</font><font style="letter-spacing:-0.1pt;">s</font><font style="letter-spacing:-0.05pt;">p</font><font style="letter-spacing:0.05pt;">e</font>c<font style="letter-spacing:0.05pt;">t</font><font style="letter-spacing:-0.05pt;">u</font>s <font style="letter-spacing:0.05pt;">a</font><font style="letter-spacing:-0.05pt;">n</font>d<font style="letter-spacing:-0.15pt;"> </font>t<font style="letter-spacing:-0.05pt;">h</font>e<font style="letter-spacing:-0.05pt;"> r</font><font style="letter-spacing:0.05pt;">e</font><font style="letter-spacing:-0.25pt;">g</font><font style="letter-spacing:0.05pt;">i</font><font style="letter-spacing:-0.1pt;">s</font><font style="letter-spacing:0.05pt;">t</font><font style="letter-spacing:-0.05pt;">r</font>a<font style="letter-spacing:0.05pt;">t</font>i<font style="letter-spacing:-0.05pt;">o</font>n<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:0.15pt;">s</font>t<font style="letter-spacing:0.05pt;">a</font>t<font style="letter-spacing:0.05pt;">e</font>m<font style="letter-spacing:0.05pt;">e</font><font style="letter-spacing:-0.25pt;">n</font>t<font style="letter-spacing:-0.05pt;"> o</font>f<font style="letter-spacing:0.1pt;"> </font><font style="letter-spacing:-0.1pt;">w</font><font style="letter-spacing:-0.25pt;">h</font><font style="letter-spacing:0.05pt;">ic</font>h<font style="letter-spacing:-0.15pt;"> </font>t<font style="letter-spacing:-0.05pt;">h</font><font style="letter-spacing:0.05pt;">is </font><font style="letter-spacing:-0.05pt;">pro</font><font style="letter-spacing:-0.1pt;">s</font><font style="letter-spacing:-0.05pt;">p</font>e<font style="letter-spacing:0.05pt;">c</font>t<font style="letter-spacing:-0.05pt;">u</font>s<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>a<font style="letter-spacing:-0.05pt;"> p</font>a<font style="letter-spacing:-0.05pt;">r</font>t<font style="letter-spacing:-0.05pt;"> </font>t<font style="letter-spacing:-0.05pt;">h</font>e<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:0.05pt;">i</font><font style="letter-spacing:-0.05pt;">nf</font><font style="letter-spacing:-0.25pt;">o</font><font style="letter-spacing:-0.05pt;">r</font><font style="letter-spacing:0.05pt;">m</font>a<font style="letter-spacing:0.05pt;">t</font>i<font style="letter-spacing:-0.05pt;">o</font>n<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.05pt;">o</font>r<font style="letter-spacing:0.1pt;"> </font><font style="letter-spacing:-0.25pt;">d</font><font style="letter-spacing:-0.05pt;">o</font><font style="letter-spacing:0.05pt;">c</font><font style="letter-spacing:-0.05pt;">u</font>me<font style="letter-spacing:-0.05pt;">n</font><font style="letter-spacing:0.05pt;">t</font>s <font style="letter-spacing:0.05pt;">li</font><font style="letter-spacing:-0.1pt;">s</font>t<font style="letter-spacing:0.05pt;">e</font>d<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.05pt;">b</font>e<font style="letter-spacing:0.05pt;">l</font><font style="letter-spacing:-0.05pt;">o</font>w <font style="letter-spacing:0.05pt;">t</font><font style="letter-spacing:-0.05pt;">h</font>at<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">w</font>e<font style="letter-spacing:-0.05pt;"> h</font><font style="letter-spacing:0.05pt;">a</font><font style="letter-spacing:-0.25pt;">v</font>e<font style="letter-spacing:-0.05pt;"> f</font><font style="letter-spacing:0.05pt;">i</font>l<font style="letter-spacing:0.05pt;">e</font>d<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.1pt;">w</font><font style="letter-spacing:0.05pt;">i</font>th<font style="letter-spacing:0.1pt;"> </font>t<font style="letter-spacing:-0.05pt;">h</font>e<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">S</font><font style="letter-spacing:0.05pt;">E</font>C<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.05pt;">(</font><font style="letter-spacing:-0.25pt;">C</font><font style="letter-spacing:-0.05pt;">o</font><font style="letter-spacing:0.05pt;">m</font>m<font style="letter-spacing:0.05pt;">i</font><font style="letter-spacing:-0.1pt;">ss</font><font style="letter-spacing:0.05pt;">i</font><font style="letter-spacing:-0.25pt;">o</font>n<font style="letter-spacing:0.1pt;"> </font><font style="letter-spacing:-0.1pt;">F</font>i<font style="letter-spacing:0.05pt;">l</font>e<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">N</font><font style="letter-spacing:-0.05pt;">o</font><font style="letter-spacing:-0.15pt;">.</font><font style="letter-spacing:-0.05pt;">000-2</font><font style="letter-spacing:-0.25pt;">2</font><font style="letter-spacing:-0.05pt;">873):</font></p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.05pt;color:#000000;">ou</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">r</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.15pt;color:#000000;"> A</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.05pt;color:#000000;">nnu</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;color:#000000;">a</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">l</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.05pt;color:#000000;"> R</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:0.05pt;color:#000000;">e</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.05pt;color:#000000;">po</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.25pt;color:#000000;">r</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">t</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.05pt;color:#000000;"> o</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">n</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.15pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:0.15pt;color:#000000;">F</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.25pt;color:#000000;">o</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.05pt;color:#000000;">r</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">m</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.05pt;color:#000000;"> 1</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.25pt;color:#000000;">0</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.05pt;color:#000000;">-</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">K</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.05pt;color:#000000;">fo</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">r</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.15pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:0.05pt;color:#000000;">t</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.05pt;color:#000000;">h</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">e</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.25pt;color:#000000;">y</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:0.05pt;color:#000000;">e</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;color:#000000;">a</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">r</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:0.1pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;color:#000000;">e</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.05pt;color:#000000;">nd</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;color:#000000;">e</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">d</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:0.1pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.1pt;color:#000000;">D</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;color:#000000;">e</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:0.05pt;color:#000000;">c</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;color:#000000;">e</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:0.05pt;color:#000000;">m</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.25pt;color:#000000;">b</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:0.05pt;color:#000000;">e</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">r</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.05pt;color:#000000;">31</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">, </font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.05pt;color:#000000;">2</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.25pt;color:#000000;">020</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">, </font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.05pt;color:#000000;">f</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;color:#000000;">i</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:0.05pt;color:#000000;">l</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;color:#000000;">e</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">d</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:0.1pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.1pt;color:#000000;">w</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;color:#000000;">i</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:0.05pt;color:#000000;">t</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">h</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.15pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:0.05pt;color:#000000;">t</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.05pt;color:#000000;">h</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">e</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.1pt;color:#000000;">S</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;color:#000000;">E</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">C</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.15pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.05pt;color:#000000;">o</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">n</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.15pt;color:#000000;"> </font><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459021014148/abio-10k_20201231.htm"><font style="text-decoration:underline;color:#0000FF;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.15pt;">March 18, 2021</font></a><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">;</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;"> </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:9pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">our Current Reports on Form 8-K filed with the SEC on </font><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459021003874/abio-8k_20210129.htm"><font style="text-decoration:underline;color:#0000FF;font-size:10pt;font-family:Times New Roman;">February 2, 2021</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (other than any portion of such current reports furnished under Item 2.02 or Item 7.01 of Form&#160;8&#8209;K and exhibits filed on such form that are related to such items unless such Form 8-K expressly provides to the contrary); and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the description of our securities set forth in our annual report on Form 10-K filed with the SEC on </font><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459020005032/abio-ex47_80.htm"><font style="text-decoration:underline;color:#0000FF;font-size:10pt;font-family:Times New Roman;">February 18, 2020</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, including any amendments thereto or reports filed for the purpose of updating such description.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also incorporate by reference any future filings (other than current reports on Form 8-K furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that are related to such items) that are subsequently filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the&#160;<font style="color:#000000;">Exchange Act</font>&#160;prior to the termination of the offering of the securities made by this prospectus (including (i) documents filed after the date of the registration statement of which this prospectus is a part and prior to the effectiveness of the registration statement and (ii) documents filed after the date of this prospectus until we file a post-effective amendment that indicates the termination of the offering of the securities covered by this prospectus, and will become a part of this from the date that such documents are filed with the SEC). These documents include periodic reports, such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as well as proxy statements. Information in such future filings updates and supplements the information provided in this prospectus. Any statements in any such future filings will automatically be deemed to modify and supersede any information in any document we previously filed with the SEC that is incorporated or deemed to be incorporated herein by reference to the extent that statements in the later filed document modify or replace such earlier statements. <font style="color:#000000;">The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. The address of that site is http://www.sec.gov.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">w</font><font style="letter-spacing:0.05pt;">i</font>ll<font style="letter-spacing:-0.05pt;"> furn</font>i<font style="letter-spacing:0.15pt;">s</font>h<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.1pt;">w</font><font style="letter-spacing:0.05pt;">i</font>t<font style="letter-spacing:-0.05pt;">hou</font>t<font style="letter-spacing:-0.05pt;"> </font>c<font style="letter-spacing:-0.05pt;">h</font>ar<font style="letter-spacing:-0.05pt;">g</font>e<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:0.05pt;">t</font>o<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.05pt;">yo</font><font style="letter-spacing:-0.25pt;">u</font>, <font style="letter-spacing:-0.05pt;">o</font>n<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.1pt;">w</font>r<font style="letter-spacing:0.05pt;">i</font>t<font style="letter-spacing:0.05pt;">te</font>n<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.05pt;">o</font>r<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.05pt;">or</font>al<font style="letter-spacing:-0.05pt;"> r</font><font style="letter-spacing:0.05pt;">e</font><font style="letter-spacing:-0.25pt;">q</font><font style="letter-spacing:-0.05pt;">u</font><font style="letter-spacing:0.05pt;">e</font><font style="letter-spacing:-0.1pt;">s</font>t, a<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:0.05pt;">c</font><font style="letter-spacing:-0.05pt;">o</font><font style="letter-spacing:-0.25pt;">p</font>y<font style="letter-spacing:0.1pt;"> </font><font style="letter-spacing:-0.25pt;">o</font>f<font style="letter-spacing:0.1pt;"> </font>a<font style="letter-spacing:-0.05pt;">n</font>y<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.05pt;">o</font>r<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:0.05pt;">al</font>l<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.25pt;">o</font>f<font style="letter-spacing:0.1pt;"> </font>t<font style="letter-spacing:-0.05pt;">h</font>e reports or<font style="letter-spacing:-0.05pt;"> do</font>c<font style="letter-spacing:-0.05pt;">u</font>m<font style="letter-spacing:0.05pt;">e</font><font style="letter-spacing:-0.05pt;">n</font>ts<font style="letter-spacing:0.05pt;"> i</font><font style="letter-spacing:-0.25pt;">n</font><font style="letter-spacing:0.05pt;">c</font><font style="letter-spacing:-0.05pt;">or</font><font style="letter-spacing:-0.25pt;">p</font><font style="letter-spacing:-0.05pt;">or</font><font style="letter-spacing:0.05pt;">a</font>t<font style="letter-spacing:0.05pt;">e</font>d<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.05pt;">b</font>y<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.05pt;">r</font>e<font style="letter-spacing:-0.05pt;">f</font><font style="letter-spacing:0.05pt;">e</font><font style="letter-spacing:-0.05pt;">r</font><font style="letter-spacing:-0.15pt;">e</font><font style="letter-spacing:-0.05pt;">n</font>c<font style="letter-spacing:0.05pt;">e</font>, <font style="letter-spacing:0.05pt;">i</font><font style="letter-spacing:-0.25pt;">n</font><font style="letter-spacing:0.05pt;">c</font>l<font style="letter-spacing:-0.05pt;">ud</font><font style="letter-spacing:0.05pt;">i</font><font style="letter-spacing:-0.05pt;">n</font>g<font style="letter-spacing:-0.15pt;"> </font>e<font style="letter-spacing:-0.05pt;">xh</font><font style="letter-spacing:0.05pt;">i</font><font style="letter-spacing:-0.25pt;">b</font><font style="letter-spacing:0.05pt;">it</font>s <font style="letter-spacing:0.05pt;">t</font>o<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:0.05pt;">t</font><font style="letter-spacing:-0.25pt;">h</font><font style="letter-spacing:0.05pt;">e</font><font style="letter-spacing:-0.1pt;">s</font>e<font style="letter-spacing:-0.05pt;"> do</font>c<font style="letter-spacing:-0.05pt;">u</font>m<font style="letter-spacing:0.05pt;">e</font><font style="letter-spacing:-0.05pt;">n</font>t<font style="letter-spacing:0.15pt;">s</font>.<font style="letter-spacing:-0.25pt;"> </font><font style="letter-spacing:-0.1pt;">Y</font><font style="letter-spacing:-0.05pt;">o</font>u<font style="letter-spacing:0.1pt;"> </font><font style="letter-spacing:-0.1pt;">s</font><font style="letter-spacing:-0.05pt;">h</font><font style="letter-spacing:-0.25pt;">o</font><font style="letter-spacing:-0.05pt;">u</font><font style="letter-spacing:0.05pt;">l</font>d<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.05pt;">d</font><font style="letter-spacing:0.05pt;">i</font><font style="letter-spacing:-0.25pt;">r</font><font style="letter-spacing:0.05pt;">e</font>ct<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:0.05pt;">a</font><font style="letter-spacing:-0.05pt;">n</font>y<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.05pt;">r</font>e<font style="letter-spacing:-0.05pt;">qu</font>e<font style="letter-spacing:0.15pt;">s</font>ts<font style="letter-spacing:0.05pt;"> </font><font style="letter-spacing:-0.05pt;">fo</font>r<font style="letter-spacing:-0.1pt;"> </font><font style="letter-spacing:-0.05pt;">do</font>c<font style="letter-spacing:-0.05pt;">u</font>m<font style="letter-spacing:0.05pt;">e</font><font style="letter-spacing:-0.05pt;">n</font>ts<font style="letter-spacing:0.05pt;"> </font>to<font style="letter-spacing:0.1pt;"> </font><font style="letter-spacing:-0.1pt;">A</font><font style="letter-spacing:-0.05pt;">RC</font>A <font style="letter-spacing:-0.05pt;">b</font><font style="letter-spacing:0.05pt;">i</font><font style="letter-spacing:-0.25pt;">o</font><font style="letter-spacing:-0.05pt;">ph</font><font style="letter-spacing:0.05pt;">a</font><font style="letter-spacing:-0.25pt;">r</font><font style="letter-spacing:0.05pt;">m</font>a, <font style="letter-spacing:-0.05pt;">In</font>c<font style="letter-spacing:0.1pt;">.</font>, Attention: Secretary, 10170 Church Ranch Way, Suite 100, Westminster, <font style="letter-spacing:-0.05pt;">C</font>O <font style="letter-spacing:-0.05pt;">80021</font>;<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:0.05pt;">te</font>l<font style="letter-spacing:0.05pt;">e</font><font style="letter-spacing:-0.25pt;">p</font><font style="letter-spacing:-0.05pt;">hon</font>e:<font style="letter-spacing:-0.05pt;"> (720</font>)<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.05pt;">940-</font><font style="letter-spacing:-0.25pt;">2</font><font style="letter-spacing:-0.05pt;">200; investors@arcabio.com.&nbsp;&nbsp;The documents outlined above are also available on our website at </font><font style="text-decoration:underline;color:#0000FF;">https://arcabio.com/investors/sec-filings/</font>. <font style="letter-spacing:-0.05pt;">Ou</font>r<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.05pt;">w</font><font style="letter-spacing:0.05pt;">e</font><font style="letter-spacing:-0.05pt;">bs</font>i<font style="letter-spacing:0.05pt;">t</font>e, <font style="letter-spacing:0.05pt;">a</font><font style="letter-spacing:-0.05pt;">n</font>d<font style="letter-spacing:-0.15pt;"> </font>t<font style="letter-spacing:-0.05pt;">h</font>e<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:0.05pt;">i</font><font style="letter-spacing:-0.05pt;">nf</font><font style="letter-spacing:-0.25pt;">o</font><font style="letter-spacing:-0.05pt;">r</font><font style="letter-spacing:0.05pt;">m</font>a<font style="letter-spacing:0.05pt;">t</font>i<font style="letter-spacing:-0.05pt;">o</font>n<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:0.05pt;">c</font><font style="letter-spacing:-0.05pt;">on</font>t<font style="letter-spacing:0.05pt;">a</font>i<font style="letter-spacing:-0.05pt;">n</font><font style="letter-spacing:0.05pt;">e</font>d<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.05pt;">o</font>n<font style="letter-spacing:-0.15pt;"> </font>t<font style="letter-spacing:-0.05pt;">h</font>e<font style="letter-spacing:-0.05pt;"> w</font><font style="letter-spacing:0.05pt;">e</font><font style="letter-spacing:-0.05pt;">bs</font>i<font style="letter-spacing:0.05pt;">t</font>e, <font style="letter-spacing:0.05pt;">i</font>s <font style="letter-spacing:-0.05pt;">no</font>t<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:0.05pt;">i</font><font style="letter-spacing:-0.05pt;">n</font>c<font style="letter-spacing:-0.05pt;">orp</font><font style="letter-spacing:-0.25pt;">o</font>r<font style="letter-spacing:0.05pt;">a</font>t<font style="letter-spacing:0.05pt;">e</font>d<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:0.05pt;">i</font><font style="letter-spacing:-0.05pt;">n</font>to<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:0.05pt;">a</font><font style="letter-spacing:-0.05pt;">n</font>d<font style="letter-spacing:-0.15pt;"> </font>are <font style="letter-spacing:-0.05pt;">no</font>t<font style="letter-spacing:-0.05pt;"> p</font>a<font style="letter-spacing:-0.05pt;">r</font>t<font style="letter-spacing:-0.05pt;"> o</font>f<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:0.05pt;">t</font><font style="letter-spacing:-0.25pt;">h</font><font style="letter-spacing:0.05pt;">i</font>s<font style="letter-spacing:0.05pt;"> </font><font style="letter-spacing:-0.25pt;">p</font>r<font style="letter-spacing:-0.05pt;">o</font><font style="letter-spacing:-0.1pt;">s</font><font style="letter-spacing:-0.05pt;">p</font><font style="letter-spacing:0.05pt;">e</font>c<font style="letter-spacing:0.05pt;">t</font><font style="letter-spacing:-0.05pt;">u</font><font style="letter-spacing:-0.1pt;">s.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</a>.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="border-bottom:Solid 2pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:2pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gp5m5bivuamv000004.jpg" title="" alt="" style="width:192px;height:77px;"><font style="color:#000000;font-size:11pt;">&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$50,000,000 </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Prospectus Supplement</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:22pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gp5m5bivuamv000005.jpg" title="" alt="" style="width:199px;height:59px;"></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">April 6, 2021 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:2pt;border-bottom:Solid 2pt #000000;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</a>.</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>gp5m5bivuamv000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gp5m5bivuamv000005.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_X0KD17AI9@  34T *@    @ ! $2  ,
M   !  $   $:  4    !    /@$;  4    !    1@$H  ,    !  (
M $X!+     $   $L     0    8! P #     0 &   !&@ %     0   )P!
M&P %     0   *0!*  #     0 "   " 0 $     0   *P" @ $     0
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MDE;NCK*X6S_Y+/J'_8+7_P!"2JH[2]":U[Q]3NZ*P.@BF65HV$+JDF/E9U+
M'W&1G\ZY31=;UO4?$-_ITSZ>D5B^)'2!]T@W$<#?\N0/?'O0!V%% !10 44
M<F;[Q/?:_JEMI[:9#86<B0K)/$[NS&-'(P' _CK,T/7_ !1KFIZQ913:3$VG
M3>4S/:R$2?,ZY'[P8^Y77&G2<6^R1QRG54TN[.@\,ZAJM]%J$6L16R7=G=F
MBVW;"NQ'!Y)/(>MZN>:2D[;'1!R<5<**@M,Y6_UO5+3QUI&D_P"BFPOA*W"-
MY@V(3R<XZX[5IW":T?$-G);S6HT<1L+F-E/FL^#M*\8QG;WK:481MYHQC*<K
MV[F=KD'C&34]VAW6F167EJ-MRK%]^3GH#QTJAX=\.^(;;Q=<:WKD^GR-+:?9
M_P#12P.0RD<%1V![UJJE*--I+6QE*%651-O2YV]'6N.YV"UPWA8A/&WBAB<*
M'!)_X$U,"SH'G>*K*;5KRZNXH99G6UM[>X>$11@X!)0@LQ/)R2/04FA7VH/J
MFJ>&[^^F:XM</;WB*GF-&<$9R-I8!EYVT 4?#5OJ7B70)9+K7+^(K/(JM ^Q
MBWJQZX'95P/7/8LO$^H-X"TZ<RLVHW=P+-)B@8@EC\^WC<P4=.[4 +?/JUF]
MO=Z'!KTTZ./M$%XQ9)TQSPQPK9_NX^E7=<UB.S\66]IJMS/:Z7+:[H7CD:-7
MFW$-N9<' 7'? W9/; !MZ+;W%O;2B>\:\C:4O;S,X8F(@%1D=<=/?K7(_#W_
M )&SQE_U^_\ M2:NFG_#GZ+\T<U7^+#U?Y%OXA7>J:;#ID^GW\D*37L5N\ P
MJOG)Y8#>!\N#@]*FFT7Q/86VL76GZ])?7MS"@MX;E L<+@_,R]0."<#&.F[=
MUJDZ:IQNMR6INI*ST1DZA?IHEWH7]GZK=W%U]OBL[]6NI+B%MV0X8ME5<$9
M&T^V*VM3O[C5?&,7ANVNY+:WAM_M=[)"Q61QNPL2MU0'.21SC@$4.'VFNC$J
MGV?-&7?:>VG_ !/\,QK=3S0,EP8TGD,C1GRSNP[98@\<,3CM5K4+S4(/BCHU
MA_:$[V5Q%+*UN0JJ"$?T )' ZDU?NRM=?9?ZF?O0O;^9?H07+:O-\2)-'37+
MN.VDL#,/D3,8,@R$P ,\8#,&(&[OS3_#LM[IGCW4?#\FH75[9BV6ZB:[D,DD
M;94$;O3G_/.1QARVMTN/FDI7;ZV':.TWBN\UYKK4;VW:TO'M+>&VN&A\E5&
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M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M 2(  A$! Q$!_\0 'P   04! 0$! 0$           $" P0%!@<("0H+_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M--_Z"%K_ -_E_P :.678.>/<O44R*9)XUDC=9$;D,IR#^-/J"PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,3QQ
M_P B5X@_[!]Q_P"BVK\:J_97QQ_R)7B#_L'W'_HMJ_&JOU'@S^'7]8_J?D7'
M?\3#^DOT"BBBOT<_+ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /U?_ &7_ /DW_P #_P#8/7_T)J]1
MKR[]E_\ Y-_\#_\ 8/7_ -":O4:_G7'?[W5_Q2_-G]/Y=_N5#_#'\D%%%%<)
MZ(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX+5_^.5]ET4?ZQ9I_P _OPC_ )!_JOE'_/C\9?YGQI_P[?TW_H>KK_P6K_\
M'*/^';^F_P#0]77_ (+5_P#CE?9=%'^L6:?\_OPC_D'^J^4?\^/QE_F?&G_#
MM_3?^AZNO_!:O_QRC_AV_IO_ $/5U_X+5_\ CE?9=%'^L6:?\_OPC_D'^J^4
M?\^/QE_F?&G_  [?TW_H>KK_ ,%J_P#QRO./C_\ L<V?P4^'<WB6#Q1/JTD=
MS%!]GDLEB!WDC.X.>F/2OT2KYX_;P_Y-_N_^PA;?^A&O2RW/<QKXVE2J5;Q<
MDGHO\CR<VX=RO#X"M6I4;2C%M.\M_O/S6HHHK]B/PX**** /U?\ V7_^3?\
MP/\ ]@]?_0FKU&O+OV7_ /DW_P #_P#8/7_T)J]1K^=<=_O=7_%+\V?T_EW^
MY4/\,?R04445PGHA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!B>./^1*\0?]@^X_]%M7XU5^ROCC_D2O$'_8/N/_ $6U
M?C57ZCP9_#K^L?U/R+CO^)A_27Z!1117Z.?E@5^@'_!.O_DF'B7_ +#'_M".
MOS_K] /^"=?_ "3#Q+_V&/\ VA'7R7%/_(LEZK\S[3A#_D;0])?D?6%%%%?B
MA^^!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7SQ^WA_R
M;_=_]A"V_P#0C7T/7SQ^WA_R;_=_]A"V_P#0C7L9/_R,*'^)?F>'GG_(LQ'^
M%_D?FM1117] '\UA1110!^K_ .R__P F_P#@?_L'K_Z$U>HUY=^R_P#\F_\
M@?\ [!Z_^A-7J-?SKCO][J_XI?FS^G\N_P!RH?X8_D@HHHKA/1"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% &)XX_Y$KQ!_P!@^X_]%M7XU5^ROCC_ )$K
MQ!_V#[C_ -%M7XU5^H\&?PZ_K']3\BX[_B8?TE^@4445^CGY8%?H!_P3K_Y)
MAXE_[#'_ +0CK\_Z_0#_ ()U_P#),/$O_88_]H1U\EQ3_P BR7JOS/M.$/\
MD;0])?D?6%%%%?BA^^!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7SQ^WA_R;_=_]A"V_]"-?0]?/'[>'_)O]W_V$+;_T(U[&3_\ (PH?
MXE^9X>>?\BS$?X7^1^:U%%%?T ?S6%%%% 'ZO_LO_P#)O_@?_L'K_P"A-7J-
M>7?LO_\ )O\ X'_[!Z_^A-7J-?SKCO\ >ZO^*7YL_I_+O]RH?X8_D@HHHKA/
M1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!B>./^1*\0?]@^X_\ 1;5^
M-5?LKXX_Y$KQ!_V#[C_T6U?C57ZCP9_#K^L?U/R+CO\ B8?TE^@4445^CGY8
M%?H!_P $Z_\ DF'B7_L,?^T(Z_/^OT _X)U_\DP\2_\ 88_]H1U\EQ3_ ,BR
M7JOS/M.$/^1M#TE^1]84445^*'[X%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %?/'[>'_ ";_ '?_ &$+;_T(U]#U\\?MX?\ )O\ =_\
M80MO_0C7L9/_ ,C"A_B7YGAYY_R+,1_A?Y'YK4445_0!_-84444 ?J_^R_\
M\F_^!_\ L'K_ .A-7J->7?LO_P#)O_@?_L'K_P"A-7J-?SKCO][J_P"*7YL_
MI_+O]RH?X8_D@HHHKA/1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-:BBBOZ /YK"BBB@#]7_ -E__DW_ ,#_ /8/7_T)J]1KR[]E_P#Y-_\  _\
MV#U_]":O4:_G7'?[W5_Q2_-G]/Y=_N5#_#'\D%%%%<)Z(4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7SQ^
MWA_R;_=_]A"V_P#0C7T/7SQ^WA_R;_=_]A"V_P#0C7L9/_R,*'^)?F>'GG_(
MLQ'^%_D?FM1117] '\UA1110!^K_ .R__P F_P#@?_L'K_Z$U>HUY=^R_P#\
MF_\ @?\ [!Z_^A-7J-?SKCO][J_XI?FS^G\N_P!RH?X8_D@HHHKA/1"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7SQ^WA_R;_=_]A"V_]"-?0]?/'[>'_)O]W_V$+;_T(U[&3_\
M(PH?XE^9X>>?\BS$?X7^1^:U%%%?T ?S6%%%% 'ZO_LO_P#)O_@?_L'K_P"A
M-7J->7?LO_\ )O\ X'_[!Z_^A-7J-?SKCO\ >ZO^*7YL_I_+O]RH?X8_D@HH
MHKA/1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***QO%?C
M'1O ^EC4=<ODT^R,@B$SJS#<02!A03V/Y4 ;-%>;?\-'?#C_ *&BW_[\S?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"_\ (/[4P'_01#_P*/\ F>OT5Y!_PUQ\(_\ H=+7_P !Y_\ XW1_PUQ\(_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHK,U[Q-H_A6S-YK6J66DVO\ SVOKA(4_-B*J,7)VBKLF4E%<
MTG9&G17SYXW_ &X_AEX3\R*PO+OQ-=+QLTR ^7GWD?:I'NNZOG;Q]_P4!\;:
M_P"9#X:TZQ\+VS<"8C[5<#_@3@(/^^/QKZ'"\/YCBM53Y5WEI^&_X'S&,XFR
MO!W3J\S[1U_';\3] =4U:QT.QEO=1O+?3[.(9DN+J58HT'J68@"N \)?M%>
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MT5]^>+OV:O 7BR-\:.NCW+=+C2SY)'_ /N'_ +YKY;^,?[/.M?"D&_23^UM
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1J0<N:VWE<^)XBR&MG,J4J4U'EOO?K;_ "/R3HK];/\ AG?X8_\ 0AZ#_P"
M*?X4?\,[_#'_ *$/0?\ P!3_  KZG_7'#?\ /J7X'Q_^HV+_ .?T?Q/R3K]
M/^"=?_),/$O_ &&/_:$=>V?\,[_#'_H0]!_\ 4_PKJ/"?@CP_P"!;.:T\/:/
M9Z+:S2>;)#90B-6? &X@=\ #\*\7..(J&981X>$&FVM[=#WLDX7Q&5XV.)J5
M$TDU97ZFY1117P)^D!1110 4444 %%%% 'XGT5^MG_#._P ,?^A#T'_P!3_"
MC_AG?X8_]"'H/_@"G^%?K'^N.&_Y]2_ _&?]1L7_ ,_H_B?DG17ZV?\ #._P
MQ_Z$/0?_  !3_"C_ (9W^&/_ $(>@_\ @"G^%'^N.&_Y]2_ /]1L7_S^C^)^
M2=%?K9_PSO\ #'_H0]!_\ 4_PH_X9W^&/_0AZ#_X I_A1_KCAO\ GU+\ _U&
MQ?\ S^C^)^2=%?K9_P ,[_#'_H0]!_\  %/\*/\ AG?X8_\ 0AZ#_P" *?X4
M?ZXX;_GU+\ _U&Q?_/Z/XGY)T5^MG_#._P ,?^A#T'_P!3_"C_AG?X8_]"'H
M/_@"G^%'^N.&_P"?4OP#_4;%_P#/Z/XGY)T5^MG_  SO\,?^A#T'_P  4_PH
M_P"&=_AC_P!"'H/_ ( I_A1_KCAO^?4OP#_4;%_\_H_B?DG17ZV?\,[_  Q_
MZ$/0?_ %/\*/^&=_AC_T(>@_^ *?X4?ZXX;_ )]2_ /]1L7_ ,_H_B?DG17Z
MV?\ #._PQ_Z$/0?_  !3_"C_ (9W^&/_ $(>@_\ @"G^%'^N.&_Y]2_ /]1L
M7_S^C^)^2=%?K9_PSO\ #'_H0]!_\ 4_PH_X9W^&/_0AZ#_X I_A1_KCAO\
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MAB@9^G-%%%9%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5^._Q4_P"2G^+_ /L,7G_H]Z_8BOQW^*G_ "4_Q?\
M]AB\_P#1[U^B\&_Q:WHOS9^7\=?P:'J_R1R]?57[!/PCC\5^-KSQEJ-OYEAH
M.U+0.,J]VPR&]_+7GV+H>U?*M?JW^S!X!7X=?!'PUISQ>5>W,']H7?')EF^?
M#>ZJ53_@ KZ7B;'/"8%P@_>GI\NO^7S/D^$\O6-S!5)J\:?O?/I^.OR/5:**
M*_%3]\"BBB@ HHHH **** "OAG_@I!_R&_ O_7O=_P#H45?<U?#/_!2#_D-^
M!?\ KWN__0HJ^HX9_P"1I3_[>_\ 26?(<6?\B>K_ -N_^E(^-:***_<#^?@H
MHHH [;X'_P#):O '_8PZ?_Z4QU^O5?D+\#_^2U> /^QAT_\ ]*8Z_7JORGC+
M^/1]'^9^Q\"_[M7_ ,2_(****_/3]-"BBB@ HHHH **** /F/]O#X6)XM^&,
M?BFUAW:IX>?>[*/F>U<A7''7:VU^>@#^M?G77[0Z]HMKXDT/4=)OD\RRO[>2
MUG3^\CJ58?D37XY>*O#USX2\3:MHEY_Q]:;=RVDO! +(Y4GZ'%?K/".,=7#S
MPLGK!W7H_P#@_F?B_&V!5'$PQ<%I-6?JO\U^1EU^O7P/_P"2*^ /^Q?T_P#]
M)HZ_(6OUZ^!__)%? '_8OZ?_ .DT=9\9?P*/J_R->!?]YK?X5^9VU%%%?E1^
MQA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !7Y0?M0?\G >./^P@W_ *"M?J_7Y0?M0?\
M)P'CC_L(-_Z"M??<'?[W4_P_JC\WXX_W*E_B_1GEU%%%?K1^+A7U%_P3P_Y+
M5K7_ &+\_P#Z4VU?+M?47_!/#_DM6M?]B_/_ .E-M7A9Y_R+:_H?0\/_ /(U
MP_\ B/T.HHHK\$/Z/"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH ^8_VWO\ D%^$O^NUS_Z#'7R;7UE^V]_R"_"7_7:Y_P#08Z^3
M:TCL2PHHHIB"M7PI_P C1H__ %^0_P#H8K*K5\*?\C1H_P#U^0_^AB@9^G-%
M%%9%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6<,8CV&91B]IIK]5^*/C.+L-]8RN<EO!J7Z/\&?"M?KU\#_^2*^ /^Q?T_\
M])HZ_(6OUZ^!_P#R17P!_P!B_I__ *31U]3QE_ H^K_(^/X%_P!YK?X5^9VU
M%%%?E1^QA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7Y0?M0?\G >./\ L(-_Z"M?J_7Y
M0?M0?\G >./^P@W_ *"M??<'?[W4_P /ZH_-^./]RI?XOT9Y=1117ZT?BX5]
M1?\ !/#_ )+5K7_8OS_^E-M7R[7U%_P3P_Y+5K7_ &+\_P#Z4VU>%GG_ "+:
M_H?0\/\ _(UP_P#B/T.HHHK\$/Z/"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH ^8_VWO^07X2_Z[7/_ *#'7R;7UE^V]_R"_"7_
M %VN?_08Z^3:TCL2PHHHIB"M7PI_R-&C_P#7Y#_Z&*RJU?"G_(T:/_U^0_\
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /F/\
M;>_Y!?A+_KM<_P#H,=?)M?67[;W_ ""_"7_7:Y_]!CKY-K2.Q+"BBBF(*U?"
MG_(T:/\ ]?D/_H8K*K5\*?\ (T:/_P!?D/\ Z&*!GZ<T445D4%%%% !1110
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MOWA^.0/2OK'X8_&_PS\4X0FG7)M=4"[I--NB%F&.I7LX]Q^(%3:Q1Z!1112
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M'?D?G5BO"/V-81%\*;QP<F759G/M^[B7^E>[U(PHHHH **** "BBB@ HHHH
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M/?BM)-;MJ+:!HC$A=,TMS&&7TDD^])QU!(7T45XO7Z%@N#W)*6,J6\H_Y_\
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M!^L?[/'Q?D^-WPXB\1SV,>G70N9;6:WA<L@9""""1W5EKTVOFK]@#_DA4_\
MV&+C_P! BKZ5K\US2C##XVK2IJT4W8_5LHKU,3@*-:J[RE%78445PGQ6^-7A
M3X-:.+WQ'J CFD&;>P@P]S<?[B9''^T2%'K7!2I5*\U3I1O)]$>C6K4\/!U:
MLE&*W;.[KSOXB?M!> ?A:SQ:_P"(K:*^3_F'VV9[C/8%$R5^K8'O7PM\8OVT
M?&WQ)DN++1YF\*:"V5%O8R?Z1*O_ $TFX//HNT=CGK7SZS%F+,223DD]Z_0<
M!PC.:4\;/E\EO\WM]U_4_,\QXVA!N& AS?WI;?);_?;T/NCQ7_P49TFW=X_#
M?A&[O1T6?4[E8/QV('S_ -]"O.=2_P""AGQ"N786>C^'K*/.1F":1_H290/T
MKY<HKZ^CP]EE%65*_JVSXFMQ-FU9W=9KT27Z7/IFW_X*"?$N&0.]CX>G7NDE
MG*!^DH-=[X4_X*-/YR1^)O!RF(GYKC2;KD?2.0<_]]BOBFBKJ9!EM56=%+TN
MOR(H\29M1=U7;];/\T?K/\+_ -HCP'\7-L6@ZT@U$C)TR]'D7(]<*?OX[E"P
M'K7I-?BE#,\$J21NT<B,&5T."I'((/8U]:_L[_MO:CX=N+;0/B%/+JFD,1'%
MK39>YMNW[WO(GO\ >'/WN@^)S/A2=&+JX)\R7V7O\N_IOZGWV4\94Z\E1Q\5
M!O[2V^:Z>NWH??%%06=Y;ZE9P7=I/'<VLZ+)%-"P9)$(R&4C@@@]:GK\]VT9
M^F)W5T%%%% PHHHH **** "BBB@ HHHH **Y;XA?$SPW\*]";5O$VJ1:=:\B
M-6^:69@/NQH.6/TZ=3@<U\1?%W]O;Q+XG:>P\%6W_",Z825%]*%DO9%]>ZQY
M'8;B.S5[67Y/B\R=Z,?=[O1?\'Y'@9GGF"RI6KRO+^5:O_@?.Q]U^*/&WA_P
M39BZU_6K'1K<_=>]N%BW>RY/)]A7B?BC]NSX7>'VD2RNM1\02+Q_Q+[,JN?]
MZ4IQ[C/XU^<>L:WJ/B+4);_5;ZYU.^E.9+F[F:61OJS$DU2K[_#<'X:"OB*C
MD_+1?JS\WQ?&^+J-K#4U%>>K_1?@S[@U?_@H_:HS+I?@6:9?X9+S4A&>W55C
M;W_BKGI/^"C7B$R,4\'::J9^4-=2$@>YP,_E7R'%"\\BQQHTCL<!4&2?PJ:X
MTV[LX]\]K- A.T-)&5&?3D5[,>'<JAI[+[V_\SP9<49Q4U]MIY*/^1];P_\
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M+CURI-:E>!*+B[25F?2QE&:YHNZ"BBBI*"BBB@ HHHH **** "BBB@ HHHH
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MB8/'+$Q5T8="".0?>H:*!'UK\"_VIEU62VT#QG,D5TV([?5FPJ2'H%E[*?\
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M-:***_<#^?@HHHH [;X'_P#):O '_8PZ?_Z4QU^O5?D+\#_^2U> /^QAT_\
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MYMC52J?!%7?IV^;?W';_  D^ '@WX,V$::'IB2:ELVS:M= /=2G&#\W\(/\
M=7 ]N]>CT45^'5JU3$3=2K)RD^K/Z$H4*6&IJE1BHQ71!1116)N%>.?'C]F/
MPQ\;--FG:"/2/$RK^XUB",!F('"S 8\Q?KR.QZ@^QT5TX?$5<+456C+EDCEQ
M.%HXRDZ.(BI1?1_U^)^-/C'PCJG@'Q/J.@:W;&TU.QE\J:,G(Z9# ]U(((/<
M$&L6ON?_ (*&?#6&?1=#\<VL06ZMY1IMX5'+QL&:)C_NL&7_ +:#TKX8K]YR
MK'K,L)#$;/9^JW_S/YSSC+GE>-GAKW2U3\GM_D%?5'['_P"U%/X%U.T\%>*+
MLR>&;I_+LKJ8Y-A*QX4D_P#+)B>?[I.>!FOE>BM\=@J.84'0K+1_@^Z.;+\?
M6RW$1Q%!V:^YKL_(_;"BOGG]BOXR2_$[X:'2=3G,VN^'REM+(YRTT!!\F0^X
M"E#_ +@)^]7T-7X%C,+/!5YX>IO%_P!/YG](X'&4\?AH8FEM)7_S7R>@4445
MQG<%%%% !1110 4444 %>&_M%?M2:)\$+)].M1'J_BV:/=#IX;Y( >DDQ'0=
MPH^8^P.:ROVJ?VHK?X-Z<V@Z$T=UXRNXMRY 9+&,])''=S_"GXGC ;\W]2U*
M[UC4+F^OKF6\O+F1I9KB9BSR.3DLQ/4DU]WD/#SQEL3BE:GT7\W_  /S/SKB
M/B98&^$P;O4ZO^7_ (/Y&YX_^(GB'XG>()M9\2:E+J-Z_"[SA(5SD)&O1%'H
M/KUR:YJBNJ^&?PUUOXL>,+/P[H-OYMW<'<\KY$4$8^])(>R@?F2 ,D@5^K?N
ML-2OI&$5Z)(_&U[;%5K:RG)^K;9D>'/#6J^+]8M]*T73[C4]1N&VQVULA=V]
M_8#N3P.M?8?PG_X)[^9!#?\ Q U9XI&&XZ1I3#*^TDQR/J$'T:OI+X)_ ?PW
M\#_#XLM)A%SJ4RC[;JLR#SKANX_V4!Z(.![G)/I%?EF:<4UJTG3P7NQ[]7_E
M^9^PY/P?0H157'^_/^7HO\W^'KN>?^$?@!\.O \:KI'A#2XI%&!<7$ N)O\
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M?$KXA>9'J7BB[MK-S_QYZ:?LL6/[I"8+#_>)KRYF+,68DDG))[U[EXN_8O\
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MQ'X;FT^1O^6EKJ%P"/H&=E_2O%/B5_P3PDM[::[\#:^]U(HRNFZP%#/[+,@
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MEK<6\MG<2P31M%-$Q1XW&"K X((]<U'7M?[67@M/"_Q.?4+>/R[368A=_*,
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MR\WT7RW]?0_7N#<H4*;S&JM7I'R75_/;T]0HHHK\Z/U$**** "BBB@ HHHH
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M*\/B'$O#9=4<=Y:??O\ A<^AX9PJQ>:4HR6D?>^[;\;'U91117X4?T.%%%%
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MM)/]/T/WK@_$.ME<8O[#:_7]0HHHKY ^V"BBB@ HHHH **** "BBB@ HHHH
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MX?RJ<^=X>-_N7W;''?#CX1>$OA/I[VGAC1H=.\P 37'+SS8Z;Y&RQ[\9P,\
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M6KWYOT/QGCF_UNCVY?U84445^@'YJ%?IU^Q)?K>?LX^'8EZVLUW"WU-Q(_\
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M@_\ (_>)?^PG<_\ HUJJ(F<_1115DA7N?['7_)6IO^P9-_Z''7AE>Y_L=?\
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MC?\ Y&-/_ O_ $J04445]R?GH5^J/[(__)NO@O\ Z]Y?_1\E?E=7ZH_LC_\
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M117Z*?EX5^GO[%%FEK^S?X9D48:XDNY6XQS]IE7^2BOS"K]4?V1_^3=?!?\
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MXIQ3_P C.7HOR/WSA#_D4P]9?F%%%%?)'V@4444 %%%% !7@O[<'_)NNO?\
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MZ#X?TS3$QLLK6*V7;TPB!?Z5,BD:-%%%0,**** "OS1^(/\ R/WB7_L)W/\
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M[G=_A<^HX9Q"P^:T6]F^7[U9?C8_1BBBBOPH_H@**** "BBB@ HHHH ****
M"OR@_:@_Y. \<?\ 80;_ -!6OU?K\H/VH/\ DX#QQ_V$&_\ 05K[[@[_ 'NI
M_A_5'YOQQ_N5+_%^C/+J***_6C\7"OJ__@G5_P E/\2_]@<_^CXZ^4*^K_\
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M^%'\I3^)A1115D'U?_P3J_Y*?XE_[ Y_]'QU^@-?G]_P3J_Y*?XE_P"P.?\
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MT*$;17]7?F%%%%<IV!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'S'^V]_R"_"7_7:Y_\ 08Z^3:^LOVWO^07X2_Z[
M7/\ Z#'7R;6D=B6%%%%,05V7P<LS??%?PA&.HU2WD/&>$D#'^5<;7J_[+NDG
M5/C5H;%=T=JLUR_MB)@I_P"^F6@9][T445D4%%%% !1110!^>/QZ\-GPO\7/
M$EH%VQ2W)NXO3;*!)Q[ L1^%>?U]2?MJ^#3YNA>*8DRI4Z?<$#I@EXS^L@_
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M */DK\KJ_5']D?\ Y-U\%_\ 7O+_ .CY*^#XP_W*G_B_1GZ+P/\ [_4_P/\
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MVC9+[K_FV?T#PG1C1RFFUO*[?WV_)(****^6/KPHHHH **** *.N?\@34/\
MKWD_]!-?B[7[1:Y_R!-0_P"O>3_T$U^+M?I_!GPU_P#MW]3\DX[^+#?]O?\
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M"=K-*=US"/57/WOHQ/L11RA<^VZ*I:+K-EXATJUU+3KA+NQNHQ+%-&<AE/\
M(^W4'BKM2,**** /F/\ ;>_Y!?A+_KM<_P#H,=?)M?5?[<$Q6W\&PX&UGNW)
M[\"$?^S&OE2M([$L****8@KZ6_8G\/&;Q!XBUQD^6WMDLXV/K(VYL>X$:_\
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M-?<'A[Q%IOBO28-3TB\BOK&892:(Y'N#Z$=P>16;5BC2HHHI %%%% !1110
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M>,OX]'T?YG['P+_NU?\ Q+\@HHHK\]/TT**** "BBB@ HHHH **** "BBB@
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M%?B1^_A1110 4444 %%%% 'XN:Y_R&M0_P"OB3_T(U2J[KG_ "&M0_Z^)/\
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M2#.#(P_[Y' [D^/U^QY!D,<!%8C$*]5_^2_\'N_EZ_AG$?$4LRD\-AG:DO\
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MQB-39@?5M%?)-U^VYJ;(1;>%K2)\\&6[=Q^05?:N3UW]KOQ[JRLEI)I^CJ>
MUG;;FQ]9"W/T HLP/MJ_U"UTNUDNKVYAL[:,9>:XD"(H]R3@5X)\3OVNM$\/
MQRV7A1%US4<$?:W!6UC/KV,GX8'O7R;XD\9:[XON/.UK5[S4W!ROVF9F5?\
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MCQ,-G&%QF,E@\/+F<5=M;;I6OUW]#U.BBBO'/</@']N[X'MX9\3)X]TFW/\
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M\1P>GWMWX'_LJC3Y;?7?&L22SKB2WT?.Y4/4--V)_P!CIZYY%?3BJ%4 # '
M J6QBT445 PHHHH **** "BBB@ HHHH *\F^.GP'L?BQIXN[0QV/B2W7$-TP
MPLR_\\Y,=O0]1],BO6:* /S"\0>']1\+:O<Z7JMG+8W]NVV2&48(]#[@CD$<
M$'-9U?HK\4O@_H/Q7TL0:G$8+^)2+;4(0/-A]O\ :7/53^&#S7Q/\3_@OXC^
M%=X1J5M]HTYFQ#J5N"87] 3_  M_LG\,]:T3)."HHHIB/J3]G[]IQ+>&V\->
M,KK:BXCM-7F;H.@28_R?\_6OJB.198U=&#HPRK*<@CU%?EG7IWPO_:$\4?#%
M8[2"9=4T=3_R#[PDJ@[^6W5/U'M4N)5S] **\7\'?M8>"/$B1QZA--X>O&',
M=XA:+/H)%R,>[!:]1TKQ?H6NJ&TW6M/OU/3[-=))_(U S7HI&8*I). .237.
MZY\1O"WAJ-FU/Q#IMF5&=DERF\_10=Q_ 4 ='7,_$#XB:+\-=!DU76KGRH^5
MA@3F6=\?<1>Y_0=3BO&?'W[9&BZ;');^%+*36+KD"[NE,5NON%X=OI\OUKY:
M\8>-M:\>ZQ)J>N7\E]=-PN[A(U_NHHX4>P^O6J2%<N_$KXBZG\3_ !1<:SJ3
M;=WR6]LI)2",'A%_F3W))KE:*Z7P+\.]>^(VK+8:%8/=/D>;,?EAA!_B=^@'
M7W.. :L1@V-C<:G>06EI!)<W4[B.*&)2S.Q.  !U.:^UOV>_V>X_AQ;IKFN(
MDWB:5"%C!#)9*1RJD<%R.K?@.,D[WP:^ 6C?">W6[8KJ?B"1-LM^ZX$>>JQ#
M^$>_4^PX'J=0V.P4445(PHHHH ***9--';PO+*ZQ11J6=W("J ,DDGH* 'T5
MP6N?'?P!X?5C=>*=/E9?X+.3[2V?3$8:O(?'/[:%E##);^$])DN9^@O-1&R-
M?<1J<M^)7Z4[ =O^U)\0K?PA\-[S2TF U36D-K%$I^81'_6L1Z;<K]6'O7PK
M6OXJ\6:MXUUJ?5M9O9+Z^F^](_  '15 X4#T'%9%6M"0HHHIB"M[P)XID\$^
M,M'UV)2YL;E)6C4X+IG#K^*DC\:P:* /U"TC5K37M+M-1L)EN;.ZC6:*5#PR
MD9!JY7P+\(_VA=?^%*BQ"+JVAEMQL)W*F/)R3&_.W/I@CKQGFOICPQ^U9X!\
M00I]JOI]$N3UAOH6QGV=-RX^I%9V*/8J*Y>S^*7@W4$W6_BO19.,X^WQ!A]0
M6R*Z6&:.XA26)UEBD4,CH058$9!!'44ACZ**QM?\9Z#X5V_VSK5AI99=RK=W
M*1LPYY )R>AZ>E &S2,P12S$*H&23T%>->*/VL? >@*ZV=U<Z[<+P$LH2$S[
MN^T8]QFOG3XI_M*>)?B1#-I\(71-$DX:TMF)>5?223@M]  /4&G9B$_:6^)L
M'Q&\?%-/F\[2-+0VUO(IRLK9S)(/8D  ]P@/>O(Z**T$%%%% @KW7]DKXB0>
M$O'%QHU],(;+6D6-'8\+<*3Y>?3<&9?J5KPJE5BC!E)5@<@CJ*!GZFT5\D?"
MG]KV;1[.'3/&5O-J$48"1ZG;8,V!P/,4D;_]X'/J">:][T/XZ^ ?$$:M:^*M
M/B+?P7DOV9L^F)-M9V*.\HJAI6O:9KJR-INHVFH+&0'-K.LH7/3.TG'0U?I
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M.TGE+?1@FW\S771PF(Q.M&FY>B;..OC<-A=*]6,?5I?F>TTA..3P*^3O%/\
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MG^3SSFA"C":C:5]>UFC\Q/A[^S7\1/B9Y<ND^'+B&P?D7^H#[-!CU#/@L/\
M=!KZ<^'G_!._2[(QW'C3Q#+J4@P38Z4ODQ?0R,"S#Z!#7V+17=C.*,=B+QI-
M4UY;_>_TL>?@>$,NPMI5DZDO/;[E^MSD? OPF\'_  TMQ%X:\/66E-MVM/''
MNG<>C2MEV_$FNNHHKY.I4G5DYU)-M]7J?9TZ5.C%0I144NB5D%%%%9FH4444
M >8_M*^!]7^)'P3\1^'=!MUNM5O/LWDQ/(L8;9<Q2-\S$ ?*C?E7PM_PP_\
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M?_%4?\,/_%S_ * -K_X,8/\ XJOTWHKU_P#6[,/Y8_<_\SQO]2<M_FG]Z_\
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MQ8^*D6M^&],@O-.73H;<R27<41WJ[DC#,#T8<UXI_P ,/_%S_H VO_@Q@_\
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MT)^TAH?P+T78YCU+Q-<H39Z4C\CKB67NL>?Q;! Z$C\S_'GCS6_B5XFN]?\
M$%ZU[J-R>6/"HH^ZB+T51V _GDU^B<+X+'.2KJ;A2[?S?)]//[O+\PXNS#+U
M!X9TU.MW_E^:UOV6W5^>+:VL]]=16UM#)<7$SB..&)2SNQ. H Y))[5V.M_
M_P"(/AQ ^H^"]<MXL9\W[#(Z#/."R@@'VS7VC^QO^S*G@/2[?QKXFM/^*EO8
M]UG:SIS80L/O$'I*PZ]U4XX)85]45Z.8<5K#XATL-!3BMW?=^7^?4\O+.#7B
ML*JV*FX2EJE;9>?F^W3\OQ2EA>"1HY$:-U."KC!'X4ROV@U;P_I>O1>7J>FV
M>HQ_W+N!)1^3 ^IKA=8_9M^%VN9-SX%T:,G_ )]+86WI_P \]OI_/UJ:?&5%
M_P 6BUZ-/_(JKP+7C_"KI^J:_*Y^3-%?IKJ'[#_PCO.8M#N['G.+?49SVZ?.
MS5BW/_!/_P"&,WF;+C7K;=T\N]C.WZ;HS^N:]&/%N72W4E\E^C/,EP7F<=G%
M_-_JD?G)17Z#W/\ P3M\ MM^SZ_XDB/?S)K=\_3$(JC<_P#!.?PHS+]G\5ZS
M$O<21Q/G\@*W7%.6/>37R9SRX0S9;03_ .WD? U%?=EQ_P $XM%<K]G\:W\0
M[^98H^?IAA5>3_@F_8&-@GCNY5\?*6TQ2 >V1YHS^=:+B;*_^?G_ )++_(R?
M">;_ //K_P FC_F?#=%?:DW_  3;D6,F'XA(\G97T8J#^(G/\JR[W_@G)K\>
M?LGC+39SMX\ZTDC^;TX+<>]:QXBRN6U;\)?Y&,N%\XCO0_&/^9\?T5].ZG_P
M3Y^(]FK-:ZCX?OU[+'=2HY_!H@/UK@_$?[(_Q8\,H\DWA&XOH5_Y::;+'<EO
MHB,7_P#':[J>;8"L[0K1^^WYG!5R7,J*O/#R^YO\CQZBK.I:9>:/>26>H6D]
MC=Q'$D%S&T<B'T*D BJU>JFFKH\9IIV9U'PS^(.I_"WQOI7B72G*W-E*&:(G
M"SQGAXV]F7(]LY'(%?KGX5\26/C'PWIFN:9+YUAJ%NES"W?:P! ([$=".Q!K
M\9*_1#_@G_XV?7OA-?Z!.^^70KTK&,](9LNH_P"^Q+7P'%V!C4P\<7%>]%V?
MH_\ )_F?I'!682IXF6"D_=FKKU7^:_(^H****_)S]G"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6/5G;_:9B6/N37TW$F9?4,,L-0TE/MTC_6B^9\EPIE7]I8IXO$:PAKKUEO\
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M?+O8K>;2^2U?Y?B?BG"&&EB<T]N]H)M^KT7YW^1[!1117XT?NP4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR_.X4445\\?3A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'_?(%>;+A''KX91?S?\ D>M#C;+I?%":^2_^2/TOHK\UO^&\/BK_ ,_>E_\
M@ O^-07/[<_Q9G*[-5L+?'7R]/B.?^^@:C_5+,.\?O?^1H^-,L[3^Y?YGZ84
M5^5VH_M<?%W5%Q-XTND&,?Z/;00?^@1BN(UWXI>,O$^Y=6\5ZUJ2-UCNK^61
M/P4M@?E773X.Q+_B58KTN_\ (XJO'.$2_=49/ULO\S]7?%7Q7\&^" _]N^)]
M*TR1.L,]T@E_",'<?P%>$>.O^"@'@;05DB\.6%_XHN1]V3;]DMS_ ,"<;_\
MQROSQHKWL-PC@Z3O7DY_@OPU_$^<Q7&N.K)K#P4/_)G^.GX'MOQ._; ^(OQ*
M66U_M/\ X1[2WX-EH^8=P]&DR7;(ZC(4^E>)9)/J:T-#T#4_$VJ0:;I&GW.I
MW\QQ';6D322-] !7UU\%/V!;N^:WU7XBW!LK?(<:'9R RN/264'"C_93)P?O
M*:]VMB,OR2E9V@NRW?RW?J_O/G:&%S//ZUU>;[O9?/9>B^X^>/@Y\"_%'QLU
MP66AVOEV,3 7>J3@BWMAUY/\38Z*.3[#)'Z6?!GX(^'?@CX:&F:+#YMU+AKS
M4IE'GW3C/+'LHR<*.![DDGL/#_AW3/"FD6VE:/86^FZ=;KMBMK9 B*/H.Y[G
MJ3R:T:_*\WSVOFCY%[M/MW]?\MC]AR3AW#Y0O:2]^J^O;R7^>[_ ****^8/K
M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** ..^*'PF\-?%_PZ^D>)+ 7
M,8RT%S'\L]L^/OQOV/MR#W!K\]/CA^R-XO\ A#)<7]I"WB+PTI++J%HAWPK_
M --HQRO^\,K[CI7Z>45]!E>=XK*W:#YH?RO;Y=OZT/FLWR#"9NN:HN6?22W^
M?=?TFC\3Z*_47XH?LA_#OXG23WC::V@:M)R;[2"(MS>KQX*-D]3@,?6OE[QS
M_P $_?'&AO++X;U'3_$UL/N1,_V6X/\ P%SL_P#'Z_3<'Q+@,4DIRY)=I?Y[
M??8_)L=PIF6#;<(^TCWCO]V_W7/ENBNS\3?!?QWX-=QK/A'6+)$ZS&T=X?PD
M4%3^!KC.0<=#7TU.K3JKFIR37D[GR52E4HOEJQ<7YJP4445J9!1110 458L[
M"ZU*<0VEO-=3'D1PQEV/X#ZUZ'X9_9K^)_BQE%AX*U6-&Z27T7V1/J&E*@_A
M6%7$4:"O5FHKS:1T4</7Q#M1@Y/R3?Y'FE%?6/@[_@GCXMU-HY/$FOZ;H<)Y
M,5JK7<P]B/E4?4,:^@/ ?[$/PS\&F.:]L;CQ/>+@^9JTN8P?:) JD>S!J^<Q
M7$V78>ZC/G?]U?KHCZG"<)YIBK.4.1=Y/]%=_@?GAX,^'?B;XA7WV/PWH=[K
M$V0&^S1$HF?[[_=0>[$"OJ?X7?\ !/6_O##>>/=86PA^\=+TI@\WT>4@JOT4
M-]17V[IFE66BV,5EIUG;V%G$,1V]K$L<:#T"J !5JOB<;Q9BZ]XX=>S7WO[]
MOP^9]]E_!F#P]IXJ3J/MM'[MW]_R.4^'_P +?"WPNTS[#X9T6VTN-@!)(B[I
M9<=WD.6;\375T45\74J3JR<ZCNWU9][3IPHP5.G%)+HM$%%%%9F@4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6/K'@_0/$1)U7
M0]-U,GK]LM(Y<_\ ?0-;%%5&4HN\78F48S5I*Z/.[[]G?X8ZAN\WP'H*;L9\
MBQCAZ>FP#%46_9=^%++@^!],Q[*P_P#9J]2HKK6.Q4=%5E_X$_\ ,XI9?@Y:
MNC%_]NK_ "/+U_9A^%<;!AX'THD'(S&2/RS6UI_P0^'FE$&U\#>'8G[/_9D)
M;_OHKFNVHI2QF)DK2JR?S8XX'"0=XTHK_MU?Y%:QTVSTN'R;*T@LXO\ GG!&
M$7\@*LT45R-MZL[4DE9!1112&%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
/ %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>gp5m5bivuamv000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gp5m5bivuamv000002.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_X0KD17AI9@  34T *@    @ ! $2  ,
M   !  $   $:  4    !    /@$;  4    !    1@$H  ,    !  (
M $X!+     $   $L     0    8! P #     0 &   !&@ %     0   )P!
M&P %     0   *0!*  #     0 "   " 0 $     0   *P" @ $     0
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MDE;NCK*X6S_Y+/J'_8+7_P!"2JH[2]":U[Q]3NZ*P.@BF65HV$+JDF/E9U+
M'W&1G\ZY31=;UO4?$-_ITSZ>D5B^)'2!]T@W$<#?\N0/?'O0!V%% !10 44
M<F;[Q/?:_JEMI[:9#86<B0K)/$[NS&-'(P' _CK,T/7_ !1KFIZQ913:3$VG
M3>4S/:R$2?,ZY'[P8^Y77&G2<6^R1QRG54TN[.@\,ZAJM]%J$6L16R7=G=F
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MUJDZ:IQNMR6INI*ST1DZA?IHEWH7]GZK=W%U]OBL[]6NI+B%MV0X8ME5<$9
M&T^V*VM3O[C5?&,7ANVNY+:WAM_M=[)"Q61QNPL2MU0'.21SC@$4.'VFNC$J
MGV?-&7?:>VG_ !/\,QK=3S0,EP8TGD,C1GRSNP[98@\<,3CM5K4+S4(/BCHU
MA_:$[V5Q%+*UN0JJ"$?T )' ZDU?NRM=?9?ZF?O0O;^9?H07+:O-\2)-'37+
MN.VDL#,/D3,8,@R$P ,\8#,&(&[OS3_#LM[IGCW4?#\FH75[9BV6ZB:[D,DD
M;94$;O3G_/.1QARVMTN/FDI7;ZV':.TWBN\UYKK4;VW:TO'M+>&VN&A\E5&
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M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M 2(  A$! Q$!_\0 'P   04! 0$! 0$           $" P0%!@<("0H+_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M--_Z"%K_ -_E_P :.678.>/<O44R*9)XUDC=9$;D,IR#^-/J"PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,3QQ
M_P B5X@_[!]Q_P"BVK\:J_97QQ_R)7B#_L'W'_HMJ_&JOU'@S^'7]8_J?D7'
M?\3#^DOT"BBBOT<_+ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /U?_ &7_ /DW_P #_P#8/7_T)J]1
MKR[]E_\ Y-_\#_\ 8/7_ -":O4:_G7'?[W5_Q2_-G]/Y=_N5#_#'\D%%%%<)
MZ(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX+5_^.5]ET4?ZQ9I_P _OPC_ )!_JOE'_/C\9?YGQI_P[?TW_H>KK_P6K_\
M'*/^';^F_P#0]77_ (+5_P#CE?9=%'^L6:?\_OPC_D'^J^4?\^/QE_F?&G_#
MM_3?^AZNO_!:O_QRC_AV_IO_ $/5U_X+5_\ CE?9=%'^L6:?\_OPC_D'^J^4
M?\^/QE_F?&G_  [?TW_H>KK_ ,%J_P#QRO./C_\ L<V?P4^'<WB6#Q1/JTD=
MS%!]GDLEB!WDC.X.>F/2OT2KYX_;P_Y-_N_^PA;?^A&O2RW/<QKXVE2J5;Q<
MDGHO\CR<VX=RO#X"M6I4;2C%M.\M_O/S6HHHK]B/PX**** /U?\ V7_^3?\
MP/\ ]@]?_0FKU&O+OV7_ /DW_P #_P#8/7_T)J]1K^=<=_O=7_%+\V?T_EW^
MY4/\,?R04445PGHA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!B>./^1*\0?]@^X_]%M7XU5^ROCC_D2O$'_8/N/_ $6U
M?C57ZCP9_#K^L?U/R+CO^)A_27Z!1117Z.?E@5^@'_!.O_DF'B7_ +#'_M".
MOS_K] /^"=?_ "3#Q+_V&/\ VA'7R7%/_(LEZK\S[3A#_D;0])?D?6%%%%?B
MA^^!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7SQ^WA_R
M;_=_]A"V_P#0C7T/7SQ^WA_R;_=_]A"V_P#0C7L9/_R,*'^)?F>'GG_(LQ'^
M%_D?FM1117] '\UA1110!^K_ .R__P F_P#@?_L'K_Z$U>HUY=^R_P#\F_\
M@?\ [!Z_^A-7J-?SKCO][J_XI?FS^G\N_P!RH?X8_D@HHHKA/1"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% &)XX_Y$KQ!_P!@^X_]%M7XU5^ROCC_ )$K
MQ!_V#[C_ -%M7XU5^H\&?PZ_K']3\BX[_B8?TE^@4445^CGY8%?H!_P3K_Y)
MAXE_[#'_ +0CK\_Z_0#_ ()U_P#),/$O_88_]H1U\EQ3_P BR7JOS/M.$/\
MD;0])?D?6%%%%?BA^^!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7SQ^WA_R;_=_]A"V_]"-?0]?/'[>'_)O]W_V$+;_T(U[&3_\ (PH?
MXE^9X>>?\BS$?X7^1^:U%%%?T ?S6%%%% 'ZO_LO_P#)O_@?_L'K_P"A-7J-
M>7?LO_\ )O\ X'_[!Z_^A-7J-?SKCO\ >ZO^*7YL_I_+O]RH?X8_D@HHHKA/
M1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!B>./^1*\0?]@^X_\ 1;5^
M-5?LKXX_Y$KQ!_V#[C_T6U?C57ZCP9_#K^L?U/R+CO\ B8?TE^@4445^CGY8
M%?H!_P $Z_\ DF'B7_L,?^T(Z_/^OT _X)U_\DP\2_\ 88_]H1U\EQ3_ ,BR
M7JOS/M.$/^1M#TE^1]84445^*'[X%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %?/'[>'_ ";_ '?_ &$+;_T(U]#U\\?MX?\ )O\ =_\
M80MO_0C7L9/_ ,C"A_B7YGAYY_R+,1_A?Y'YK4445_0!_-84444 ?J_^R_\
M\F_^!_\ L'K_ .A-7J->7?LO_P#)O_@?_L'K_P"A-7J-?SKCO][J_P"*7YL_
MI_+O]RH?X8_D@HHHKA/1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-:BBBOZ /YK"BBB@#]7_ -E__DW_ ,#_ /8/7_T)J]1KR[]E_P#Y-_\  _\
MV#U_]":O4:_G7'?[W5_Q2_-G]/Y=_N5#_#'\D%%%%<)Z(4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7SQ^
MWA_R;_=_]A"V_P#0C7T/7SQ^WA_R;_=_]A"V_P#0C7L9/_R,*'^)?F>'GG_(
MLQ'^%_D?FM1117] '\UA1110!^K_ .R__P F_P#@?_L'K_Z$U>HUY=^R_P#\
MF_\ @?\ [!Z_^A-7J-?SKCO][J_XI?FS^G\N_P!RH?X8_D@HHHKA/1"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7SQ^WA_R;_=_]A"V_]"-?0]?/'[>'_)O]W_V$+;_T(U[&3_\
M(PH?XE^9X>>?\BS$?X7^1^:U%%%?T ?S6%%%% 'ZO_LO_P#)O_@?_L'K_P"A
M-7J->7?LO_\ )O\ X'_[!Z_^A-7J-?SKCO\ >ZO^*7YL_I_+O]RH?X8_D@HH
MHKA/1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***QO%?C
M'1O ^EC4=<ODT^R,@B$SJS#<02!A03V/Y4 ;-%>;?\-'?#C_ *&BW_[\S?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"_\ (/[4P'_01#_P*/\ F>OT5Y!_PUQ\(_\ H=+7_P !Y_\ XW1_PUQ\(_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHK,U[Q-H_A6S-YK6J66DVO\ SVOKA(4_-B*J,7)VBKLF4E%<
MTG9&G17SYXW_ &X_AEX3\R*PO+OQ-=+QLTR ^7GWD?:I'NNZOG;Q]_P4!\;:
M_P"9#X:TZQ\+VS<"8C[5<#_@3@(/^^/QKZ'"\/YCBM53Y5WEI^&_X'S&,XFR
MO!W3J\S[1U_';\3] =4U:QT.QEO=1O+?3[.(9DN+J58HT'J68@"N \)?M%>
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MT5]^>+OV:O 7BR-\:.NCW+=+C2SY)'_ /N'_ +YKY;^,?[/.M?"D&_23^UM
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1J0<N:VWE<^)XBR&MG,J4J4U'EOO?K;_ "/R3HK];/\ AG?X8_\ 0AZ#_P"
M*?X4?\,[_#'_ *$/0?\ P!3_  KZG_7'#?\ /J7X'Q_^HV+_ .?T?Q/R3K]
M/^"=?_),/$O_ &&/_:$=>V?\,[_#'_H0]!_\ 4_PKJ/"?@CP_P"!;.:T\/:/
M9Z+:S2>;)#90B-6? &X@=\ #\*\7..(J&981X>$&FVM[=#WLDX7Q&5XV.)J5
M$TDU97ZFY1117P)^D!1110 4444 %%%% 'XGT5^MG_#._P ,?^A#T'_P!3_"
MC_AG?X8_]"'H/_@"G^%?K'^N.&_Y]2_ _&?]1L7_ ,_H_B?DG17ZV?\ #._P
MQ_Z$/0?_  !3_"C_ (9W^&/_ $(>@_\ @"G^%'^N.&_Y]2_ /]1L7_S^C^)^
M2=%?K9_PSO\ #'_H0]!_\ 4_PH_X9W^&/_0AZ#_X I_A1_KCAO\ GU+\ _U&
MQ?\ S^C^)^2=%?K9_P ,[_#'_H0]!_\  %/\*/\ AG?X8_\ 0AZ#_P" *?X4
M?ZXX;_GU+\ _U&Q?_/Z/XGY)T5^MG_#._P ,?^A#T'_P!3_"C_AG?X8_]"'H
M/_@"G^%'^N.&_P"?4OP#_4;%_P#/Z/XGY)T5^MG_  SO\,?^A#T'_P  4_PH
M_P"&=_AC_P!"'H/_ ( I_A1_KCAO^?4OP#_4;%_\_H_B?DG17ZV?\,[_  Q_
MZ$/0?_ %/\*/^&=_AC_T(>@_^ *?X4?ZXX;_ )]2_ /]1L7_ ,_H_B?DG17Z
MV?\ #._PQ_Z$/0?_  !3_"C_ (9W^&/_ $(>@_\ @"G^%'^N.&_Y]2_ /]1L
M7_S^C^)^2=%?K9_PSO\ #'_H0]!_\ 4_PH_X9W^&/_0AZ#_X I_A1_KCAO\
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MAB@9^G-%%%9%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5^._Q4_P"2G^+_ /L,7G_H]Z_8BOQW^*G_ "4_Q?\
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MQA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !7Y0?M0?\G >./^P@W_ *"M?J_7Y0?M0?\
M)P'CC_L(-_Z"M??<'?[W4_P_JC\WXX_W*E_B_1GEU%%%?K1^+A7U%_P3P_Y+
M5K7_ &+\_P#Z4VU?+M?47_!/#_DM6M?]B_/_ .E-M7A9Y_R+:_H?0\/_ /(U
MP_\ B/T.HHHK\$/Z/"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH ^8_VWO\ D%^$O^NUS_Z#'7R;7UE^V]_R"_"7_7:Y_P#08Z^3
M:TCL2PHHHIB"M7PI_P C1H__ %^0_P#H8K*K5\*?\C1H_P#U^0_^AB@9^G-%
M%%9%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6<,8CV&91B]IIK]5^*/C.+L-]8RN<EO!J7Z/\&?"M?KU\#_^2*^ /^Q?T_\
M])HZ_(6OUZ^!_P#R17P!_P!B_I__ *31U]3QE_ H^K_(^/X%_P!YK?X5^9VU
M%%%?E1^QA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7Y0?M0?\G >./\ L(-_Z"M?J_7Y
M0?M0?\G >./^P@W_ *"M??<'?[W4_P /ZH_-^./]RI?XOT9Y=1117ZT?BX5]
M1?\ !/#_ )+5K7_8OS_^E-M7R[7U%_P3P_Y+5K7_ &+\_P#Z4VU>%GG_ "+:
M_H?0\/\ _(UP_P#B/T.HHHK\$/Z/"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH ^8_VWO^07X2_Z[7/_ *#'7R;7UE^V]_R"_"7_
M %VN?_08Z^3:TCL2PHHHIB"M7PI_R-&C_P#7Y#_Z&*RJU?"G_(T:/_U^0_\
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /F/\
M;>_Y!?A+_KM<_P#H,=?)M?67[;W_ ""_"7_7:Y_]!CKY-K2.Q+"BBBF(*U?"
MG_(T:/\ ]?D/_H8K*K5\*?\ (T:/_P!?D/\ Z&*!GZ<T445D4%%%% !1110
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MOWA^.0/2OK'X8_&_PS\4X0FG7)M=4"[I--NB%F&.I7LX]Q^(%3:Q1Z!1112
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M'?D?G5BO"/V-81%\*;QP<F759G/M^[B7^E>[U(PHHHH **** "BBB@ HHHH
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M/?BM)-;MJ+:!HC$A=,TMS&&7TDD^])QU!(7T45XO7Z%@N#W)*6,J6\H_Y_\
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M!^L?[/'Q?D^-WPXB\1SV,>G70N9;6:WA<L@9""""1W5EKTVOFK]@#_DA4_\
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MTV[LX]\]K- A.T-)&5&?3D5[,>'<JAI[+[V_\SP9<49Q4U]MIY*/^1];P_\
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M+CURI-:E>!*+B[25F?2QE&:YHNZ"BBBI*"BBB@ HHHH **** "BBB@ HHHH
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MB8/'+$Q5T8="".0?>H:*!'UK\"_VIEU62VT#QG,D5TV([?5FPJ2'H%E[*?\
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M-:***_<#^?@HHHH [;X'_P#):O '_8PZ?_Z4QU^O5?D+\#_^2U> /^QAT_\
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MYMC52J?!%7?IV^;?W';_  D^ '@WX,V$::'IB2:ELVS:M= /=2G&#\W\(/\
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M^9^PY/P?0H157'^_/^7HO\W^'KN>?^$?@!\.O \:KI'A#2XI%&!<7$ N)O\
MOY)N;]:[V*%((UCC18T7@*HP!^%/HKX>K6JUGS59.3\W<_0:5"EAX\M&"BO)
M)?D5=0TNSU:W:WOK2"]@;K%<1K(I_ C%>-_$+]COX9^/HY'311X=OV^[=:+B
M  ^\6#&1GK\H/N*]NHK3#XJOA9<U";B_)F6)P>&QD>7$4U)>:/S'^-7['OC+
MX2Q7&I6JCQ+X=C!9K^R0B2%?66+DJ/=2R@=2*\'K]KSSP>17R;^TU^QGI_BJ
MUO?$_@2TCT_745I;C285VPWO<F,=$DZ\#ACZ$DG]'RGBGVDE0Q^C>TNGS73U
M6GD?EN=<'^RB\1EVJ6\>O_;KZ^CU\WL?)7P2^/'B/X&^(1?:1+]ITV9A]MTJ
M9CY-POK_ ++@=''([Y&0<OXS>,++X@?%#Q#XCTY98[+4KG[1&DRX=057(8#N
M#D<>E<=-"\$KQ2(T<B,59'&"I'!!'8TROO(X6C&N\3&-IM6;[KS/SF6,KRPZ
MPDI7@G=+L_(****ZSC"OJ+_@GA_R6K6O^Q?G_P#2FVKY=KZB_P"">'_):M:_
M[%^?_P!*;:O"SS_D6U_0^AX?_P"1KA_\1^AU%%%?@A_1X4444 %5=2U.ST>S
MEO+^[@L;2(9>>YD6.-!ZEB<"K5?E7:?#+XR?'*\CO9M,\0:]NY2]U9W2$ _W
M7F(7'LIKW\JRR&8<\JM54XPM=OSOYKL?-YQFU3+/9PHT74G.]DO*W9-]3[>\
M=?MI?##P7YD4&K2>([Q1Q#H\?FKGM^])"8^C'Z5\[>._^"A?BK5]\'A;1++P
M_">!<73&[G^HR%0?0JWUIGAO_@GAXRU"$2:UX@TG1RW(BA#W+C_>X5?R)JSX
M@_X)U>*+.P:71_%.F:I<J"?L]Q"]MN]@V7&?K@>]?786APWA9*,JG/+N[M?@
MN7[SXG%XCBG%P<H4G3CVC9/\7S?=8^<O&WQ4\7_$:<R>)/$5_JXW;A#/,1"I
M]5C&$7\ *Y6MOQAX+UOX?Z_<:+X@TZ;2]3@^_#,!R#T92.&4]F!(/K6)7Z+1
MC2C37L4N7I;;\#\PK2JRJ/V[?-UO>_SOJ%%%%;& 5]Y_\$Y?^1*\8?\ 80B_
M]%U\&5]Y_P#!.7_D2O&'_80B_P#1=?*<3_\ (KJ>J_-'V/"/_(WI^DOR9]>T
M445^)'[^%%%% '$?%3XQ>%_@UH]OJ/B:[EMHKF0Q6\<$#RO*X&2!@8''=B!7
MR[XZ_P""BQ_>0^#_  MC^Y>:U+S_ -^8S_[/7J?[8WP:\3_&;P[X;L?#-K#<
MS6EY)+.9YUB5%*8!YZ\^E?.-K_P3W^)-Q%ODU+PW;-G_ %<MY.3_ ..PD?KV
MK[S)\-DWU>-;&S7.[Z-[:Z:+]3\YSS%Y]]9E0R^#]FK:I;Z:ZO\ 0\U\=?M.
M?$KXA>9'J7BB[MK-S_QYZ:?LL6/[I"8+#_>)KRYF+,68DDG))[U[EXN_8O\
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MQ'X;FT^1O^6EKJ%P"/H&=E_2O%/B5_P3PDM[::[\#:^]U(HRNFZP%#/[+,@
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MEK<6\MG<2P31M%-$Q1XW&"K X((]<U'7M?[67@M/"_Q.?4+>/R[368A=_*,
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MR\WT7RW]?0_7N#<H4*;S&JM7I'R75_/;T]0HHHK\Z/U$**** "BBB@ HHHH
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M*\/B'$O#9=4<=Y:??O\ A<^AX9PJQ>:4HR6D?>^[;\;'U91117X4?T.%%%%
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MM)/]/T/WK@_$.ME<8O[#:_7]0HHHKY ^V"BBB@ HHHH **** "BBB@ HHHH
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MX?RJ<^=X>-_N7W;''?#CX1>$OA/I[VGAC1H=.\P 37'+SS8Z;Y&RQ[\9P,\
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M6KWYOT/QGCF_UNCVY?U84445^@'YJ%?IU^Q)?K>?LX^'8EZVLUW"WU-Q(_\
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M@_\ (_>)?^PG<_\ HUJJ(F<_1115DA7N?['7_)6IO^P9-_Z''7AE>Y_L=?\
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MC?\ Y&-/_ O_ $J04445]R?GH5^J/[(__)NO@O\ Z]Y?_1\E?E=7ZH_LC_\
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M117Z*?EX5^GO[%%FEK^S?X9D48:XDNY6XQS]IE7^2BOS"K]4?V1_^3=?!?\
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MXIQ3_P C.7HOR/WSA#_D4P]9?F%%%%?)'V@4444 %%%% !7@O[<'_)NNO?\
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MZ#X?TS3$QLLK6*V7;TPB!?Z5,BD:-%%%0,**** "OS1^(/\ R/WB7_L)W/\
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M[G=_A<^HX9Q"P^:T6]F^7[U9?C8_1BBBBOPH_H@**** "BBB@ HHHH ****
M"OR@_:@_Y. \<?\ 80;_ -!6OU?K\H/VH/\ DX#QQ_V$&_\ 05K[[@[_ 'NI
M_A_5'YOQQ_N5+_%^C/+J***_6C\7"OJ__@G5_P E/\2_]@<_^CXZ^4*^K_\
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M^%'\I3^)A1115D'U?_P3J_Y*?XE_[ Y_]'QU^@-?G]_P3J_Y*?XE_P"P.?\
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MT*$;17]7?F%%%%<IV!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'S'^V]_R"_"7_7:Y_\ 08Z^3:^LOVWO^07X2_Z[
M7/\ Z#'7R;6D=B6%%%%,05V7P<LS??%?PA&.HU2WD/&>$D#'^5<;7J_[+NDG
M5/C5H;%=T=JLUR_MB)@I_P"^F6@9][T445D4%%%% !1110!^>/QZ\-GPO\7/
M$EH%VQ2W)NXO3;*!)Q[ L1^%>?U]2?MJ^#3YNA>*8DRI4Z?<$#I@EXS^L@_
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M */DK\KJ_5']D?\ Y-U\%_\ 7O+_ .CY*^#XP_W*G_B_1GZ+P/\ [_4_P/\
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MVC9+[K_FV?T#PG1C1RFFUO*[?WV_)(****^6/KPHHHH **** *.N?\@34/\
MKWD_]!-?B[7[1:Y_R!-0_P"O>3_T$U^+M?I_!GPU_P#MW]3\DX[^+#?]O?\
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M"=K-*=US"/57/WOHQ/L11RA<^VZ*I:+K-EXATJUU+3KA+NQNHQ+%-&<AE/\
M(^W4'BKM2,**** /F/\ ;>_Y!?A+_KM<_P#H,=?)M?5?[<$Q6W\&PX&UGNW)
M[\"$?^S&OE2M([$L****8@KZ6_8G\/&;Q!XBUQD^6WMDLXV/K(VYL>X$:_\
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M-?<'A[Q%IOBO28-3TB\BOK&892:(Y'N#Z$=P>16;5BC2HHHI %%%% !1110
M4444 %<O\1?B)I/PS\-SZOJTN ORP6ZG]Y<28X11_,] .347Q(^)VA_"_0VU
M#6)_G;(M[2,@RW#>BCT]2>!^5?!WQ,^*&L_%/7FU'59=L4>5MK.,_N[=">@]
M3TRW4X^@%)7$4?'WCK4_B-XGN];U63=/,<1Q*?DAC'W8U'H!^9R3R372_ 7X
M:O\ $SXA6=I-%OTJS(NKYB.#&IX3_@1POT)/:O/+>WEN[B*""-IIY6")&@RS
M,3@ #N2>U?H#\!?A6GPL\$16TZ*=9O<7%_(,'#X^6,'T0''U+'O5/01Z0JA5
M  P!P *6BBLR@HHHH ^)/VQ?^2M0_P#8,A_]#DJK^R7XJ_X1_P"*\-C(^VWU
M:W>U.3@>8/G0_7*E1_OU:_;%_P"2M0_]@R'_ -#DKQG1=6N-!UBRU.S?R[JS
MG2XB;T96##]15]">I^H-%9?A?Q!;>+/#FFZS9G-M?6Z3H,Y*[ADJ?<'(/N*U
M*@H**** "BBB@ HHHH *\Q_:&^&T?Q&^'EXD4._5M.5KNR8#YBP&6C'^^HQC
MUVGM7IU% 'Y8T5U'Q0T-/#7Q%\2:9$H2"WOYEB48XC+$H/\ ODBN7K4@*7KP
M.325O> ](;7_ !MH&FKR;J_@A/L"X!/X#/Y4#/TPHHHK(H**** "BBB@ HHH
MH *^%_\ @H_*C>(/ \88>8MK=,5[@%X\']#^5?=%? __  48N%;Q]X4MQN#I
MICN3CC#2D#_T$U]5PPKYI3])?DSX[BV5LHJ+NX_^E(^1Z***_;C\ "BBB@#M
MO@?_ ,EJ\ ?]C#I__I3'7Z]5^0?P3D6+XS> G=E1%U^P+,QP /M$?)K]?*_*
M>,OX]'T?YG['P+_NU?\ Q+\@HHHK\]/TT**** "BBB@ HHHH **** "BBB@
MHHHH \3_ &T/^3:?&/\ VY_^ED%?EW7ZB?MH?\FT^,?^W/\ ]+(*_+NOU_@_
M_<)_XW_Z3$_$>-_^1C3_ ,"_]*D%%%%?<GYZ%?JC^R/_ ,FZ^"_^O>7_ -'R
M5^5U?JC^R/\ \FZ^"_\ KWE_]'R5\'QA_N5/_%^C/T7@?_?ZG^!_^E1/7Z**
M*_(S]K"BBB@ HHHH **** "N ^/VN-X;^"?C:_C8I*FE7$<;#&5=T**?P+ _
MA7?UY!^UQ_R;KXT_Z]XO_1\==V!BIXNE%[.4?S1Y^8S=/!5IQW49/\&?E=11
M17]%'\OA1110!]R?\$X=5231_'&F\"2*>UN!ZD,LBG\M@_.OLROS4_8<\?Q^
M#?C9;Z?=2+'9Z];MI^6. )LAXC]2R[!_OU^E=?B?%%!T<RE-[32:^ZWYH_?>
M$<1&ME4(+>#:?WW7X,****^3/LPHHHH **** ,_Q%*D'A_4Y)&VHEK*S,>P"
M')K\7Z_5#]JWXD0?#?X*Z]*9E34=4A;3;*//S,\H*LP_W4W-^ ]:_*^OU;@Z
MC*-"K5:TDTE\K_YGXYQS7A/$4:*>L4V_G;_(****_0C\R"OTV_8?_P"3==!_
MZ^+O_P!'O7YDU^FG[#LBR?L[:(JL"4N;I6 /0^<QQ^1'YU\3Q=_R+X_XE^3/
MO^"?^1E+_ _SB>^4445^.G[B%%%% !7P7_P4+^')TWQ7HGC2VBQ;ZG%]ANW4
M<">,90GW9"0/^N5?>E>?_'CX8Q?%WX6ZUX=(07LD?G6,C_P7"?-&<]@3\I/H
MQKV\FQW]GXV%:7P[/T?^6_R/ SW+_P"TLOJ4(KWMUZK_ #V^9^1]%37EI/I]
MU-:W,307,+M%+%(-K(RG!4CL014-?ON^J/YNU6C"BBB@#V+]E?XP#X/_ !6L
MKN[EV:'J0%CJ.XX5(V8;93_N-@_[NX=Z_4U6#*"I!!&017XH5^B7[$OQ\C\>
M>$4\&ZQ<?\5#HL(6W>1N;JU& I'JR<*?;:>><?G'%F6.<5CJ2U6DO3H_EL_E
MV/U'@S-E3D\NK/1ZQ]>J^>Z^?<^GJ***_+C]?"BBB@ HHHH **** "OR@_:@
M_P"3@/''_80;_P!!6OU;N+B*UMY)YI%BAC4N\CG"JH&22>P K\?OBMXN3Q]\
M2O$WB&(%8-0OYIX01@B(L=F??:%K]!X.IR>(JU+:*-OO?_ /S/CFI%8:C3OJ
MY7^27_!1RE%%%?JY^-A7U?\ \$ZO^2G^)?\ L#G_ -'QU\H5]/?\$]]06T^-
M6IVSN0+K1)D5<CEUFA;_ -!#5X6>IRRVLEV/HN'I*.:X=OO^A^B5%%%?@A_1
MP4444 %%%% !1110!B>./^1*\0?]@^X_]%M7XU5^ROCC_D2O$'_8/N/_ $6U
M?C57ZCP9_#K^L?U/R+CO^)A_27Z!1117Z.?E@5]Y_P#!.7_D2O&'_80B_P#1
M=?!E?>?_  3E_P"1*\8?]A"+_P!%U\IQ/_R*ZGJOS1]CPC_R-Z?I+\F?7M%%
M%?B1^_A1110 4444 %%%% 'XN:Y_R&M0_P"OB3_T(U2J[KG_ "&M0_Z^)/\
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M2#.#(P_[Y' [D^/U^QY!D,<!%8C$*]5_^2_\'N_EZ_AG$?$4LRD\-AG:DO\
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MQB-39@?5M%?)-U^VYJ;(1;>%K2)\\&6[=Q^05?:N3UW]KOQ[JRLEI)I^CJ>
MUG;;FQ]9"W/T HLP/MJ_U"UTNUDNKVYAL[:,9>:XD"(H]R3@5X)\3OVNM$\/
MQRV7A1%US4<$?:W!6UC/KV,GX8'O7R;XD\9:[XON/.UK5[S4W!ROVF9F5?\
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MCQ,-G&%QF,E@\/+F<5=M;;I6OUW]#U.BBBO'/</@']N[X'MX9\3)X]TFW/\
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M\1P>GWMWX'_LJC3Y;?7?&L22SKB2WT?.Y4/4--V)_P!CIZYY%?3BJ%4 # '
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M/B+?P7DOV9L^F)-M9V*.\HJAI6O:9KJR-INHVFH+&0'-K.LH7/3.TG'0U?I
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M.TGE+?1@FW\S771PF(Q.M&FY>B;..OC<-A=*]6,?5I?F>TTA..3P*^3O%/\
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MG^3SSFA"C":C:5]>UFC\Q/A[^S7\1/B9Y<ND^'+B&P?D7^H#[-!CU#/@L/\
M=!KZ<^'G_!._2[(QW'C3Q#+J4@P38Z4ODQ?0R,"S#Z!#7V+17=C.*,=B+QI-
M4UY;_>_TL>?@>$,NPMI5DZDO/;[E^MSD? OPF\'_  TMQ%X:\/66E-MVM/''
MNG<>C2MEV_$FNNHHKY.I4G5DYU)-M]7J?9TZ5.C%0I144NB5D%%%%9FH4444
M >8_M*^!]7^)'P3\1^'=!MUNM5O/LWDQ/(L8;9<Q2-\S$ ?*C?E7PM_PP_\
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M?_%4?\,/_%S_ * -K_X,8/\ XJOTWHKU_P#6[,/Y8_<_\SQO]2<M_FG]Z_\
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MQ8^*D6M^&],@O-.73H;<R27<41WJ[DC#,#T8<UXI_P ,/_%S_H VO_@Q@_\
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MT)^TAH?P+T78YCU+Q-<H39Z4C\CKB67NL>?Q;! Z$C\S_'GCS6_B5XFN]?\
M$%ZU[J-R>6/"HH^ZB+T51V _GDU^B<+X+'.2KJ;A2[?S?)]//[O+\PXNS#+U
M!X9TU.MW_E^:UOV6W5^>+:VL]]=16UM#)<7$SB..&)2SNQ. H Y))[5V.M_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6/5G;_:9B6/N37TW$F9?4,,L-0TE/MTC_6B^9\EPIE7]I8IXO$:PAKKUEO\
MAN_EW-ZBBBOQT_<PHHHH **** "BBB@ HHHH **** "BBB@#F/'?PT\,?$S2
MSI_B;1;75H,'8TR8DB]TD&&0^ZD5^>W[3G[*]Y\$;A=9TB:74_"-S)Y:S2@>
M=9N>D<F.H/9P!Z$ XS^F%87CKPC9>/O!^L>'M00/::C;/;OD?=)'RL/=6PP]
MP*^ARG.*^6U8^]>GU73U79GS.=9'A\VHRO%*HEI+K?L^Z_I'XV5]>_\ !.75
M'A\:>,-.!;R[C3X;AAVS'(5'_HT_K7R1>VDNGWD]K.NR:&1HY%/9@<$?F*^J
MO^"=:G_A9OB5@,C^Q\$_]MHZ_5L_M+*ZWHOS1^-<-MQS>AZO\F?H!1117X0?
MT6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %>#?M4_M(0?!/PX--TIXY_%^I1M]EC
M.&%K'R//<'WX53U(/8&O7_&GBRQ\"^$]6\0:DVVRTVV>YDP>6VC(4>Y. /<B
MOR)\?>.-3^)'C#5/$>L3&6^OYC(W/$:]%1?]E5 4>PK[#AS*8YA6=6LOW</Q
M?;T[_P#!/A^*,ZEEE!4:#_>3Z]EW]>B^_H9&I:E=ZQJ%S?7US+>7ES(TLUQ,
MQ9Y')R68GJ2:K445^SI)*R/PAMMW9]5?\$]O!D>L_$W6O$4T8==%L0D)(^Y-
M.2H8?\ 24?\  J_0:OC?_@G#Y7_"/^.,!O/^U6N_IC;LDV_CG=^E?9%?B/$U
M653,ZB?V;)?<G^;9_0'"=&-+*:3C]J[?WM?DD%%%%?+'UX4444 %%%% !111
M0 4444 %%%% !1110 4V218HV=V"(HW,S'  '<TZO%OVMOBE#\,O@YJP294U
M?6(VTZQCS\V7&)''^ZA8Y]2H[UTX;#SQ5:%"GO)V.3%XF&#H3Q%3:*O_ %ZG
MYD>(M075O$&IWR#"7-U+,H]F<L/YU]E?\$X?#SB/QMKKH=C&VLHG[$C>\@_6
M/\Z^):_5#]D_X=R?#?X(:%9W,9BU#4 =3NU(P5>4 JI'8B,1J?=37ZYQ1B(X
M?+O8K>;2^2U?Y?B?BG"&&EB<T]N]H)M^KT7YW^1[!1117XT?NP4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR_.X4445\\?3A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'_?(%>;+A''KX91?S?\ D>M#C;+I?%":^2_^2/TOHK\UO^&\/BK_ ,_>E_\
M@ O^-07/[<_Q9G*[-5L+?'7R]/B.?^^@:C_5+,.\?O?^1H^-,L[3^Y?YGZ84
M5^5VH_M<?%W5%Q-XTND&,?Z/;00?^@1BN(UWXI>,O$^Y=6\5ZUJ2-UCNK^61
M/P4M@?E773X.Q+_B58KTN_\ (XJO'.$2_=49/ULO\S]7?%7Q7\&^" _]N^)]
M*TR1.L,]T@E_",'<?P%>$>.O^"@'@;05DB\.6%_XHN1]V3;]DMS_ ,"<;_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
/ %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>gp5m5bivuamv000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gp5m5bivuamv000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !- , # 2(  A$! Q$!_\0
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M8VQC&/>O0B,C!KFM2\-M),TMHP&[DJ:\#.<'7JRC6HZM=#MPE6$;QGU(;74
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MMU:FZBE!A'&ZN<CL%U;QA/</&?LUH-HR.'<UJ>()([/1GCBA4M(=B(J]S]*
M)?\ A(M+V!OM:%2VW/O4]MJME=W+6\$P>11D@5Q*Z,HDATS:=D2^?=OMY/?
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>gp5m5bivuamv000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gp5m5bivuamv000003.jpg
M_]C_X  02D9)1@ ! @$       #_[@ .061O8F4 9      !_]L 0P ! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! @(" @("
M @(" @(# P,# P,# P,#_]L 0P$! 0$! 0$" 0$" @(! @(# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#_\  $0@
M30#$ P$1  (1 0,1 ?_$ !X   $#!0$!               '" D! @4&"@,$
M_\0 0A   0,# P,"! ,$!P4)     0(#!!$%!@ A!S$2"$$346$4"7$B%?"1
ML2.!H3)2)!87P='Q0C/A8G*"DE,E)AC_Q  > 0$!  $% 0$!
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M3\#H0:_XK>4MA\FK9G$ZUQ6;;(P_*)-F$)MTK?D6[O<3#N2VUK*PF1[1J>T
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M.N%*-?U'FON=,SC5Z:>F4(WL)QORSJU3OPQ[.X9=R1<+8PX\ZW+FK4%I*EW
M(]Y+!J%&0Y[P6"%[  J /IKSO]Q7]*>EUURQ-W+T+$\)+AQ2>!SIR58N-VUA
MBEEXDB7 [R7.*\3<0:H7;RM)INI)42/0&I'X:]$_;1<GJ>C>QQ<5;N+167@Z
MJG NW\CKQSI'TN:-9;E\_P!1)?;465+B2$[T*@>T4.]"!TH/B-=@Z..#=6;7
M>#H\R"/,O*[CZ[?<(O>29I$RB\<?^/EIGXEC+F,X[<<CB/9M+0&[HX?I N*I
MQL))17\R#ZC;5(1]?<EYOP3(N?\ C+R/X?@9C99D!$5O))V1XY<<=3*N-BD1
MY%N4PY/;4AQ],5*T]@*2#0TUH2JI&DE/B?\ "=07 7*5KYDX>P#D:T/(?C9-
MCL"6X6N]0;F)CH1-:5W)!]QF0E25#H%[:U%-4QS-86#<HVV/::'UK38@?CK)
MI,AR+X?E7(-O^ZSE,KC&R6;),N;SK(6[?CN33?TV!*;$>0)"7)<=F0^POV4J
M6D]M JAWIK!0=<<BCI?+G[CWDWCN:N^-_)& V'@!O)78EIR#,[7/F96^,:O3
MS<5VX6"1V6]*@J,X2M8_Z8*J]-:G%!9UJ3$EV\,_%3AOQOX[AN\8O')Y^7P8
M]TN_(%P6W(NU_;D)^H90AYLJ^G@MK>5VMI)-?[1)U*H$(/WQ[M=&>;>++?,(
M194V5+L)WJ/?=<2B4M[W$GHV:?DZ [ZQ=R"?"WB#HI\>C"_T-XG-O2T(B\"Q
MEQD,=OM*"[5&6I3?;1)"E*)^==9*2>0%D!! (-1\=4 2 :5WH33J:#KL-] '
M</F>G05Z_AH"'S[IW.-OL_\ I%X_)3>9+7(>3P[WG;>/0E7.Y,8599;#TE+,
M*.'9"G7W$;@H[2@]= -<^XEY <#\\>,;6$X1C7(\/(, ?MTW%ES<"NMMA184
M&.F!.:,QY+4>*A<)(JL^@.V^L)2HUW =;]G/R#8Y7\;T8'<YR'LGXPFNVMYE
M2JOJLKJZP7W$ E+*4FJ GT U5)/($O-0?V^.K6H*ZH*'IJ8@AQ\KKF;?SY?E
M-J"3^FVI1 "E=SR8?N,E14: 400H)V H=>!_O WJSLONNWB[>B_2E8T=6ZTP
ML]G8_([A=+-%/4\@6'IOYW%<K_KP/KXXY5C0"W^HW .(CMMN,0 .T29 *F?8
MDK_)[\2J.]0IL=O77/W23JUHM-I]/K;MQ7]!6BM/*JJFG3'_  /@YIY5GJ8Z
M=:>JORN3XJ>7Y"L/XMQS>9SUX=<DVNX-6IR\7&);0EF-/DN.!YUAI*U!;#2$
MT%?^8G7+,^G_ "#=OZ[F3;-6MOX+"U%RW""E&7$ZM5E*N+=73$VC8W7F?2VG
MM]^%8SK;3;^6*R;\<,SVR7-\;QJS1[+:%MQHJF&;E$N$:2\J6)8:]B3&N#W?
MVO>PZY0))H$T/6NMP\R<X[%RGL%O3;.X0L0L1NQOQ?Q.ZX8IQJUAF:.T['O^
MJUOU^JL\5IOAH^Y.M<LF,OS;-S=79"S,;D2$"4D/>V%(4XBCJG7.[;M&Z2$F
M@4!KS$Z]]2;&X>O9=WBU]V,G7MDI)YTPQ?9V'./+VQSTE+]Q*,4OSR)@?'ES
MW>',%=7[E9-GC/!3P <6' :+4  !7^&O:GVL6KBZ';&[B:E/;;,FWXP61TZY
M\AZG->NG!U2U,G^)I?F9Y 6;QC\;^3^7+G)99EV/'9D;&V%J'?.R6YMFWV6+
M'34>\Y]<^EQ21N&T*/IKL1!.,%&M:+[S:CQQ$"^V5PD]@?BQA^1YY:X4G/\
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MJDTZIY'9?3W]MW)K4Z2Y;N1XFU5I9^;[C:F,JS6,76?H,@?>F,]J)(MTUYM
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M>\2['F_->3RKG/C6:3DEUE3Y(?N42+-6J1;K*I;SB/J)[3;B44%"2=9)-NB
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K.ZE- ._13L33I3:E*?T4VIH"[0!H T : - &@#0!H U%7M :H#0!H#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>gp5m5bivuamv000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gp5m5bivuamv000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !- , # 2(  A$! Q$!_\0
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M8VQC&/>O0B,C!KFM2\-M),TMHP&[DJ:\#.<'7JRC6HZM=#MPE6$;QGU(;74
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MMU:FZBE!A'&ZN<CL%U;QA/</&?LUH-HR.'<UJ>()([/1GCBA4M(=B(J]S]*
M)?\ A(M+V!OM:%2VW/O4]MJME=W+6\$P>11D@5Q*Z,HDATS:=D2^?=OMY/?
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!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
